{"nct_id": "NCT00736970", "eligibility_text": "Inclusion Criteria:\n\n* Female, 18 years of age or older\n* Histologically confirmed HER2-positive metastatic breast cancer\n* Trastuzumab-resistance\n* Measurable disease, according to RECIST guidelines\n* ECOG performance status less than or equal to 1\n* Life expectancy greater than 3 months\n* No prior treatment with temsirolimus, everolimus, rapamycin, or any other mTOR inhibitor\n* At least 4 weeks must have lapsed between prior investigational therapy, chemotherapy or radiotherapy, and the first dose of ridaforolimus\n* Left ventricular ejection greater than or equal to 50%\n* Adequate cardiovascular function\n* Adequate hematological, hepatic, and renal function\n* Serum cholesterol less than or equal to 350 mg/dL and triglycerides less than or equal to 400 mg/dL\n* Negative pregnancy test within 7 days prior to first dose of study drug and must use an approved contraceptive method from screening to 30 days after the last dose of study drug\n* Availability and patient consent to obtain archival tissue samples\n* Signed informed consent\n\nExclusion Criteria:\n\n* Inadequate recovery from any prior surgical procedure or having undergone any major surgery within 2 weeks before trial entry\n* Grade 1 or Grade 2 hypersensitivity reactions to prior trastuzumab therapy if these reactions prevented further trastuzumab administration\n* Grade 3 or Grade 4 hypersensitivity reaction to prior trastuzumab\n* Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest\n* Known allergy to macrolide antibiotics\n* Pregnant or breast-feeding\n* Know history of HIV\n* Diagnosis of brain metastasis or leptomeningeal carcinomatosis within 3 months\n* Other malignancies within the past 3 years, except for adequately treated carcinoma of the cervix or basal or squamous cell carcinoma of the skin\n* Active infection requiring prescription intervention\n* Newly diagnosed or poorly controlled Type 1 or 2 diabetes\n* Other concurrent illness which, in the Investigator's judgment, would either compromise the patient's safety or interfere with the evaluation of the safety of the study drug\n* Concurrent treatment with medications that strongly induce or inhibit cytochrome P450.\n* Any condition that renders patient unable to fully understand and provide informed consent and/or comply with the protocol", "labeled_rules": [{"type": "inclusion", "field": "age", "operator": ">=", "value": "18", "unit": "years", "evidence_text": "Female, 18 years of age or older"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Histologically confirmed HER2-positive metastatic breast cancer", "unit": "NA", "evidence_text": "Histologically confirmed HER2-positive metastatic breast cancer"}, {"type": "inclusion", "field": "medication", "operator": "not_contains", "value": "Trastuzumab-resistance", "unit": "NA", "evidence_text": "Trastuzumab-resistance"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Measurable disease, according to RECIST guidelines", "unit": "NA", "evidence_text": "Measurable disease, according to RECIST guidelines"}, {"type": "inclusion", "field": "lab", "operator": "<=", "value": "1", "unit": "NA", "evidence_text": "ECOG performance status less than or equal to 1"}, {"type": "inclusion", "field": "medication", "operator": "not_contains", "value": "No prior treatment with temsirolimus, everolimus, rapamycin, or any other mTOR inhibitor", "unit": "NA", "evidence_text": "No prior treatment with temsirolimus, everolimus, rapamycin, or any other mTOR inhibitor"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "At least 4 weeks must have lapsed between prior investigational therapy, chemotherapy or radiotherapy, and the first dose of ridaforolimus", "unit": "NA", "evidence_text": "At least 4 weeks must have lapsed between prior investigational therapy, chemotherapy or radiotherapy, and the first dose of ridaforolimus"}, {"type": "inclusion", "field": "lab", "operator": "<=", "value": "350", "unit": "mg/dl", "evidence_text": "Serum cholesterol less than or equal to 350 mg/dL and triglycerides less than or equal to 400 mg/dL"}, {"type": "inclusion", "field": "lab", "operator": "=", "value": "negative", "unit": "NA", "evidence_text": "Negative pregnancy test within 7 days prior to first dose of study drug and must use an approved contraceptive method from screening to 30 days after the last dose of study drug"}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Availability and patient consent to obtain archival tissue samples", "unit": "NA", "evidence_text": "Availability and patient consent to obtain archival tissue samples"}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Signed informed consent", "unit": "NA", "evidence_text": "Signed informed consent"}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Inadequate recovery from any prior surgical procedure or having undergone any major surgery within 2 weeks before trial entry", "unit": "NA", "evidence_text": "Inadequate recovery from any prior surgical procedure or having undergone any major surgery within 2 weeks before trial entry"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Grade 1 or Grade 2 hypersensitivity reactions to prior trastuzumab therapy if these reactions prevented further trastuzumab administration", "unit": "NA", "evidence_text": "Grade 1 or Grade 2 hypersensitivity reactions to prior trastuzumab therapy if these reactions prevented further trastuzumab administration"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Grade 3 or Grade 4 hypersensitivity reaction to prior trastuzumab", "unit": "NA", "evidence_text": "Grade 3 or Grade 4 hypersensitivity reaction to prior trastuzumab"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest", "unit": "NA", "evidence_text": "Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Known allergy to macrolide antibiotics", "unit": "NA", "evidence_text": "Known allergy to macrolide antibiotics"}, {"type": "exclusion", "field": "history", "operator": "!=", "value": "pregnant_or_breastfeeding", "unit": "NA", "evidence_text": "Pregnant or breast-feeding"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Know history of HIV", "unit": "NA", "evidence_text": "Know history of HIV"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Diagnosis of brain metastasis or leptomeningeal carcinomatosis within 3 months", "unit": "NA", "evidence_text": "Diagnosis of brain metastasis or leptomeningeal carcinomatosis within 3 months"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Other malignancies within the past 3 years, except for adequately treated carcinoma of the cervix or basal or squamous cell carcinoma of the skin", "unit": "NA", "evidence_text": "Other malignancies within the past 3 years, except for adequately treated carcinoma of the cervix or basal or squamous cell carcinoma of the skin"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Active infection requiring prescription intervention", "unit": "NA", "evidence_text": "Active infection requiring prescription intervention"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Newly diagnosed or poorly controlled Type 1 or 2 diabetes", "unit": "NA", "evidence_text": "Newly diagnosed or poorly controlled Type 1 or 2 diabetes"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Other concurrent illness which, in the Investigator's judgment, would either compromise the patient's safety or interfere with the evaluation of the safety of t", "unit": "NA", "evidence_text": "Other concurrent illness which, in the Investigator's judgment, would either compromise the patient's safety or interfere with the evaluation of the safety of the study drug"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Concurrent treatment with medications that strongly induce or inhibit cytochrome P450.", "unit": "NA", "evidence_text": "Concurrent treatment with medications that strongly induce or inhibit cytochrome P450."}, {"type": "exclusion", "field": "other", "operator": "contains", "value": "Any condition that renders patient unable to fully understand and provide informed consent and/or comply with the protocol", "unit": "NA", "evidence_text": "Any condition that renders patient unable to fully understand and provide informed consent and/or comply with the protocol"}]}
{"nct_id": "NCT00737789", "eligibility_text": "Inclusion Criteria:\n\nPatients will be included if they comply with the following inclusion criteria determined at baseline, prior to first drug administration:\n\n* Aged over 18 years.\n* Newly diagnosed or relapsing mild to moderate ulcerative colitis with disease extension beyond rectum (of at least 12-18 cm from the anorectal junction). All patients must have had at least one total colonoscopy in their disease history (within the previous 5 years).\n* Disease activity will be assessed on the 15 days before inclusion and according to ulcerative colitis disease activity index (UC-DAI) score. The UC-DAI score will be from 3 to 8 (mild: 3-5 or moderate: 6-8).\n* Men or non pregnant women.\n* Women with childbearing potential must be using a contraceptive method judged effective by the investigator.\n* Oral maintenance treatment with azathioprine or 6-mercaptopurine (taken for at least 6 months at stable dose and continued at the same dose throughout the study) is permitted.\n* Informed consent given.\n\nExclusion Criteria:\n\nThe patients will not be included in the study if one of the following exclusion criteria is fulfilled at baseline, prior to first drug administration:\n\n* Proctitis (less than 12-18 cm from the anorectal junction).\n* Previous colonic surgery.\n* Previously failed to respond to steroids within the previous year.\n* Non-response to rectal 5-Amino Salicylic Acid (5-ASA) therapy or to oral 5-ASA therapy at a dose \\> 3g/day for induction of remission within the previous year.\n* Current relapse lasting more than 6 weeks (for patient recently diagnosed the period of 6 weeks runs from the endoscopic diagnosis)(from what patient says).\n* Severe/fulminant ulcerative colitis.\n* Evidence of other forms of inflammatory bowel disease or infectious disease.\n* Allergy to aspirin or salicylate derivatives.\n* The following treatment will be forbidden during the study (if present at selection, a wash-out will be necessary):\n* Loperamide and other antidiarrheal agents, mucilages, antibiotics: 1 week wash-out.\n* Oral steroids: 4 weeks wash-out.\n* Rectal steroids: 2 weeks wash-out\n* Repeated treatment (\\> 3days of use) of non steroidal anti-inflammatory drugs (NSAID) oral or rectal route: 1 week wash-out (aspirin ≤ 325 mg/day used for cardioprotection is allowed).\n* Sulfasalazine \\> 4g/day or mesalazine or 4-ASA at a higher dose than what is permitted in the local formulary or standard care for maintenance treatment: 4 weeks wash-out\n* Immunomodulating/suppressing drugs: 3 month for wash out (except for patients maintained on azathioprine or 6-mercaptopurine -see above).\n* Known significant hepatic or renal function abnormalities.\n* Moderate/severe abnormal renal, hepatic or blood count tests defined as: creatinine plasma value \\> 1.5 x Upper Limit of Normal (ULN) or white blood cells \\< 3500/mm˄3 or \\> 15000/mm˄3 or Platelets \\< 100000/mm˄3 or \\> 800000/mm˄3 or aspartate aminotransferase/alanine Aminotransferase (ASAT/ALAT) \\> 3 x ULN or Gamma glutamyl transpeptidase (GGT)/Alkaline Phosphatase's \\> 3 x ULN (Primary Sclerosing Cholangitis is not an exclusion criteria).\n* History or physical examination findings indicative of active alcohol or drug abuse,\n* Pregnancy or breast-feeding,\n* History of disease, including mental/emotional disorder, that might interfere with their participation in the study,\n* Participation in another clinical study in the last 3 months.\n* Inability to comply with the protocol requirements.\n* Inability to fill in the diary cards.", "labeled_rules": [{"type": "inclusion", "field": "age", "operator": ">=", "value": "18", "unit": "years", "evidence_text": "Aged over 18 years."}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Newly diagnosed or relapsing mild to moderate ulcerative colitis with disease extension beyond rectum (of at least 12-18 cm from the anorectal junction).", "unit": "NA", "evidence_text": "Newly diagnosed or relapsing mild to moderate ulcerative colitis with disease extension beyond rectum (of at least 12-18 cm from the anorectal junction)."}, {"type": "inclusion", "field": "procedure", "operator": "not_contains", "value": "All patients must have had at least one total colonoscopy in their disease history (within the previous 5 years).", "unit": "NA", "evidence_text": "All patients must have had at least one total colonoscopy in their disease history (within the previous 5 years)."}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Disease activity will be assessed on the 15 days before inclusion and according to ulcerative colitis disease activity index (UC-DAI) score. The UC-DAI score wi", "unit": "NA", "evidence_text": "Disease activity will be assessed on the 15 days before inclusion and according to ulcerative colitis disease activity index (UC-DAI) score. The UC-DAI score will be from 3 to 8 (mild: 3-5 or moderate: 6-8)."}, {"type": "inclusion", "field": "sex", "operator": "in", "value": "male,female", "unit": "NA", "evidence_text": "Men or non pregnant women."}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Women with childbearing potential must be using a contraceptive method judged effective by the investigator."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Oral maintenance treatment with azathioprine or 6-mercaptopurine (taken for at least 6 months at stable dose and continued at the same dose throughout the study", "unit": "NA", "evidence_text": "Oral maintenance treatment with azathioprine or 6-mercaptopurine (taken for at least 6 months at stable dose and continued at the same dose throughout the study) is permitted."}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Informed consent given.", "unit": "NA", "evidence_text": "Informed consent given."}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Previous colonic surgery.", "unit": "NA", "evidence_text": "Previous colonic surgery."}, {"type": "exclusion", "field": "medication", "operator": "not_contains", "value": "Previously failed to respond to steroids within the previous year.", "unit": "NA", "evidence_text": "Previously failed to respond to steroids within the previous year."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Non-response to rectal 5-Amino Salicylic Acid (5-ASA) therapy or to oral 5-ASA therapy at a dose \\> 3g/day for induction of remission within the previous year.", "unit": "NA", "evidence_text": "Non-response to rectal 5-Amino Salicylic Acid (5-ASA) therapy or to oral 5-ASA therapy at a dose \\> 3g/day for induction of remission within the previous year."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Current relapse lasting more than 6 weeks (for patient recently diagnosed the period of 6 weeks runs from the endoscopic diagnosis)(from what patient says).", "unit": "NA", "evidence_text": "Current relapse lasting more than 6 weeks (for patient recently diagnosed the period of 6 weeks runs from the endoscopic diagnosis)(from what patient says)."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Severe/fulminant ulcerative colitis.", "unit": "NA", "evidence_text": "Severe/fulminant ulcerative colitis."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Evidence of other forms of inflammatory bowel disease or infectious disease.", "unit": "NA", "evidence_text": "Evidence of other forms of inflammatory bowel disease or infectious disease."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Allergy to aspirin or salicylate derivatives.", "unit": "NA", "evidence_text": "Allergy to aspirin or salicylate derivatives."}, {"type": "exclusion", "field": "medication", "operator": "not_contains", "value": "Oral steroids: 4 weeks wash-out.", "unit": "NA", "evidence_text": "Oral steroids: 4 weeks wash-out."}, {"type": "exclusion", "field": "medication", "operator": "not_contains", "value": "Rectal steroids: 2 weeks wash-out", "unit": "NA", "evidence_text": "Rectal steroids: 2 weeks wash-out"}, {"type": "exclusion", "field": "medication", "operator": "not_contains", "value": "Repeated treatment (\\> 3days of use) of non steroidal anti-inflammatory drugs (NSAID) oral or rectal route: 1 week wash-out (aspirin ≤ 325 mg/day used for cardi", "unit": "NA", "evidence_text": "Repeated treatment (\\> 3days of use) of non steroidal anti-inflammatory drugs (NSAID) oral or rectal route: 1 week wash-out (aspirin ≤ 325 mg/day used for cardioprotection is allowed)."}, {"type": "exclusion", "field": "medication", "operator": "not_contains", "value": "Immunomodulating/suppressing drugs: 3 month for wash out (except for patients maintained on azathioprine or 6-mercaptopurine -see above).", "unit": "NA", "evidence_text": "Immunomodulating/suppressing drugs: 3 month for wash out (except for patients maintained on azathioprine or 6-mercaptopurine -see above)."}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "1.5", "unit": "x", "evidence_text": "Moderate/severe abnormal renal, hepatic or blood count tests defined as: creatinine plasma value \\> 1.5 x Upper Limit of Normal (ULN) or white blood cells \\< 3500/mm˄3 or \\> 15000/mm˄3 or Platelets \\< 100000/mm˄3 or \\> 800000/mm˄3 or aspartate aminotransferase/alanine Aminotransferase (ASAT/ALAT) \\> 3 x ULN or Gamma glutamyl transpeptidase (GGT)/Alkaline Phosphatase's \\> 3 x ULN (Primary Sclerosing Cholangitis is not an exclusion criteria)."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "History or physical examination findings indicative of active alcohol or drug abuse,", "unit": "NA", "evidence_text": "History or physical examination findings indicative of active alcohol or drug abuse,"}, {"type": "exclusion", "field": "history", "operator": "!=", "value": "pregnant_or_breastfeeding", "unit": "NA", "evidence_text": "Pregnancy or breast-feeding,"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "History of disease, including mental/emotional disorder, that might interfere with their participation in the study,", "unit": "NA", "evidence_text": "History of disease, including mental/emotional disorder, that might interfere with their participation in the study,"}, {"type": "exclusion", "field": "other", "operator": "contains", "value": "Inability to comply with the protocol requirements.", "unit": "NA", "evidence_text": "Inability to comply with the protocol requirements."}, {"type": "exclusion", "field": "other", "operator": "contains", "value": "Inability to fill in the diary cards.", "unit": "NA", "evidence_text": "Inability to fill in the diary cards."}]}
{"nct_id": "NCT00738023", "eligibility_text": "Inclusion Criteria:\n\n* Males or females between the ages of 18 and 70 years.\n* Subjects must have a BMI of ≥ 30 kg/m2.\n* Subjects must have a BP \\< 130/80 mm Hg and no prior history of hypertension.\n* A known history of type 2 diabetes mellitus \\< 3 years (now 5 years).\n* Subjects must have an HbA1c of \\< 9%.\n* Diabetic subjects must have been receiving as their only current anti-diabetic therapy stable doses of sulfonylureas for the last 2 months.\n* Subjects must be able to understand and willing to adhere to the study protocol.\n\nExclusion Criteria:\n\n* Subjects with history of hypertension (BP \\> 140/90 mm HG) or who have received antihypertensive drug therapy prior to the study.\n* Obese nondiabetic controls with impaired glucose tolerance (2-hour glucose between 140 - 199 mg/dl) during a 75-g OGTT.\n* Diabetic subjects who require insulin therapy or have received an insulin sensitizer agent (metformin, rosiglitazone, pioglitazone) within 3 months of entering the study (at SV1, week-2).\n* Subjects with fasting triglyceride levels \\> 250 mg/dL prior to the study (at SV1, week-2).\n* Clinically relevant hepatic disease (ALT 2.5x \\> upper limit of normal), or other significant medical or surgical illness.\n* Renal failure, as shown by a serum creatinine ≥1.5 mg/dL for males, or ≥ 1.4 mg/dL for females.\n* Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.\n* Female subjects are pregnant or breast feeding at time of enrollment into the study.", "labeled_rules": [{"type": "inclusion", "field": "sex", "operator": "in", "value": "male,female", "unit": "NA", "evidence_text": "Males or females between the ages of 18 and 70 years."}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "130", "unit": "/80", "evidence_text": "Subjects must have a BP \\< 130/80 mm Hg and no prior history of hypertension."}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "A known history of type 2 diabetes mellitus \\< 3 years (now 5 years).", "unit": "NA", "evidence_text": "A known history of type 2 diabetes mellitus \\< 3 years (now 5 years)."}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "9", "unit": "%", "evidence_text": "Subjects must have an HbA1c of \\< 9%."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Diabetic subjects must have been receiving as their only current anti-diabetic therapy stable doses of sulfonylureas for the last 2 months.", "unit": "NA", "evidence_text": "Diabetic subjects must have been receiving as their only current anti-diabetic therapy stable doses of sulfonylureas for the last 2 months."}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Subjects must be able to understand and willing to adhere to the study protocol.", "unit": "NA", "evidence_text": "Subjects must be able to understand and willing to adhere to the study protocol."}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "140", "unit": "/90", "evidence_text": "Subjects with history of hypertension (BP \\> 140/90 mm HG) or who have received antihypertensive drug therapy prior to the study."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Diabetic subjects who require insulin therapy or have received an insulin sensitizer agent (metformin, rosiglitazone, pioglitazone) within 3 months of entering ", "unit": "NA", "evidence_text": "Diabetic subjects who require insulin therapy or have received an insulin sensitizer agent (metformin, rosiglitazone, pioglitazone) within 3 months of entering the study (at SV1, week-2)."}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "250", "unit": "mg/dl", "evidence_text": "Subjects with fasting triglyceride levels \\> 250 mg/dL prior to the study (at SV1, week-2)."}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Clinically relevant hepatic disease (ALT 2.5x \\> upper limit of normal), or other significant medical or surgical illness.", "unit": "NA", "evidence_text": "Clinically relevant hepatic disease (ALT 2.5x \\> upper limit of normal), or other significant medical or surgical illness."}, {"type": "exclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Female subjects are pregnant or breast feeding at time of enrollment into the study."}]}
{"nct_id": "NCT00743496", "eligibility_text": "Inclusion Criteria:\n\n* Diagnosis:\n\n  * Part A: Recurrent or refractory neuroblastoma or melanoma.\n  * Part B: Recurrent or refractory neuroblastoma or melanoma.\n  * Part C: Recurrent or refractory osteosarcoma and Ewing sarcoma.\n* Age: ≤ 21 years of age at the time of enrollment (i.e. participants are eligible until they reach their 22nd birthday).\n* Does not have a clinically significant neurologic deficit or objective peripheral neuropathy (greater than or equal to grade 2). Peripheral (sensory or motor) neuropathy related to limb sparing procedure or amputation is allowed.\n* Life expectancy: at least 8 weeks.\n* Organ Function: Must have adequate organ and marrow function\n* Performance status: Karnofsky ≥ 50 for \\> 10 years of age; Lansky ≥ 50 for children \\< 10 years of age.\n* Prior Therapy: Patient must have fully recovered from the acute toxic effects of all prior therapy prior to enrolling on study.\n\n  * Myelosuppressive Chemotherapy: Must not have received myelosuppressive therapy within 2 weeks prior to study entry (4 weeks if nitrosurea).\n  * Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with biologic agent, including retinoic acid. Participants receiving IVIG are eligible; however, participant must not receive IVIG during the 4 days of antibody infusion.\n  * Radiation therapy: At least 2 weeks since prior local radiation therapy at the time of study entry.\n  * Growth factors: Must not have received hematopoietic growth factors (G-CSF, GM-CSF) for at least 1 week prior to study entry.\n  * Investigational agent: Must not have received investigational agent within 14 days of study entry.\n  * Immune therapy: Must not have received immunosuppressive (including glucocorticoids), immunostimulatory or any immunomodulatory treatment within 2 weeks of study entry. Steroid containing inhalers, steroid replacement for adrenal insufficiency and steroid premedication for prevention of transfusion or imaging contrast agent-related allergic reaction will be permitted.\n* Patients may have had prior CNS metastasis providing: CNS disease has been previously treated and CNS disease has been clinically stable for 4 weeks prior to study entry (assessment must be made by CT or MRI).\n* Written informed consent following institutional and federal guidelines.\n\nExclusion Criteria:\n\n* Prior monoclonal antibody: Participants having received in vivo monoclonal antibodies for biologic therapy or for tumor imaging are eligible provided they did not experience a severe allergic reaction with the antibody.\n* Pregnancy or Breast Feeding: Study participants who are pregnant are not eligible for this study. Pregnancy tests must be obtained in girls who are \\> 10 years of age or post-menarchal within 7 days prior to study enrollment. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during participation in the trial. Breast feeding should be discontinued if a mother wishes to participate in this study.\n* Allergy: known hypersensitivity to other recombinant human antibodies.\n* An uncontrolled infection.", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "Diagnosis:", "unit": "NA", "evidence_text": "Diagnosis:"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Part A: Recurrent or refractory neuroblastoma or melanoma.", "unit": "NA", "evidence_text": "Part A: Recurrent or refractory neuroblastoma or melanoma."}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Part B: Recurrent or refractory neuroblastoma or melanoma.", "unit": "NA", "evidence_text": "Part B: Recurrent or refractory neuroblastoma or melanoma."}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Part C: Recurrent or refractory osteosarcoma and Ewing sarcoma.", "unit": "NA", "evidence_text": "Part C: Recurrent or refractory osteosarcoma and Ewing sarcoma."}, {"type": "inclusion", "field": "procedure", "operator": "contains", "value": "Peripheral (sensory or motor) neuropathy related to limb sparing procedure or amputation is allowed.", "unit": "NA", "evidence_text": "Peripheral (sensory or motor) neuropathy related to limb sparing procedure or amputation is allowed."}, {"type": "inclusion", "field": "age", "operator": "<", "value": "10", "unit": "years", "evidence_text": "Performance status: Karnofsky ≥ 50 for \\> 10 years of age; Lansky ≥ 50 for children \\< 10 years of age."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Prior Therapy: Patient must have fully recovered from the acute toxic effects of all prior therapy prior to enrolling on study.", "unit": "NA", "evidence_text": "Prior Therapy: Patient must have fully recovered from the acute toxic effects of all prior therapy prior to enrolling on study."}, {"type": "inclusion", "field": "medication", "operator": "not_contains", "value": "Myelosuppressive Chemotherapy: Must not have received myelosuppressive therapy within 2 weeks prior to study entry (4 weeks if nitrosurea).", "unit": "NA", "evidence_text": "Myelosuppressive Chemotherapy: Must not have received myelosuppressive therapy within 2 weeks prior to study entry (4 weeks if nitrosurea)."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with biologic agent, including retinoic acid.", "unit": "NA", "evidence_text": "Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with biologic agent, including retinoic acid."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Radiation therapy: At least 2 weeks since prior local radiation therapy at the time of study entry.", "unit": "NA", "evidence_text": "Radiation therapy: At least 2 weeks since prior local radiation therapy at the time of study entry."}, {"type": "inclusion", "field": "history", "operator": "not_contains", "value": "Growth factors: Must not have received hematopoietic growth factors (G-CSF, GM-CSF) for at least 1 week prior to study entry.", "unit": "NA", "evidence_text": "Growth factors: Must not have received hematopoietic growth factors (G-CSF, GM-CSF) for at least 1 week prior to study entry."}, {"type": "inclusion", "field": "history", "operator": "not_contains", "value": "Investigational agent: Must not have received investigational agent within 14 days of study entry.", "unit": "NA", "evidence_text": "Investigational agent: Must not have received investigational agent within 14 days of study entry."}, {"type": "inclusion", "field": "medication", "operator": "not_contains", "value": "Immune therapy: Must not have received immunosuppressive (including glucocorticoids), immunostimulatory or any immunomodulatory treatment within 2 weeks of stud", "unit": "NA", "evidence_text": "Immune therapy: Must not have received immunosuppressive (including glucocorticoids), immunostimulatory or any immunomodulatory treatment within 2 weeks of study entry."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Steroid containing inhalers, steroid replacement for adrenal insufficiency and steroid premedication for prevention of transfusion or imaging contrast agent-rel", "unit": "NA", "evidence_text": "Steroid containing inhalers, steroid replacement for adrenal insufficiency and steroid premedication for prevention of transfusion or imaging contrast agent-related allergic reaction will be permitted."}, {"type": "inclusion", "field": "procedure", "operator": "contains", "value": "Patients may have had prior CNS metastasis providing: CNS disease has been previously treated and CNS disease has been clinically stable for 4 weeks prior to st", "unit": "NA", "evidence_text": "Patients may have had prior CNS metastasis providing: CNS disease has been previously treated and CNS disease has been clinically stable for 4 weeks prior to study entry (assessment must be made by CT or MRI)."}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Written informed consent following institutional and federal guidelines.", "unit": "NA", "evidence_text": "Written informed consent following institutional and federal guidelines."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Prior monoclonal antibody: Participants having received in vivo monoclonal antibodies for biologic therapy or for tumor imaging are eligible provided they did n", "unit": "NA", "evidence_text": "Prior monoclonal antibody: Participants having received in vivo monoclonal antibodies for biologic therapy or for tumor imaging are eligible provided they did not experience a severe allergic reaction with the antibody."}, {"type": "exclusion", "field": "history", "operator": "!=", "value": "pregnant_or_breastfeeding", "unit": "NA", "evidence_text": "Pregnancy or Breast Feeding: Study participants who are pregnant are not eligible for this study."}, {"type": "exclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Pregnancy tests must be obtained in girls who are \\> 10 years of age or post-menarchal within 7 days prior to study enrollment."}, {"type": "exclusion", "field": "sex", "operator": "in", "value": "male,female", "unit": "NA", "evidence_text": "Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during participation in the trial."}, {"type": "exclusion", "field": "history", "operator": "!=", "value": "pregnant_or_breastfeeding", "unit": "NA", "evidence_text": "Breast feeding should be discontinued if a mother wishes to participate in this study."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Allergy: known hypersensitivity to other recombinant human antibodies.", "unit": "NA", "evidence_text": "Allergy: known hypersensitivity to other recombinant human antibodies."}]}
{"nct_id": "NCT00774241", "eligibility_text": "Inclusion Criteria:\n\n* male and female patients, \\>=18 years of age;\n* stage IV, HER2 negative metastatic breast cancer;\n* candidate for taxane-based therapy;\n* ECOG performance status 0-2.\n\nExclusion Criteria:\n\n* prior chemotherapy for metastatic breast cancer;\n* concomitant primary malignant disease, except for adequately treated cervical cancer in situ, or basal or squamous cell skin cancer within last 5 years;\n* suspicion of CNS metastasis;\n* clinically significant cardiovascular disease.", "labeled_rules": [{"type": "inclusion", "field": "age", "operator": ">=", "value": "18", "unit": "years", "evidence_text": "male and female patients, \\>=18 years of age;"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "stage IV, HER2 negative metastatic breast cancer;", "unit": "NA", "evidence_text": "stage IV, HER2 negative metastatic breast cancer;"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "candidate for taxane-based therapy;", "unit": "NA", "evidence_text": "candidate for taxane-based therapy;"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "prior chemotherapy for metastatic breast cancer;", "unit": "NA", "evidence_text": "prior chemotherapy for metastatic breast cancer;"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "concomitant primary malignant disease, except for adequately treated cervical cancer in situ, or basal or squamous cell skin cancer within last 5 years;", "unit": "NA", "evidence_text": "concomitant primary malignant disease, except for adequately treated cervical cancer in situ, or basal or squamous cell skin cancer within last 5 years;"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "clinically significant cardiovascular disease.", "unit": "NA", "evidence_text": "clinically significant cardiovascular disease."}]}
{"nct_id": "NCT00776945", "eligibility_text": "Inclusion Criteria:\n\n* Adult patients (\\> 18 yrs of age) with recently diagnosed or a history of, Stage I - III melanoma who are able to give informed consent.\n\nExclusion Criteria:\n\n* Patients with melanomas \\< 1mm.\n* Pregnant females.\n* Children and young adults \\< 18 yrs of age and patients who are unable to give informed consent.", "labeled_rules": [{"type": "inclusion", "field": "history", "operator": "contains", "value": "Adult patients (\\> 18 yrs of age) with recently diagnosed or a history of, Stage I - III melanoma who are able to give informed consent.", "unit": "NA", "evidence_text": "Adult patients (\\> 18 yrs of age) with recently diagnosed or a history of, Stage I - III melanoma who are able to give informed consent."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Patients with melanomas \\< 1mm.", "unit": "NA", "evidence_text": "Patients with melanomas \\< 1mm."}, {"type": "exclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Pregnant females."}, {"type": "exclusion", "field": "other", "operator": "contains", "value": "Children and young adults \\< 18 yrs of age and patients who are unable to give informed consent.", "unit": "NA", "evidence_text": "Children and young adults \\< 18 yrs of age and patients who are unable to give informed consent."}]}
{"nct_id": "NCT00778986", "eligibility_text": "Inclusion Criteria:\n\n* Clinical diagnosis of Heart Failure (NYHA Class II-IV)\n* Out-patients attending the University Health Network Heart Failure Clinic\n* English-speaking and able to read English\n* 18 years old or over\n\nExclusion Criteria:\n\n* Awaiting heart transplantation\n* Not expected to survive over a year (as determined by their cardiologist)\n* Unable to read text on a mobile phone due to vision disability\n* Unable to self-care due to anxiety, depression, or decreased cognitive function\n* Lack of manual dexterity to accurately press buttons on the mobile phone", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "Clinical diagnosis of Heart Failure (NYHA Class II-IV)", "unit": "NA", "evidence_text": "Clinical diagnosis of Heart Failure (NYHA Class II-IV)"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Out-patients attending the University Health Network Heart Failure Clinic", "unit": "NA", "evidence_text": "Out-patients attending the University Health Network Heart Failure Clinic"}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Awaiting heart transplantation", "unit": "NA", "evidence_text": "Awaiting heart transplantation"}, {"type": "exclusion", "field": "other", "operator": "contains", "value": "Unable to read text on a mobile phone due to vision disability", "unit": "NA", "evidence_text": "Unable to read text on a mobile phone due to vision disability"}]}
{"nct_id": "NCT00781456", "eligibility_text": "Inclusion Criteria:\n\n* Premenopausal, non-pregnant, non-lactating\n* History of migraine headaches without aura for at least 6 months\n* History of migraine headaches associated with menstruation\n* Others as directed by FDA-approved protocol\n\nExclusion Criteria:\n\n* History of migraine headaches with aura or focal neurological symptoms\n* Any contraindication to the use of oral contraceptives\n* Others as dictated by FDA-approved protocol", "labeled_rules": [{"type": "inclusion", "field": "history", "operator": "contains", "value": "pregnancy_related", "unit": "NA", "evidence_text": "Premenopausal, non-pregnant, non-lactating"}, {"type": "inclusion", "field": "history", "operator": "not_contains", "value": "History of migraine headaches without aura for at least 6 months", "unit": "NA", "evidence_text": "History of migraine headaches without aura for at least 6 months"}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "History of migraine headaches associated with menstruation", "unit": "NA", "evidence_text": "History of migraine headaches associated with menstruation"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "History of migraine headaches with aura or focal neurological symptoms", "unit": "NA", "evidence_text": "History of migraine headaches with aura or focal neurological symptoms"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Any contraindication to the use of oral contraceptives", "unit": "NA", "evidence_text": "Any contraindication to the use of oral contraceptives"}]}
{"nct_id": "NCT00781638", "eligibility_text": "Inclusion Criteria:\n\n1. Children and adolescents \\< 18 years\n2. Ulcerative colitis documented by clinical symptoms, endoscopic findings and histology (in patient history)\n3. Moderate active ulcerative colitis at baseline evaluation, defined as follows:PUCAI between 35 and 64\n4. Pancolitis or left-sided colitis\n5. Ulcerative colitis for at least 3 months\n6. Receiving or having received one or more of the following medicinal products before screening:\n\n   * Sulfasalazine, mesalamine and other 5-aminosalicylic acid (5-ASA) agents for 4 weeks or more with a stable dose for the last 2 weeks,\n   * 0.5mg/kg/body weight with a maximum of 20 mg per day of prednisone with a stable dose for the last 2 weeks, or\n   * 6-mercaptopurine or azathioprine for 12 weeks or more with a stable dose for the last 4 weeks Other UC medication is not allowed (see also Chapter 4.4.2).\n7. For female patients of child-bearing potential, a negative pregnancy test and agreement to use an effective contraceptive method or abstain from sexual activities during the course of the clinical investigation\n8. Agreement to participate in all visits\n9. Signed written informed consent document by patients and their legal guardian or representative\n10. Body weight must be more or equal 30kg\n11. Adequate peripheral venous access to allow for completion of the apheresis treatments\n\nExclusion Criteria:\n\n1. Febrile (\\>38ºC)\n2. Evidence of toxic megacolon\n3. Anticipated need for surgery within 12 weeks after Day 00\n4. Major surgery within the past 6 weeks\n5. Known obstructive diseases of the gastrointestinal system\n6. Proctocolectomy, total colectomy, ileostomy, stoma or ileal pouch-anal anastomosis\n7. A history of allergic reaction to heparin or heparin-induced thrombocytopenia\n8. A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures\n9. Known infection with enteric pathogens, pathogenic ova or parasites, or a positive assay for C. difficile toxin\n10. Symptomatic hypotension\n11. Pediatric heart conditions and problems at high susceptibility for thrombotic events (e.g. valve defects or similar)\n12. A history of physical findings compatible with a cerebrovascular accident\n13. Prosthetic heart valve, pacemaker or other permanent implant\n14. Severe cardiovascular or peripheral vascular disease\n15. Liver disease defined as levels of GOT \\[AST\\], GPT \\[ALT\\] or alkaline phosphatase \\>2.5x the upper limit of the normal range for the laboratory performing test\n16. History of cirrhosis\n17. Renal insufficiency, defined as serum creatinine \\>150% of the upper limit of the normal range for the laboratory performing the test\n18. Known bleeding disorder (PT or PTT\\>1.5x the upper limit of the normal range for the laboratory performing the test), or concomitant anticoagulant therapy for purposes other than apheresis treatment\n19. Prior history suggestive of a hypercoagulable disorder, including 1 or more episodes of pulmonary embolism or deep vein thrombosis\n20. Known infection with Hepatitis B or C, or HIV\n21. Abnormal hematology parameters defined as severe anemia with hemoglobin \\<8.5g/dL, white blood cell count of \\<3,500/μl and a granulocyte count \\<2,000/μl\n22. Fibrinogen level \\>700mg/dL\n23. Infection:\n\n    * Active infections from successful completion of antibiotic treatment for routine bacterial infection less than 4 weeks of entry into the clinical investigation (screening)\n    * Febrile viral infection within 4 weeks of entry into the clinical investigation (screening)\n    * Less than 12 weeks from conclusion of therapy for systemic fungal infections to screening\n24. Malignancy within the past 2 years other than surgically cured skin carcinoma or cervical dysplasia (CIN I-II)\n25. History of dysplasia or carcinoma of the colon\n26. Current drug or alcohol abuse\n27. Pregnant, lactating or planning to become pregnant during the course of the clinical investigation\n28. Used within the last 30 days an investigational medicinal product, biologic or device\n29. Pre-treatment of UC with drugs other than 5-ASA and derivatives, azathioprine and or corticosteroids, e.g. immunosuppressants and biologics\n30. Steroid-resistance or -dependency, defined as inability to completely withdraw steroids without inducing a relapse or flare-up of the disease\n31. Topical therapy for ulcerative colitis within the last 2 weeks.", "labeled_rules": [{"type": "inclusion", "field": "age", "operator": "<", "value": "18", "unit": "years", "evidence_text": "Children and adolescents \\< 18 years"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Ulcerative colitis documented by clinical symptoms, endoscopic findings and histology (in patient history)", "unit": "NA", "evidence_text": "Ulcerative colitis documented by clinical symptoms, endoscopic findings and histology (in patient history)"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Moderate active ulcerative colitis at baseline evaluation, defined as follows:PUCAI between 35 and 64", "unit": "NA", "evidence_text": "Moderate active ulcerative colitis at baseline evaluation, defined as follows:PUCAI between 35 and 64"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Ulcerative colitis for at least 3 months", "unit": "NA", "evidence_text": "Ulcerative colitis for at least 3 months"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "mercaptopurine or azathioprine for 12 weeks or more with a stable dose for the last 4 weeks Other UC medication is not allowed (see also Chapter 4.4.2).", "unit": "NA", "evidence_text": "mercaptopurine or azathioprine for 12 weeks or more with a stable dose for the last 4 weeks Other UC medication is not allowed (see also Chapter 4.4.2)."}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "For female patients of child-bearing potential, a negative pregnancy test and agreement to use an effective contraceptive method or abstain from sexual activities during the course of the clinical investigation"}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Signed written informed consent document by patients and their legal guardian or representative", "unit": "NA", "evidence_text": "Signed written informed consent document by patients and their legal guardian or representative"}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Anticipated need for surgery within 12 weeks after Day 00", "unit": "NA", "evidence_text": "Anticipated need for surgery within 12 weeks after Day 00"}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Major surgery within the past 6 weeks", "unit": "NA", "evidence_text": "Major surgery within the past 6 weeks"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Known obstructive diseases of the gastrointestinal system", "unit": "NA", "evidence_text": "Known obstructive diseases of the gastrointestinal system"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "A history of allergic reaction to heparin or heparin-induced thrombocytopenia", "unit": "NA", "evidence_text": "A history of allergic reaction to heparin or heparin-induced thrombocytopenia"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures", "unit": "NA", "evidence_text": "A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "A history of physical findings compatible with a cerebrovascular accident", "unit": "NA", "evidence_text": "A history of physical findings compatible with a cerebrovascular accident"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Severe cardiovascular or peripheral vascular disease", "unit": "NA", "evidence_text": "Severe cardiovascular or peripheral vascular disease"}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "2.5", "unit": "x", "evidence_text": "Liver disease defined as levels of GOT \\[AST\\], GPT \\[ALT\\] or alkaline phosphatase \\>2.5x the upper limit of the normal range for the laboratory performing test"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "History of cirrhosis", "unit": "NA", "evidence_text": "History of cirrhosis"}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "150", "unit": "%", "evidence_text": "Renal insufficiency, defined as serum creatinine \\>150% of the upper limit of the normal range for the laboratory performing the test"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Known bleeding disorder (PT or PTT\\>1.5x the upper limit of the normal range for the laboratory performing the test), or concomitant anticoagulant therapy for p", "unit": "NA", "evidence_text": "Known bleeding disorder (PT or PTT\\>1.5x the upper limit of the normal range for the laboratory performing the test), or concomitant anticoagulant therapy for purposes other than apheresis treatment"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Prior history suggestive of a hypercoagulable disorder, including 1 or more episodes of pulmonary embolism or deep vein thrombosis", "unit": "NA", "evidence_text": "Prior history suggestive of a hypercoagulable disorder, including 1 or more episodes of pulmonary embolism or deep vein thrombosis"}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "8.5", "unit": "g/dl", "evidence_text": "Abnormal hematology parameters defined as severe anemia with hemoglobin \\<8.5g/dL, white blood cell count of \\<3,500/μl and a granulocyte count \\<2,000/μl"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Active infections from successful completion of antibiotic treatment for routine bacterial infection less than 4 weeks of entry into the clinical investigation ", "unit": "NA", "evidence_text": "Active infections from successful completion of antibiotic treatment for routine bacterial infection less than 4 weeks of entry into the clinical investigation (screening)"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Febrile viral infection within 4 weeks of entry into the clinical investigation (screening)", "unit": "NA", "evidence_text": "Febrile viral infection within 4 weeks of entry into the clinical investigation (screening)"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Less than 12 weeks from conclusion of therapy for systemic fungal infections to screening", "unit": "NA", "evidence_text": "Less than 12 weeks from conclusion of therapy for systemic fungal infections to screening"}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Malignancy within the past 2 years other than surgically cured skin carcinoma or cervical dysplasia (CIN I-II)", "unit": "NA", "evidence_text": "Malignancy within the past 2 years other than surgically cured skin carcinoma or cervical dysplasia (CIN I-II)"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "History of dysplasia or carcinoma of the colon", "unit": "NA", "evidence_text": "History of dysplasia or carcinoma of the colon"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Current drug or alcohol abuse", "unit": "NA", "evidence_text": "Current drug or alcohol abuse"}, {"type": "exclusion", "field": "history", "operator": "!=", "value": "pregnant_or_breastfeeding", "unit": "NA", "evidence_text": "Pregnant, lactating or planning to become pregnant during the course of the clinical investigation"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Used within the last 30 days an investigational medicinal product, biologic or device", "unit": "NA", "evidence_text": "Used within the last 30 days an investigational medicinal product, biologic or device"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Pre-treatment of UC with drugs other than 5-ASA and derivatives, azathioprine and or corticosteroids, e.g. immunosuppressants and biologics", "unit": "NA", "evidence_text": "Pre-treatment of UC with drugs other than 5-ASA and derivatives, azathioprine and or corticosteroids, e.g. immunosuppressants and biologics"}, {"type": "exclusion", "field": "medication", "operator": "not_contains", "value": "Steroid-resistance or -dependency, defined as inability to completely withdraw steroids without inducing a relapse or flare-up of the disease", "unit": "NA", "evidence_text": "Steroid-resistance or -dependency, defined as inability to completely withdraw steroids without inducing a relapse or flare-up of the disease"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Topical therapy for ulcerative colitis within the last 2 weeks.", "unit": "NA", "evidence_text": "Topical therapy for ulcerative colitis within the last 2 weeks."}]}
{"nct_id": "NCT00785083", "eligibility_text": "Inclusion Criteria:\n\n* Forced Expiratory Volume in 1 second of at least 60%\n* History of asthma for at least 6 months\n* Current use of short-acting beta agonists, inhaled long-acting beta agonists and inhaled corticosteroids (up to a specified dose)\n\nExclusion Criteria:\n\n* History of lung disease other than asthma\n* Smokers\n* Use of inhaled corticosteroid above specified dose\n* Use of oral beta agonists or corticosteroids or other asthma medications\n* Hypersensitivity to the drug\n* Respiratory tract infections within 1 month of the study\n\nOther protocol-defined inclusion/exclusion criteria may apply", "labeled_rules": [{"type": "inclusion", "field": "history", "operator": "contains", "value": "History of asthma for at least 6 months", "unit": "NA", "evidence_text": "History of asthma for at least 6 months"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Current use of short-acting beta agonists, inhaled long-acting beta agonists and inhaled corticosteroids (up to a specified dose)", "unit": "NA", "evidence_text": "Current use of short-acting beta agonists, inhaled long-acting beta agonists and inhaled corticosteroids (up to a specified dose)"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "History of lung disease other than asthma", "unit": "NA", "evidence_text": "History of lung disease other than asthma"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Use of inhaled corticosteroid above specified dose", "unit": "NA", "evidence_text": "Use of inhaled corticosteroid above specified dose"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Use of oral beta agonists or corticosteroids or other asthma medications", "unit": "NA", "evidence_text": "Use of oral beta agonists or corticosteroids or other asthma medications"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Hypersensitivity to the drug", "unit": "NA", "evidence_text": "Hypersensitivity to the drug"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Respiratory tract infections within 1 month of the study", "unit": "NA", "evidence_text": "Respiratory tract infections within 1 month of the study"}]}
{"nct_id": "NCT00791557", "eligibility_text": "Inclusion Criteria:\n\n* Must Be ages 18-75\n* Must have both inflammatory bowel disease and moderate to severe pyoderma gangrenosum\n* Must never have received Infliximab for the treatment of pyoderma gangrenosum\n\nExclusion Criteria:\n\n* Have had any previous treatment with monoclonal antibodies other than infliximab used to treat IBD or antibody fragments.\n* Have a history of serious infections", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "Must have both inflammatory bowel disease and moderate to severe pyoderma gangrenosum", "unit": "NA", "evidence_text": "Must have both inflammatory bowel disease and moderate to severe pyoderma gangrenosum"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Must never have received Infliximab for the treatment of pyoderma gangrenosum", "unit": "NA", "evidence_text": "Must never have received Infliximab for the treatment of pyoderma gangrenosum"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Have had any previous treatment with monoclonal antibodies other than infliximab used to treat IBD or antibody fragments.", "unit": "NA", "evidence_text": "Have had any previous treatment with monoclonal antibodies other than infliximab used to treat IBD or antibody fragments."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Have a history of serious infections", "unit": "NA", "evidence_text": "Have a history of serious infections"}]}
{"nct_id": "NCT00793403", "eligibility_text": "Inclusion Criteria:\n\n* Eighteen years of age or older with diagnosis of RA based on the 1987 American College of Rheumatology (ACR) criteria and in accordance with local guidelines.\n* Patients eligible to anti-TNF therapy\n* Patients naïve to anti-TNFa drugs\n* Patients with radiography (hands and feet) executed by 6 months before the baseline or at baseline according to modified Sharp Van der Hejde method \\[Sharp JT et al. 1985; Sharp JT. Et al. 1989; Van der Heijde DM et al. 1989\\] Patients capable of understanding and completing the questionnaire Patients capable of understanding and signing an informed consent form\n\nExclusion Criteria:\n\n* Patients with tumors\n* Patients already included in clinical trials", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "Eighteen years of age or older with diagnosis of RA based on the 1987 American College of Rheumatology (ACR) criteria and in accordance with local guidelines.", "unit": "NA", "evidence_text": "Eighteen years of age or older with diagnosis of RA based on the 1987 American College of Rheumatology (ACR) criteria and in accordance with local guidelines."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Patients eligible to anti-TNF therapy", "unit": "NA", "evidence_text": "Patients eligible to anti-TNF therapy"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Patients naïve to anti-TNFa drugs", "unit": "NA", "evidence_text": "Patients naïve to anti-TNFa drugs"}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "1989\\] Patients capable of understanding and completing the questionnaire Patients capable of understanding and signing an informed consent form", "unit": "NA", "evidence_text": "1989\\] Patients capable of understanding and completing the questionnaire Patients capable of understanding and signing an informed consent form"}]}
{"nct_id": "NCT00811486", "eligibility_text": "Inclusion Criteria:\n\n1\\. Patients with World Health Organization (WHO) group 1 pulmonary arterial hypertension \\[51\\], excluding patients with portal hypertension, meeting the following hemodynamic parameters:\n\n* Mean pulmonary artery pressure (mPAP) \\>35 mmHg at rest, and\n* Pulmonary capillary wedge pressure (PCWP) \\<15 mmHg, and\n* Pulmonary vascular resistance (PVR) \\>1.5 wood units, and 2. Age 18 to 75 years 3. Right ventricular failure defined by right atrial pressure \\>7 mmHg along with either dilated right ventricle, or absence of inferior vena cava collapse or BNP \\>100 pg/ml 4. Patients of childbearing age must be practicing effective birth control. 5. Normal left ventricular function as assessed by echocardiogram, multiple gated acquisition (MUGA) cardiac scan, or invasive left ventriculography.\n\nExclusion Criteria:\n\n1\\. Group 2-5 pulmonary hypertension as defined by WHO.\n\n* Pulmonary hypertension with left heart failure (as assessed by echocardiogram, multiple gated acquisition (MUGA) cardiac scan, or invasive left ventriculography).\n* Pulmonary hypertension associated with lung disease and/or hypoxemia (e.g. chronic obstructive pulmonary disease, interstitial lung disease, sleep disordered breathing, chronic exposure to high altitude, alveolar hypoventilation syndrome.\n* Pulmonary hypertension due to chronic thrombotic and/or embolic diseases\n* Miscellaneous such as sarcoidosis, compression of pulmonary vessels by adenopathy, tumor 2. Systemic hypertension, defined as a systolic pressure \\>140 mmHg or a diastolic blood pressure \\>90 mmHg 3. Patients taking angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blockers (ARBs) 4. Pregnancy 5. Chronic kidney disease (serum creatinine \\> 2.5mg/dl, proteinuria \\>500 mg/day, hematuria) 6. Cirrhosis or portal hypertension 7. Inability to provide informed consent. 8. Allergy to conivaptan or spironolactone. 9. Active malignancy 10. Patients receiving spironolactone 11. Enrollment in other interventional studies. 12. Patients on Highly Active Antiretroviral Therapy (HAART)", "labeled_rules": [{"type": "inclusion", "field": "age", "operator": "between", "value": "18-75", "unit": "years", "evidence_text": "Age 18 to 75 years 3."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Pulmonary hypertension with left heart failure (as assessed by echocardiogram, multiple gated acquisition (MUGA) cardiac scan, or invasive left ventriculography", "unit": "NA", "evidence_text": "Pulmonary hypertension with left heart failure (as assessed by echocardiogram, multiple gated acquisition (MUGA) cardiac scan, or invasive left ventriculography)."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Pulmonary hypertension associated with lung disease and/or hypoxemia (e.g.", "unit": "NA", "evidence_text": "Pulmonary hypertension associated with lung disease and/or hypoxemia (e.g."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "chronic obstructive pulmonary disease, interstitial lung disease, sleep disordered breathing, chronic exposure to high altitude, alveolar hypoventilation syndro", "unit": "NA", "evidence_text": "chronic obstructive pulmonary disease, interstitial lung disease, sleep disordered breathing, chronic exposure to high altitude, alveolar hypoventilation syndrome."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Pulmonary hypertension due to chronic thrombotic and/or embolic diseases", "unit": "NA", "evidence_text": "Pulmonary hypertension due to chronic thrombotic and/or embolic diseases"}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "140", "unit": "mmhg", "evidence_text": "Systemic hypertension, defined as a systolic pressure \\>140 mmHg or a diastolic blood pressure \\>90 mmHg 3."}, {"type": "exclusion", "field": "history", "operator": "!=", "value": "pregnant_or_breastfeeding", "unit": "NA", "evidence_text": "Pregnancy 5."}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "2.5", "unit": "mg/dl", "evidence_text": "Chronic kidney disease (serum creatinine \\> 2.5mg/dl, proteinuria \\>500 mg/day, hematuria) 6."}, {"type": "exclusion", "field": "other", "operator": "contains", "value": "Inability to provide informed consent.", "unit": "NA", "evidence_text": "Inability to provide informed consent."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Allergy to conivaptan or spironolactone.", "unit": "NA", "evidence_text": "Allergy to conivaptan or spironolactone."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Patients on Highly Active Antiretroviral Therapy (HAART)", "unit": "NA", "evidence_text": "Patients on Highly Active Antiretroviral Therapy (HAART)"}]}
{"nct_id": "NCT00811759", "eligibility_text": "DISEASE CHARACTERISTICS:\n\n* Diagnosis of unresectable or metastatic melanoma\n\n  * Stage III or IV disease\n* Previously treated or untreated metastatic disease\n* At least one unidimensionally measurable lesion by RECIST criteria by scan or MRI\n* No concurrent brain or CNS metastases\n\nPATIENT CHARACTERISTICS:\n\n* WHO performance status 0-1\n* Life expectancy ≥ 3 months\n* ANC ≥ 1,500/mm\\^3\n* Platelet count ≥ 100,000/mm\\^3\n* Hemoglobin \\> 9 g/dL\n* PT, INR, and PTT \\< 1.5 times upper limit of normal (ULN)\n* Transaminases \\< 2.5 times ULN (\\< 5 in the case of liver metastases)\n* Amylase and lipase \\< 1.5 times ULN\n* Bilirubin ≤ 1.5 times ULN\n* Serum creatinine \\< 1.5 times ULN\n* Normal respiratory, cardiac, and neurological function\n* Not pregnant or nursing\n* No history of any of the following cardiac conditions:\n\n  * NYHA class II-IV heart failure\n  * Coronary disease\n  * Myocardial infarction within the past 6 months\n  * Cardiac arrhythmia requiring treatment with something other than beta-blockers or digoxin\n  * Severe uncontrolled hypertension\n* No severe active infection \\> grade 2\n* No epilepsy requiring medical treatment\n* No other cancer except for carcinoma in situ of the cervix, basal cell carcinoma, superficial bladder tumors, or curatively treated cancer \\> 3 years ago\n* No HIV or hepatitis B or C positivity\n* No lactase or galactokinase deficiency, galactose intolerance, or disease accompanied by malabsorption of glucose or galactose\n* No allergy to the study drugs or to dacarbazine\n* Able to swallow medications\n* No patients deprived of liberty\n* No psychological, familial, social, or geographic conditions that would preclude clinical follow up\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No prior organ transplantation\n* No prior temozolomide or sorafenib tosylate\n* More than 30 days since other prior antitumor chemotherapy, immunotherapy, hormonal therapy, or investigational agent\n* More than 30 days since prior study drugs\n* More than 3 weeks since prior radiotherapy\n* More than 3 weeks since prior biological response modifiers (i.e., filgrastim \\[G-CSF\\])", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "DISEASE CHARACTERISTICS:", "unit": "NA", "evidence_text": "DISEASE CHARACTERISTICS:"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Diagnosis of unresectable or metastatic melanoma", "unit": "NA", "evidence_text": "Diagnosis of unresectable or metastatic melanoma"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Stage III or IV disease", "unit": "NA", "evidence_text": "Stage III or IV disease"}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "Previously treated or untreated metastatic disease", "unit": "NA", "evidence_text": "Previously treated or untreated metastatic disease"}, {"type": "inclusion", "field": "procedure", "operator": "contains", "value": "At least one unidimensionally measurable lesion by RECIST criteria by scan or MRI", "unit": "NA", "evidence_text": "At least one unidimensionally measurable lesion by RECIST criteria by scan or MRI"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "9", "unit": "g/dl", "evidence_text": "Hemoglobin \\> 9 g/dL"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "2.5", "unit": "times", "evidence_text": "Transaminases \\< 2.5 times ULN (\\< 5 in the case of liver metastases)"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "1.5", "unit": "times", "evidence_text": "Serum creatinine \\< 1.5 times ULN"}, {"type": "inclusion", "field": "history", "operator": "!=", "value": "pregnant_or_breastfeeding", "unit": "NA", "evidence_text": "Not pregnant or nursing"}, {"type": "inclusion", "field": "history", "operator": "not_contains", "value": "No history of any of the following cardiac conditions:", "unit": "NA", "evidence_text": "No history of any of the following cardiac conditions:"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "NYHA class II-IV heart failure", "unit": "NA", "evidence_text": "NYHA class II-IV heart failure"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Coronary disease", "unit": "NA", "evidence_text": "Coronary disease"}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "Myocardial infarction within the past 6 months", "unit": "NA", "evidence_text": "Myocardial infarction within the past 6 months"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Cardiac arrhythmia requiring treatment with something other than beta-blockers or digoxin", "unit": "NA", "evidence_text": "Cardiac arrhythmia requiring treatment with something other than beta-blockers or digoxin"}, {"type": "inclusion", "field": "history", "operator": "not_contains", "value": "No severe active infection \\> grade 2", "unit": "NA", "evidence_text": "No severe active infection \\> grade 2"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "No other cancer except for carcinoma in situ of the cervix, basal cell carcinoma, superficial bladder tumors, or curatively treated cancer \\> 3 years ago", "unit": "NA", "evidence_text": "No other cancer except for carcinoma in situ of the cervix, basal cell carcinoma, superficial bladder tumors, or curatively treated cancer \\> 3 years ago"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "No lactase or galactokinase deficiency, galactose intolerance, or disease accompanied by malabsorption of glucose or galactose", "unit": "NA", "evidence_text": "No lactase or galactokinase deficiency, galactose intolerance, or disease accompanied by malabsorption of glucose or galactose"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "No allergy to the study drugs or to dacarbazine", "unit": "NA", "evidence_text": "No allergy to the study drugs or to dacarbazine"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Able to swallow medications", "unit": "NA", "evidence_text": "Able to swallow medications"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "PRIOR CONCURRENT THERAPY:", "unit": "NA", "evidence_text": "PRIOR CONCURRENT THERAPY:"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "See Disease Characteristics", "unit": "NA", "evidence_text": "See Disease Characteristics"}, {"type": "inclusion", "field": "procedure", "operator": "not_contains", "value": "No prior organ transplantation", "unit": "NA", "evidence_text": "No prior organ transplantation"}, {"type": "inclusion", "field": "history", "operator": "not_contains", "value": "No prior temozolomide or sorafenib tosylate", "unit": "NA", "evidence_text": "No prior temozolomide or sorafenib tosylate"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "More than 30 days since other prior antitumor chemotherapy, immunotherapy, hormonal therapy, or investigational agent", "unit": "NA", "evidence_text": "More than 30 days since other prior antitumor chemotherapy, immunotherapy, hormonal therapy, or investigational agent"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "More than 30 days since prior study drugs", "unit": "NA", "evidence_text": "More than 30 days since prior study drugs"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "More than 3 weeks since prior radiotherapy", "unit": "NA", "evidence_text": "More than 3 weeks since prior radiotherapy"}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "More than 3 weeks since prior biological response modifiers (i.e., filgrastim \\[G-CSF\\])", "unit": "NA", "evidence_text": "More than 3 weeks since prior biological response modifiers (i.e., filgrastim \\[G-CSF\\])"}]}
{"nct_id": "NCT00843024", "eligibility_text": "Inclusion Criteria: Subjects eligible for enrollment in the study must meet all of the following criteria:\n\n1. Subject is \\>/=12 years of age and \\</=17 years of age at the Screening Visit.\n2. Subject has migraine with or without aura (ICHD-II criteria, 1.2.1 or 1.1). A history of at least two, but no more than eight attacks per month, for the six months prior to the Screening Visit is required. Attacks should last a minimum of three hours and be associated with moderate-to-severe headache pain.\n3. Subject is able to distinguish migraine from other headaches (i.e., tension-type headaches).\n4. Male or female subjects. Female subjects are eligible for participation in the study if they are:\n\n   1. Females of non-childbearing potential; or\n   2. Females of childbearing potential, and who have a negative urine pregnancy test at screening, and agree to use one of the GlaxoSmithKline (GSK)-specified highly effective methods for avoiding pregnancy\n5. Any subject taking oral contraceptives at enrollment must be on a stable regimen for at least 2 months prior to screening.\n6. Subject and subject's parent or legal guardian are able to read and write English or Spanish.\n7. Subject is able to read, comprehend, and complete subject diaries.\n8. Subject's parent or legal guardian is willing and able to provide Informed Consent prior to subject entry into the study.\n9. Subject is willing and able to provide Informed Assent prior to entry into the study (if required).\n\n   \\-\n\nExclusion Criteria:\n\n* Subjects meeting any of the following criteria must not be enrolled in the study:\n\n  1. Subject is \\< 74 pounds (33.3 kg).\n  2. Subject has ≥15 headache days per month in total (migraine, probable migraine, or tension-type), retinal (ICHD-II 1.4), basilar (ICHD-II 1.2.6), or hemiplegic migraine (ICHD-II 1.2.4), or secondary headaches.\n  3. Subject, in the investigator's opinion is likely to have unrecognized cardiovascular or cerebrovascular disease.\n  4. Subject has uncontrolled hypertension at screening or is taking any angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker.\n  5. Subject has a history of congenital heart disease, cardiac arrhythmias requiring medication, or a history of a clinically significant electrocardiogram abnormality that, in the investigator's opinion, contraindicates participation in this study.\n  6. Subject has evidence or history of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease, or signs/symptoms consistent with any of the above.\n  7. Subject has evidence or history of central nervous system pathology including stroke and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesions which lower the convulsive threshold, or has been treated with an antiepileptic drug for seizure control within 5 years prior to screening.\n  8. Subject has a history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study.\n  9. Subject has hypersensitivity, allergy, intolerance, or contraindication to the use of any triptan, NSAID, or aspirin (including all sumatriptan and naproxen preparations) or has nasal polyps and asthma.\n  10. Subject has used an ergot medication in the previous three months for migraine prophylaxis or is taking a medication that is not stabilized (i.e., change of dose within the past 2 months) for either chronic or intermittent migraine prophylaxis or for a co-morbid condition that is not stabilized.\n  11. Subject has a recent history of regular use of opioids or barbiturates for treatment of their migraine headache and/or other non-migraine pain. Regular use is defined as an average of 4 days per month over the last 6 months.\n  12. Subject has taken, or plans to take, a monoamine oxidase inhibitor (MAOI), including herbal preparations containing St. John's Wort (Hypericum perforatum), anytime within the two weeks prior to screening through two weeks post treatment.\n  13. Subject has a history of any bleeding disorder or is currently taking any anti-coagulant or any antiplatelet agent.\n  14. Subject has evidence or history of any gastrointestinal surgery, GI ulceration, or perforation in the past six months, gastrointestinal bleeding in the past year, or evidence or history of inflammatory bowel disease.\n  15. Subject is pregnant, actively trying to become pregnant, or breast feeding or subject is not willing to have pregnancy test(s).\n  16. Subject tests positive for illicit substances on toxicology screen, or has evidence of alcohol or substance abuse within the last year, or any concurrent medical or psychiatric condition which, in the investigator's judgment, will likely interfere with the study conduct, subject cooperation, or evaluation and interpretation of the study results, or which otherwise contraindicates participation in this clinical trial.\n  17. Subject has participated in any investigational drug trial within the previous 4 weeks or plans to participate in another study at any time during this study.", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "Subject has migraine with or without aura (ICHD-II criteria, 1.2.1 or 1.1).", "unit": "NA", "evidence_text": "Subject has migraine with or without aura (ICHD-II criteria, 1.2.1 or 1.1)."}, {"type": "inclusion", "field": "history", "operator": "not_contains", "value": "A history of at least two, but no more than eight attacks per month, for the six months prior to the Screening Visit is required.", "unit": "NA", "evidence_text": "A history of at least two, but no more than eight attacks per month, for the six months prior to the Screening Visit is required."}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Subject is able to distinguish migraine from other headaches (i.e., tension-type headaches).", "unit": "NA", "evidence_text": "Subject is able to distinguish migraine from other headaches (i.e., tension-type headaches)."}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Females of non-childbearing potential; or"}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Females of childbearing potential, and who have a negative urine pregnancy test at screening, and agree to use one of the GlaxoSmithKline (GSK)-specified highly effective methods for avoiding pregnancy"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Any subject taking oral contraceptives at enrollment must be on a stable regimen for at least 2 months prior to screening.", "unit": "NA", "evidence_text": "Any subject taking oral contraceptives at enrollment must be on a stable regimen for at least 2 months prior to screening."}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "Subject's parent or legal guardian is willing and able to provide Informed Consent prior to subject entry into the study.", "unit": "NA", "evidence_text": "Subject's parent or legal guardian is willing and able to provide Informed Consent prior to subject entry into the study."}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "Subject is willing and able to provide Informed Assent prior to entry into the study (if required).", "unit": "NA", "evidence_text": "Subject is willing and able to provide Informed Assent prior to entry into the study (if required)."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Subject has ≥15 headache days per month in total (migraine, probable migraine, or tension-type), retinal (ICHD-II 1.4), basilar (ICHD-II 1.2.6), or hemiplegic m", "unit": "NA", "evidence_text": "Subject has ≥15 headache days per month in total (migraine, probable migraine, or tension-type), retinal (ICHD-II 1.4), basilar (ICHD-II 1.2.6), or hemiplegic migraine (ICHD-II 1.2.4), or secondary headaches."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Subject, in the investigator's opinion is likely to have unrecognized cardiovascular or cerebrovascular disease.", "unit": "NA", "evidence_text": "Subject, in the investigator's opinion is likely to have unrecognized cardiovascular or cerebrovascular disease."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Subject has a history of congenital heart disease, cardiac arrhythmias requiring medication, or a history of a clinically significant electrocardiogram abnormal", "unit": "NA", "evidence_text": "Subject has a history of congenital heart disease, cardiac arrhythmias requiring medication, or a history of a clinically significant electrocardiogram abnormality that, in the investigator's opinion, contraindicates participation in this study."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Subject has evidence or history of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease, ", "unit": "NA", "evidence_text": "Subject has evidence or history of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease, or signs/symptoms consistent with any of the above."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Subject has evidence or history of central nervous system pathology including stroke and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesi", "unit": "NA", "evidence_text": "Subject has evidence or history of central nervous system pathology including stroke and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesions which lower the convulsive threshold, or has been treated with an antiepileptic drug for seizure control within 5 years prior to screening."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Subject has a history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study.", "unit": "NA", "evidence_text": "Subject has a history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Subject has hypersensitivity, allergy, intolerance, or contraindication to the use of any triptan, NSAID, or aspirin (including all sumatriptan and naproxen pre", "unit": "NA", "evidence_text": "Subject has hypersensitivity, allergy, intolerance, or contraindication to the use of any triptan, NSAID, or aspirin (including all sumatriptan and naproxen preparations) or has nasal polyps and asthma."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Subject has used an ergot medication in the previous three months for migraine prophylaxis or is taking a medication that is not stabilized (i.e., change of dos", "unit": "NA", "evidence_text": "Subject has used an ergot medication in the previous three months for migraine prophylaxis or is taking a medication that is not stabilized (i.e., change of dose within the past 2 months) for either chronic or intermittent migraine prophylaxis or for a co-morbid condition that is not stabilized."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Subject has a recent history of regular use of opioids or barbiturates for treatment of their migraine headache and/or other non-migraine pain.", "unit": "NA", "evidence_text": "Subject has a recent history of regular use of opioids or barbiturates for treatment of their migraine headache and/or other non-migraine pain."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "John's Wort (Hypericum perforatum), anytime within the two weeks prior to screening through two weeks post treatment.", "unit": "NA", "evidence_text": "John's Wort (Hypericum perforatum), anytime within the two weeks prior to screening through two weeks post treatment."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Subject has a history of any bleeding disorder or is currently taking any anti-coagulant or any antiplatelet agent.", "unit": "NA", "evidence_text": "Subject has a history of any bleeding disorder or is currently taking any anti-coagulant or any antiplatelet agent."}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Subject has evidence or history of any gastrointestinal surgery, GI ulceration, or perforation in the past six months, gastrointestinal bleeding in the past yea", "unit": "NA", "evidence_text": "Subject has evidence or history of any gastrointestinal surgery, GI ulceration, or perforation in the past six months, gastrointestinal bleeding in the past year, or evidence or history of inflammatory bowel disease."}, {"type": "exclusion", "field": "lab", "operator": "required", "value": "pregnancy test", "unit": "NA", "evidence_text": "Subject is pregnant, actively trying to become pregnant, or breast feeding or subject is not willing to have pregnancy test(s)."}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Subject tests positive for illicit substances on toxicology screen, or has evidence of alcohol or substance abuse within the last year, or any concurrent medica", "unit": "NA", "evidence_text": "Subject tests positive for illicit substances on toxicology screen, or has evidence of alcohol or substance abuse within the last year, or any concurrent medical or psychiatric condition which, in the investigator's judgment, will likely interfere with the study conduct, subject cooperation, or evaluation and interpretation of the study results, or which otherwise contraindicates participation in this clinical trial."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Subject has participated in any investigational drug trial within the previous 4 weeks or plans to participate in another study at any time during this study.", "unit": "NA", "evidence_text": "Subject has participated in any investigational drug trial within the previous 4 weeks or plans to participate in another study at any time during this study."}]}
{"nct_id": "NCT00843154", "eligibility_text": "Inclusion Criteria:\n\n* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.\n* Stable, symptomatic New York Heart Association II-IV Chronic Heart Failure with Left Ventricular Ejection Fraction less than or greater than or greater than or equal to 40% treated with standard therapy including Angiotensin Converting Enzyme-inhibitors and/or beta-blockers. Patients with Left Ventricular Ejection Fraction greater than or equal to 40% had to be hospitalized for cardiovascular events during the past 12 months.\n\nExclusion Criteria:\n\n* History of prior treatment with Angiotensin-Receptor Blockers within two weeks from first.\n* Severe or malignant hypertension (Systolic Blood Pressure / Diastolic Blood Pressure greater than 180/110 mmHg).\n* Symptomatic hypotension.\n* Acute myocardial infarction within one month from first visit.\n* Stroke or transient ischemic attack within one month from first visit.\n* Percutaneous transluminal coronary angioplasty or coronary artery by-pass graft within one month from first visit.\n* Hemodynamically relevant arrhythmias.\n* Implant of pacemakers, cardiac resynchronization therapy or cardioverters within 6 months prior the randomization.\n* Hemodynamically relevant cardiac valvular defect.\n* Constrictive pericarditis or active myocarditis.\n* Likelihood of cardiac surgical intervention (of any type) during the overall treatment period.\n* Evidence of angina pectoris in the previous month.\n* Poorly controlled diabetes mellitus (glycemia greater than 140mg/mL or glycosylated hemoglobin greater than 8% obtained within three months from the study initiation).\n* Untreated thyroid dysfunction.\n* Renal artery stenosis.\n* Angioedema of any etiology.\n* Significant liver (aspartate aminotransferase, alanine aminotransferase, total bilirubin or alkaline phosphatase greater than twice the upper limit of normal range) or renal (serum creatinine greater than 2.0 mg/dL or serum potassium greater than 5.0 mmol/L) impairment.\n* Anemia of any etiology (defined as hemoglobin levels less than 10.5 g/dL) or any other clinically relevant hematological disease.\n* Any disease with malabsorption.\n* Presence of any non-cardiac (e.g. cancer) disease that is likely to significantly (i.e. below 1 year from randomization) shorten life expectancy.\n* History of chronic alcohol or drug/substance abuse, or presence of other conditions potentially able to affect study subjects' compliance.\n* Known allergy, sensitivity or intolerance to study drugs and/or study drugs' formulation ingredients.\n* Participation in another trial in the month preceding study entry.", "labeled_rules": [{"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study."}, {"type": "inclusion", "field": "lab", "operator": ">=", "value": "40", "unit": "%", "evidence_text": "Stable, symptomatic New York Heart Association II-IV Chronic Heart Failure with Left Ventricular Ejection Fraction less than or greater than or greater than or equal to 40% treated with standard therapy including Angiotensin Converting Enzyme-inhibitors and/or beta-blockers."}, {"type": "inclusion", "field": "lab", "operator": ">=", "value": "40", "unit": "%", "evidence_text": "Patients with Left Ventricular Ejection Fraction greater than or equal to 40% had to be hospitalized for cardiovascular events during the past 12 months."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "History of prior treatment with Angiotensin-Receptor Blockers within two weeks from first.", "unit": "NA", "evidence_text": "History of prior treatment with Angiotensin-Receptor Blockers within two weeks from first."}, {"type": "exclusion", "field": "lab", "operator": ">", "value": "180", "unit": "/110", "evidence_text": "Severe or malignant hypertension (Systolic Blood Pressure / Diastolic Blood Pressure greater than 180/110 mmHg)."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Acute myocardial infarction within one month from first visit.", "unit": "NA", "evidence_text": "Acute myocardial infarction within one month from first visit."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Stroke or transient ischemic attack within one month from first visit.", "unit": "NA", "evidence_text": "Stroke or transient ischemic attack within one month from first visit."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Percutaneous transluminal coronary angioplasty or coronary artery by-pass graft within one month from first visit.", "unit": "NA", "evidence_text": "Percutaneous transluminal coronary angioplasty or coronary artery by-pass graft within one month from first visit."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Implant of pacemakers, cardiac resynchronization therapy or cardioverters within 6 months prior the randomization.", "unit": "NA", "evidence_text": "Implant of pacemakers, cardiac resynchronization therapy or cardioverters within 6 months prior the randomization."}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Likelihood of cardiac surgical intervention (of any type) during the overall treatment period.", "unit": "NA", "evidence_text": "Likelihood of cardiac surgical intervention (of any type) during the overall treatment period."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Evidence of angina pectoris in the previous month.", "unit": "NA", "evidence_text": "Evidence of angina pectoris in the previous month."}, {"type": "exclusion", "field": "lab", "operator": ">", "value": "140", "unit": "mg/ml", "evidence_text": "Poorly controlled diabetes mellitus (glycemia greater than 140mg/mL or glycosylated hemoglobin greater than 8% obtained within three months from the study initiation)."}, {"type": "exclusion", "field": "lab", "operator": ">", "value": "2.0", "unit": "mg/dl", "evidence_text": "Significant liver (aspartate aminotransferase, alanine aminotransferase, total bilirubin or alkaline phosphatase greater than twice the upper limit of normal range) or renal (serum creatinine greater than 2.0 mg/dL or serum potassium greater than 5.0 mmol/L) impairment."}, {"type": "exclusion", "field": "lab", "operator": "<", "value": "10.5", "unit": "g/dl", "evidence_text": "Anemia of any etiology (defined as hemoglobin levels less than 10.5 g/dL) or any other clinically relevant hematological disease."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Any disease with malabsorption.", "unit": "NA", "evidence_text": "Any disease with malabsorption."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Presence of any non-cardiac (e.g. cancer) disease that is likely to significantly (i.e. below 1 year from randomization) shorten life expectancy.", "unit": "NA", "evidence_text": "Presence of any non-cardiac (e.g. cancer) disease that is likely to significantly (i.e. below 1 year from randomization) shorten life expectancy."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "History of chronic alcohol or drug/substance abuse, or presence of other conditions potentially able to affect study subjects' compliance.", "unit": "NA", "evidence_text": "History of chronic alcohol or drug/substance abuse, or presence of other conditions potentially able to affect study subjects' compliance."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Known allergy, sensitivity or intolerance to study drugs and/or study drugs' formulation ingredients.", "unit": "NA", "evidence_text": "Known allergy, sensitivity or intolerance to study drugs and/or study drugs' formulation ingredients."}]}
{"nct_id": "NCT00843388", "eligibility_text": "Inclusion Criteria:\n\n* type 1 diabetes\n* age 18-80 years\n* microalbuminuria\n\nExclusion Criteria:\n\n* blood pressure\\> 160/100 mmHg\n* persistent macroalbuminuria\n* pregnancy or in risc of this\n* P-Potassium\\>5.7 mmol/l\n* Eplerone treatment", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "type 1 diabetes", "unit": "NA", "evidence_text": "type 1 diabetes"}, {"type": "inclusion", "field": "age", "operator": "between", "value": "18-80", "unit": "years", "evidence_text": "age 18-80 years"}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "160", "unit": "/100", "evidence_text": "blood pressure\\> 160/100 mmHg"}, {"type": "exclusion", "field": "history", "operator": "!=", "value": "pregnant_or_breastfeeding", "unit": "NA", "evidence_text": "pregnancy or in risc of this"}]}
{"nct_id": "NCT00861705", "eligibility_text": "Inclusion Criteria:\n\n* Invasive breast cancer, diagnosed by core needle or incisional biopsy (excisional biopsy not permitted)\n* The invasive tumor must be hormone receptor-poor, defined as both estrogen receptor (ER) and progesterone receptor (PgR) negative or staining present in =\\< 10% of invasive cancer cells by immunohistochemistry (IHC)\n* The invasive tumor must be HER2-negative, defined as IHC 0-1+ or with a fluorescent in situ hybridization (FISH) ratio (HER2 gene copy/chromosome 17) of \\< 2.0 if IHC 2+\n* Clinical stage II-III invasive breast cancer with intent to perform surgical resection after neoadjuvant therapy; patients with inflammatory breast cancer are not eligible; staging to rule out metastatic disease is recommended for clinical stage III patients\n* Patients with multicentric or bilateral disease are eligible if the target lesion meets eligibility criteria\n* Patient agrees to undergo pretreatment research biopsies\n* No prior chemotherapy, hormone therapy, or radiation therapy with therapeutic intent for this cancer\n* The target lesion in the breast must be \\>= 1 cm, clinically or radiographically; palpable or radiographically measurable axillary adenopathy will be recorded but will not serve as measurable disease for the primary endpoint; patients with axillary disease only (no identifiable tumor in the breast that is \\>= 1 cm on physical exam or radiographic study) are not eligible to participate\n* Patients with a history of significant bleeding episodes (e.g., hemoptysis, upper or lower gastrointestinal \\[GI\\] bleeding) within 6 months of registration are not eligible\n* No serious or non-healing wound, skin ulcers or bone fracture; no abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within the past 6 months; no major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during the course of study\n* The following are not considered to be major surgical procedures that would be prohibited in the 28 days prior to, or following study randomization: obtaining the required research needle biopsies; placement of a radiopaque clip to localize a tumor or tumors for subsequent surgical resection; placement of a port for central venous access; fine needle aspiration of a prominent or suspicious axillary lymph node; needle biopsy of a clinically or radiographically detected lesion to rule out metastatic disease; or pretreatment sentinel lymph node sampling\n* No baseline neuropathy grade \\>= 2\n* Zubrod performance status 0-1\n* Pregnant or nursing women are not eligible; all women of reproductive potential must have a negative pregnancy test at baseline and agree to use an effective, non-hormonal method of contraception during the entire period of treatment on the study\n* Patients with congestive heart failure are not eligible, nor are patients with myocardial infarction, unstable angina pectoris, an arterial thrombotic event, stroke or transient ischemia attack (TIA) within the past 12 months, uncontrolled hypertension (systolic blood pressure \\[SBP\\] \\> 160 or diastolic blood pressure \\[DBP\\] \\> 90), uncontrolled or symptomatic arrhythmia, or grade II or greater peripheral vascular disease\n* Patients must have a pretreatment multi gated acquisition (MUGA) scan or echocardiogram with a left ventricular ejection fraction (LVEF) above the institutional lower limit of normal\n* Granulocytes \\> 1,000/mcl\n* Platelets \\> 100,000/mcl\n* Total bilirubin =\\< 1.5 x upper limits of normal\n* Calculated or measured \\> 30 ml/min\n* Urine protein =\\< 1+ or urine protein to creatinine (UPC) ratio \\< 1\n\n  * Patients discovered to have \\>= 2+ proteinuria at baseline must undergo a 24-hour urine collection that must demonstrate \\< 1 g of protein/24 hr, or UPC ratio \\< 1 to allow participation in the study\n* Serum alanine aminotransferase (ALT) =\\< 2.5 x upper limits of normal\n* Serum beta human chorionic gonadotropin (HCG) negative (for women of child bearing potential)\n* Prothrombin time (PT)/international normalized ratio (INR) =\\< 1.5 x upper limit of normal (ULN)\n\n  * Unless patient is on therapeutic doses of warfarin; if so, the patient must have an INR =\\< 3 on a stable dose of warfarin, must have not active bleeding or pathologic condition that is associated with a high risk of bleeding", "labeled_rules": [{"type": "inclusion", "field": "procedure", "operator": "not_contains", "value": "Invasive breast cancer, diagnosed by core needle or incisional biopsy (excisional biopsy not permitted)", "unit": "NA", "evidence_text": "Invasive breast cancer, diagnosed by core needle or incisional biopsy (excisional biopsy not permitted)"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "The invasive tumor must be hormone receptor-poor, defined as both estrogen receptor (ER) and progesterone receptor (PgR) negative or staining present in =\\< 10%", "unit": "NA", "evidence_text": "The invasive tumor must be hormone receptor-poor, defined as both estrogen receptor (ER) and progesterone receptor (PgR) negative or staining present in =\\< 10% of invasive cancer cells by immunohistochemistry (IHC)"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Clinical stage II-III invasive breast cancer with intent to perform surgical resection after neoadjuvant therapy;", "unit": "NA", "evidence_text": "Clinical stage II-III invasive breast cancer with intent to perform surgical resection after neoadjuvant therapy;"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "patients with inflammatory breast cancer are not eligible;", "unit": "NA", "evidence_text": "patients with inflammatory breast cancer are not eligible;"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "staging to rule out metastatic disease is recommended for clinical stage III patients", "unit": "NA", "evidence_text": "staging to rule out metastatic disease is recommended for clinical stage III patients"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Patients with multicentric or bilateral disease are eligible if the target lesion meets eligibility criteria", "unit": "NA", "evidence_text": "Patients with multicentric or bilateral disease are eligible if the target lesion meets eligibility criteria"}, {"type": "inclusion", "field": "medication", "operator": "not_contains", "value": "No prior chemotherapy, hormone therapy, or radiation therapy with therapeutic intent for this cancer", "unit": "NA", "evidence_text": "No prior chemotherapy, hormone therapy, or radiation therapy with therapeutic intent for this cancer"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "1", "unit": "cm", "evidence_text": "The target lesion in the breast must be \\>= 1 cm, clinically or radiographically;"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "palpable or radiographically measurable axillary adenopathy will be recorded but will not serve as measurable disease for the primary endpoint;", "unit": "NA", "evidence_text": "palpable or radiographically measurable axillary adenopathy will be recorded but will not serve as measurable disease for the primary endpoint;"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "1", "unit": "cm", "evidence_text": "patients with axillary disease only (no identifiable tumor in the breast that is \\>= 1 cm on physical exam or radiographic study) are not eligible to participate"}, {"type": "inclusion", "field": "history", "operator": "not_contains", "value": "Patients with a history of significant bleeding episodes (e.g., hemoptysis, upper or lower gastrointestinal \\[GI\\] bleeding) within 6 months of registration are", "unit": "NA", "evidence_text": "Patients with a history of significant bleeding episodes (e.g., hemoptysis, upper or lower gastrointestinal \\[GI\\] bleeding) within 6 months of registration are not eligible"}, {"type": "inclusion", "field": "history", "operator": "not_contains", "value": "no abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within the past 6 months;", "unit": "NA", "evidence_text": "no abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within the past 6 months;"}, {"type": "inclusion", "field": "procedure", "operator": "not_contains", "value": "no major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during the course of study", "unit": "NA", "evidence_text": "no major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during the course of study"}, {"type": "inclusion", "field": "procedure", "operator": "not_contains", "value": "The following are not considered to be major surgical procedures that would be prohibited in the 28 days prior to, or following study randomization: obtaining t", "unit": "NA", "evidence_text": "The following are not considered to be major surgical procedures that would be prohibited in the 28 days prior to, or following study randomization: obtaining the required research needle biopsies;"}, {"type": "inclusion", "field": "procedure", "operator": "contains", "value": "placement of a radiopaque clip to localize a tumor or tumors for subsequent surgical resection;", "unit": "NA", "evidence_text": "placement of a radiopaque clip to localize a tumor or tumors for subsequent surgical resection;"}, {"type": "inclusion", "field": "procedure", "operator": "contains", "value": "needle biopsy of a clinically or radiographically detected lesion to rule out metastatic disease;", "unit": "NA", "evidence_text": "needle biopsy of a clinically or radiographically detected lesion to rule out metastatic disease;"}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Pregnant or nursing women are not eligible;"}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "all women of reproductive potential must have a negative pregnancy test at baseline and agree to use an effective, non-hormonal method of contraception during the entire period of treatment on the study"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "160", "unit": "or", "evidence_text": "Patients with congestive heart failure are not eligible, nor are patients with myocardial infarction, unstable angina pectoris, an arterial thrombotic event, stroke or transient ischemia attack (TIA) within the past 12 months, uncontrolled hypertension (systolic blood pressure \\[SBP\\] \\> 160 or diastolic blood pressure \\[DBP\\] \\> 90), uncontrolled or symptomatic arrhythmia, or grade II or greater peripheral vascular disease"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "100", "unit": "NA", "evidence_text": "Platelets \\> 100,000/mcl"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "1.5", "unit": "x", "evidence_text": "Total bilirubin =\\< 1.5 x upper limits of normal"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "1", "unit": "NA", "evidence_text": "Urine protein =\\< 1+ or urine protein to creatinine (UPC) ratio \\< 1"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "2.5", "unit": "x", "evidence_text": "Serum alanine aminotransferase (ALT) =\\< 2.5 x upper limits of normal"}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Serum beta human chorionic gonadotropin (HCG) negative (for women of child bearing potential)"}]}
{"nct_id": "NCT00872794", "eligibility_text": "Inclusion Criteria:\n\ni) Male or female subjects, aged between 18 and 65 years inclusive.\n\nii) Subjects with current indications for standard MoM hip resurfacing arthroplasty suitable for cementless fixation in the acetabulum. These include pain, deformity, and loss of function, which are not responsive to medical treatment.\n\niii) Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained.\n\niv) Subjects, who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.\n\nExclusion Criteria:\n\ni) Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study.\n\nii) Subjects with proven significant osteoporosis and poor bone quality.\n\niii) Subjects with compromised renal function.\n\niv) Subjects with proven metal sensitivity.\n\nv) Subjects with infectious, highly communicable diseases, which may limit follow-up i.e. Active tuberculosis, hepatitis, immuno-compromised conditions, etc.\n\nvi) Women who are pregnant.\n\nvii) Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.\n\nviii) Subjects who have participated in a clinical study with an investigational product in the last 6 month(s).\n\nix) Subjects who are currently, or have been in the last 12 months, participating in a clinical study which involves exposure to ionising radiation.\n\nx) Subjects who are currently involved in any injury litigation claims.\n\nAdditional Exclusion Criteria for Subjects Undergoing Blood Analysis\n\n1. Subjects who currently have other metallic foreign bodies including trauma products and joint arthroplasties unless known to be pure titanium, titanium alloy.\n2. Subjects who, in the opinion of the investigator, will possibly require a separate joint replacement operation within the next two years, including revision operations", "labeled_rules": [{"type": "inclusion", "field": "age", "operator": "between", "value": "18-65", "unit": "years", "evidence_text": "i) Male or female subjects, aged between 18 and 65 years inclusive."}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "iii) Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained.", "unit": "NA", "evidence_text": "iii) Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained."}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "iv) Subjects, who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing", "unit": "NA", "evidence_text": "iv) Subjects, who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "v) Subjects with infectious, highly communicable diseases, which may limit follow-up i.e. Active tuberculosis, hepatitis, immuno-compromised conditions, etc.", "unit": "NA", "evidence_text": "v) Subjects with infectious, highly communicable diseases, which may limit follow-up i.e. Active tuberculosis, hepatitis, immuno-compromised conditions, etc."}, {"type": "exclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "vi) Women who are pregnant."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "vii) Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.", "unit": "NA", "evidence_text": "vii) Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes."}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "ix) Subjects who are currently, or have been in the last 12 months, participating in a clinical study which involves exposure to ionising radiation.", "unit": "NA", "evidence_text": "ix) Subjects who are currently, or have been in the last 12 months, participating in a clinical study which involves exposure to ionising radiation."}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Subjects who, in the opinion of the investigator, will possibly require a separate joint replacement operation within the next two years, including revision ope", "unit": "NA", "evidence_text": "Subjects who, in the opinion of the investigator, will possibly require a separate joint replacement operation within the next two years, including revision operations"}]}
{"nct_id": "NCT00877318", "eligibility_text": "Inclusion Criteria:\n\n* Patient with a dysfunction of left ventricle with ejection fraction of left ventricle \\< 40 % appreciated by echocardiogram at hospital discharge for cardiac rehabilitation.\n\nExclusion Criteria:\n\n* Patient non authorized to follow an effort training\n* Therapeutic education impossible\n* Pregnant woman or breast-feeding\n* No assent\n* Incapacity to use the terminal\n* Minor patient or under supervision", "labeled_rules": [{"type": "inclusion", "field": "lab", "operator": "contains", "value": "40", "unit": "%", "evidence_text": "Patient with a dysfunction of left ventricle with ejection fraction of left ventricle \\< 40 % appreciated by echocardiogram at hospital discharge for cardiac rehabilitation."}, {"type": "exclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Pregnant woman or breast-feeding"}]}
{"nct_id": "NCT00878527", "eligibility_text": "Inclusion Criteria:\n\n* Maximum tolerable medical therapy including ACE inhibitors and Beta Blockers\n* NYHA Class III or IV despite maximal tolerable medical therapy\n* Ambulatory (inpatient or outpatient)\n* Patients on the heart transplant list (or, not currently listed but otherwise suitable for heart transplant)\n* Life expectancy of at least 6 months without full VAD support\n\nExclusion Criteria:\n\n* Age \\>75 years\n* Exercise tolerance limited by factors other than heart failure\n* Presence of intra-atrial thrombus\n* Clinically significant right heart failure\n* Serum creatinine \\>/= 2.5 mg/dl or any dialysis in previous 3 months\n* Evidence of intrinsic hepatic disease\n* Previous episode of resuscitated sudden death without subsequent treatment with AICD\n* Subclavian artery stenosis\n* Low platelet count, INR that cannot be corrected prior to implant or contraindication to anticoagulation", "labeled_rules": [{"type": "inclusion", "field": "medication", "operator": "contains", "value": "Maximum tolerable medical therapy including ACE inhibitors and Beta Blockers", "unit": "NA", "evidence_text": "Maximum tolerable medical therapy including ACE inhibitors and Beta Blockers"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "NYHA Class III or IV despite maximal tolerable medical therapy", "unit": "NA", "evidence_text": "NYHA Class III or IV despite maximal tolerable medical therapy"}, {"type": "inclusion", "field": "procedure", "operator": "not_contains", "value": "Patients on the heart transplant list (or, not currently listed but otherwise suitable for heart transplant)", "unit": "NA", "evidence_text": "Patients on the heart transplant list (or, not currently listed but otherwise suitable for heart transplant)"}, {"type": "exclusion", "field": "age", "operator": ">", "value": "75", "unit": "years", "evidence_text": "Age \\>75 years"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Exercise tolerance limited by factors other than heart failure", "unit": "NA", "evidence_text": "Exercise tolerance limited by factors other than heart failure"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Clinically significant right heart failure", "unit": "NA", "evidence_text": "Clinically significant right heart failure"}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Serum creatinine \\>/= 2.5 mg/dl or any dialysis in previous 3 months", "unit": "NA", "evidence_text": "Serum creatinine \\>/= 2.5 mg/dl or any dialysis in previous 3 months"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Evidence of intrinsic hepatic disease", "unit": "NA", "evidence_text": "Evidence of intrinsic hepatic disease"}, {"type": "exclusion", "field": "medication", "operator": "not_contains", "value": "Previous episode of resuscitated sudden death without subsequent treatment with AICD", "unit": "NA", "evidence_text": "Previous episode of resuscitated sudden death without subsequent treatment with AICD"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Low platelet count, INR that cannot be corrected prior to implant or contraindication to anticoagulation", "unit": "NA", "evidence_text": "Low platelet count, INR that cannot be corrected prior to implant or contraindication to anticoagulation"}]}
{"nct_id": "NCT00889161", "eligibility_text": "Inclusion Criteria:\n\n* Children and adolescents eight to eighteen years old\n* Diagnosis of inflammatory bowel disease (IBD) made by a pediatric gastroenterologist based upon history, physical examination, laboratory/radiological studies and gastrointestinal histology\n* Mild disease or in clinical remission based upon PUCAI or PCDAI score (score \\<34 on the PUCAI or score \\<30 on the PCDAI)\n* Parent/guardian and participant must be able to attend study visits at screening, baseline, and weeks three, six, and nine\n* Patient must be on a stable dose of IBD medications for at least 3 months\n* Patient must be able to swallow study medication\n\nExclusion Criteria:\n\n* Abnormal laboratory values as defined in the protocol\n* History of increased gastrointestinal symptoms (\"flare\") in the last 3 months\n* Current use (past use of these medications is not an exclusion) of medications such as azathioprine, methotrexate or 6-mercaptopurine used to treat IBD\n* Current use (past use of these medications is not an exclusion) of medications or over-the-counter treatments including but not limited to aspirin, NSAID, botanical treatments (ginger, feverfew, yellow clover, Salix species, Populus species, Betula species, and Gaultheria species), essential fatty acids (flax oil and fish oil). Allowed supplementation includes multivitamin, vitamin D \\& calcium, folate and vitamin B12, and Iron.\n* Other serious medical conditions such as neurological, liver, kidney, auto- immune or systemic disease.\n* History of gastrointestinal surgery or planned gastrointestinal surgery in the future.\n* Tobacco, alcohol, or illicit drug abuse\n* Planned surgery during the potential study participation time\n* Inability to swallow study medication", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "Diagnosis of inflammatory bowel disease (IBD) made by a pediatric gastroenterologist based upon history, physical examination, laboratory/radiological studies a", "unit": "NA", "evidence_text": "Diagnosis of inflammatory bowel disease (IBD) made by a pediatric gastroenterologist based upon history, physical examination, laboratory/radiological studies and gastrointestinal histology"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "34", "unit": "on", "evidence_text": "Mild disease or in clinical remission based upon PUCAI or PCDAI score (score \\<34 on the PUCAI or score \\<30 on the PCDAI)"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Patient must be on a stable dose of IBD medications for at least 3 months", "unit": "NA", "evidence_text": "Patient must be on a stable dose of IBD medications for at least 3 months"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Patient must be able to swallow study medication", "unit": "NA", "evidence_text": "Patient must be able to swallow study medication"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "History of increased gastrointestinal symptoms (\"flare\") in the last 3 months", "unit": "NA", "evidence_text": "History of increased gastrointestinal symptoms (\"flare\") in the last 3 months"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Current use (past use of these medications is not an exclusion) of medications such as azathioprine, methotrexate or 6-mercaptopurine used to treat IBD", "unit": "NA", "evidence_text": "Current use (past use of these medications is not an exclusion) of medications such as azathioprine, methotrexate or 6-mercaptopurine used to treat IBD"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Current use (past use of these medications is not an exclusion) of medications or over-the-counter treatments including but not limited to aspirin, NSAID, botan", "unit": "NA", "evidence_text": "Current use (past use of these medications is not an exclusion) of medications or over-the-counter treatments including but not limited to aspirin, NSAID, botanical treatments (ginger, feverfew, yellow clover, Salix species, Populus species, Betula species, and Gaultheria species), essential fatty acids (flax oil and fish oil)."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Other serious medical conditions such as neurological, liver, kidney, auto- immune or systemic disease.", "unit": "NA", "evidence_text": "Other serious medical conditions such as neurological, liver, kidney, auto- immune or systemic disease."}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "History of gastrointestinal surgery or planned gastrointestinal surgery in the future.", "unit": "NA", "evidence_text": "History of gastrointestinal surgery or planned gastrointestinal surgery in the future."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Tobacco, alcohol, or illicit drug abuse", "unit": "NA", "evidence_text": "Tobacco, alcohol, or illicit drug abuse"}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Planned surgery during the potential study participation time", "unit": "NA", "evidence_text": "Planned surgery during the potential study participation time"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Inability to swallow study medication", "unit": "NA", "evidence_text": "Inability to swallow study medication"}]}
{"nct_id": "NCT00890253", "eligibility_text": "Inclusion Criteria:\n\n1. Patients undergoing primary liver transplantation.\n2. Patients older than 18 years.\n3. Patients with a hepatorenal syndrome.\n4. Female patients of childbearing potential willing to perform a highly effective contraception during the study and 12 weeks after conclusion of study participation.\n5. eGFR \\< 50 ml/min at the time point of transplantation.\n6. Serum creatinine levels \\> 1.5 mg/dL at the time-point of transplantation.\n\nExclusion Criteria:\n\n1. Patients with pre-transplant renal replacement therapy \\> 14 days.\n2. Patients with a reason for renal impairment other than a hepatorenal syndrome.\n3. Patients with a known hypersensitivity to mTOR-inhibitors.\n4. Patients with a known hypersensitivity to mycophenolate acid.\n5. Patients with a known hypersensitivity to anti CD 25-monoclonal antibodies.\n6. Patients with platelets \\< 50.000/nl prior to initiation of therapy with mTOR inhibition.\n7. Patients with triglycerides \\> 350 mg/dl and cholesterol \\> 300 mg/dl refractory to optimal medical treatment prior to initiation of therapy with mTOR inhibition.\n8. Severe systemic infections and wound-healing disturbances.\n9. Multiple organ graft recipients.\n10. Patients with signs of a hepatic artery stenosis directly prior to initiation of therapy with everolimus.\n11. Pregnant women will not be included in the study.\n12. Patients with a psychological, familial, sociologic or geographic condition potentially hampering compliance with the study protocol and follow-up schedule.\n13. Patients under guardianship (e.g., individuals who are not able to freely give their informed consent).", "labeled_rules": [{"type": "inclusion", "field": "procedure", "operator": "contains", "value": "Patients undergoing primary liver transplantation.", "unit": "NA", "evidence_text": "Patients undergoing primary liver transplantation."}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Female patients of childbearing potential willing to perform a highly effective contraception during the study and 12 weeks after conclusion of study participation."}, {"type": "inclusion", "field": "procedure", "operator": "contains", "value": "eGFR \\< 50 ml/min at the time point of transplantation.", "unit": "NA", "evidence_text": "eGFR \\< 50 ml/min at the time point of transplantation."}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "1.5", "unit": "mg/dl", "evidence_text": "Serum creatinine levels \\> 1.5 mg/dL at the time-point of transplantation."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Patients with pre-transplant renal replacement therapy \\> 14 days.", "unit": "NA", "evidence_text": "Patients with pre-transplant renal replacement therapy \\> 14 days."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Patients with a known hypersensitivity to mTOR-inhibitors.", "unit": "NA", "evidence_text": "Patients with a known hypersensitivity to mTOR-inhibitors."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Patients with a known hypersensitivity to mycophenolate acid.", "unit": "NA", "evidence_text": "Patients with a known hypersensitivity to mycophenolate acid."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Patients with a known hypersensitivity to anti CD 25-monoclonal antibodies.", "unit": "NA", "evidence_text": "Patients with a known hypersensitivity to anti CD 25-monoclonal antibodies."}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "50.000", "unit": "/nl", "evidence_text": "Patients with platelets \\< 50.000/nl prior to initiation of therapy with mTOR inhibition."}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "350", "unit": "mg/dl", "evidence_text": "Patients with triglycerides \\> 350 mg/dl and cholesterol \\> 300 mg/dl refractory to optimal medical treatment prior to initiation of therapy with mTOR inhibition."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Patients with signs of a hepatic artery stenosis directly prior to initiation of therapy with everolimus.", "unit": "NA", "evidence_text": "Patients with signs of a hepatic artery stenosis directly prior to initiation of therapy with everolimus."}, {"type": "exclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Pregnant women will not be included in the study."}, {"type": "exclusion", "field": "other", "operator": "contains", "value": "Patients with a psychological, familial, sociologic or geographic condition potentially hampering compliance with the study protocol and follow-up schedule.", "unit": "NA", "evidence_text": "Patients with a psychological, familial, sociologic or geographic condition potentially hampering compliance with the study protocol and follow-up schedule."}, {"type": "exclusion", "field": "other", "operator": "contains", "value": "Patients under guardianship (e.g., individuals who are not able to freely give their informed consent).", "unit": "NA", "evidence_text": "Patients under guardianship (e.g., individuals who are not able to freely give their informed consent)."}]}
{"nct_id": "NCT00897481", "eligibility_text": "DISEASE CHARACTERISTICS:\n\n* Confirmed diagnosis of cutaneous melanoma\n\n  * Breslow thickness \\> 0.75 mm\n* Has undergone sentinel lymph node biopsy\n* No primary melanoma that has not originated in the skin\n* No multiple primary melanomas\n* Currently under clinical followup OR discharged from follow up within the past 3 months\n\nPATIENT CHARACTERISTICS:\n\n* No other malignancy except for nonmelanoma skin cancer or cervical carcinoma in situ\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "DISEASE CHARACTERISTICS:", "unit": "NA", "evidence_text": "DISEASE CHARACTERISTICS:"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Confirmed diagnosis of cutaneous melanoma", "unit": "NA", "evidence_text": "Confirmed diagnosis of cutaneous melanoma"}, {"type": "inclusion", "field": "procedure", "operator": "contains", "value": "Has undergone sentinel lymph node biopsy", "unit": "NA", "evidence_text": "Has undergone sentinel lymph node biopsy"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "No primary melanoma that has not originated in the skin", "unit": "NA", "evidence_text": "No primary melanoma that has not originated in the skin"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "No multiple primary melanomas", "unit": "NA", "evidence_text": "No multiple primary melanomas"}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "Currently under clinical followup OR discharged from follow up within the past 3 months", "unit": "NA", "evidence_text": "Currently under clinical followup OR discharged from follow up within the past 3 months"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "No other malignancy except for nonmelanoma skin cancer or cervical carcinoma in situ", "unit": "NA", "evidence_text": "No other malignancy except for nonmelanoma skin cancer or cervical carcinoma in situ"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "PRIOR CONCURRENT THERAPY:", "unit": "NA", "evidence_text": "PRIOR CONCURRENT THERAPY:"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "See Disease Characteristics", "unit": "NA", "evidence_text": "See Disease Characteristics"}]}
{"nct_id": "NCT00901953", "eligibility_text": "Inclusion Criteria:\n\n* migraine according to IHS criteria\n* migrainous vertigo according to the Neuhauser-criteria\n\nExclusion Criteria:\n\n* no history of other neurological, vestibular, opthalmologic and ENT disorders\n* no medications that could possibly influence test results\n* intact hearing measured by audiometry\n* pregnancy", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "migraine according to IHS criteria", "unit": "NA", "evidence_text": "migraine according to IHS criteria"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "no history of other neurological, vestibular, opthalmologic and ENT disorders", "unit": "NA", "evidence_text": "no history of other neurological, vestibular, opthalmologic and ENT disorders"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "no medications that could possibly influence test results", "unit": "NA", "evidence_text": "no medications that could possibly influence test results"}, {"type": "exclusion", "field": "history", "operator": "!=", "value": "pregnant_or_breastfeeding", "unit": "NA", "evidence_text": "pregnancy"}]}
{"nct_id": "NCT00910689", "eligibility_text": "Inclusion Criteria:\n\n* 18 to 65 years\n* Diagnosis of migraine with or without aura (International Classification of Headache Disorders)\n* 3 or more migraine episodes/month with disability for the past 6 months\n* Less than 20 total headache days/month for the past 6 months\n\nExclusion Criteria:\n\n* Medication overuse headaches\n* Currently taking medications contraindicated by study protocol and unable or unwilling to withdraw\n* Concurrently undergoing counseling/psychotherapy treatment\n* Unable to read, understand or record information in study diaries, questionnaires, and migraine management manual.\n* Unable/unwilling to give written informed consent\n* History of exclusionary medical condition such as, but not limited to, epilepsy, heart disease, kidney disease, liver disease, hepatic or renal impairment, stroke, ischemic abdominal syndromes, peripheral vascular disease.\n* Uncontrolled hypertension at screening (sitting systolic pressure \\> 160 mmHg, diastolic pressure \\> 95 mmHg)\n* Fertile female who is breastfeeding, pregnant planning a pregnancy within the next year or is unwilling to use adequate contraception.\n* Has exclusionary medical condition such as but not limited to diabetes (insulin dependent), tuberculosis, bronchospastic disease (asthma), heart disease (or multiple risk factors for heart disease), angina pectoris, documented silent ischemia, or cardiac arrythmias requiring medication, or a clinically significant EKG abnormality.\n* Other pain diagnosis is primary presenting problem (e.g., fibromyalgia)\n* Has a substance abuse problem or a psychological disorder that prevents participation in study (e.g., unmanaged severe depression that requires immediate treatment or limits participation in home-based treatment)\n* Hypersensitivity, intolerance or contraindication to use of Propranolol, Nadolol, Sumatriptan, or Rizatriptan", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "Diagnosis of migraine with or without aura (International Classification of Headache Disorders)", "unit": "NA", "evidence_text": "Diagnosis of migraine with or without aura (International Classification of Headache Disorders)"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "3 or more migraine episodes/month with disability for the past 6 months", "unit": "NA", "evidence_text": "3 or more migraine episodes/month with disability for the past 6 months"}, {"type": "inclusion", "field": "lab", "operator": "<", "value": "20", "unit": "total", "evidence_text": "Less than 20 total headache days/month for the past 6 months"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Medication overuse headaches", "unit": "NA", "evidence_text": "Medication overuse headaches"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Currently taking medications contraindicated by study protocol and unable or unwilling to withdraw", "unit": "NA", "evidence_text": "Currently taking medications contraindicated by study protocol and unable or unwilling to withdraw"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Concurrently undergoing counseling/psychotherapy treatment", "unit": "NA", "evidence_text": "Concurrently undergoing counseling/psychotherapy treatment"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Unable to read, understand or record information in study diaries, questionnaires, and migraine management manual.", "unit": "NA", "evidence_text": "Unable to read, understand or record information in study diaries, questionnaires, and migraine management manual."}, {"type": "exclusion", "field": "other", "operator": "contains", "value": "Unable/unwilling to give written informed consent", "unit": "NA", "evidence_text": "Unable/unwilling to give written informed consent"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "History of exclusionary medical condition such as, but not limited to, epilepsy, heart disease, kidney disease, liver disease, hepatic or renal impairment, stro", "unit": "NA", "evidence_text": "History of exclusionary medical condition such as, but not limited to, epilepsy, heart disease, kidney disease, liver disease, hepatic or renal impairment, stroke, ischemic abdominal syndromes, peripheral vascular disease."}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "160", "unit": "mmhg", "evidence_text": "Uncontrolled hypertension at screening (sitting systolic pressure \\> 160 mmHg, diastolic pressure \\> 95 mmHg)"}, {"type": "exclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Fertile female who is breastfeeding, pregnant planning a pregnancy within the next year or is unwilling to use adequate contraception."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Has exclusionary medical condition such as but not limited to diabetes (insulin dependent), tuberculosis, bronchospastic disease (asthma), heart disease (or mul", "unit": "NA", "evidence_text": "Has exclusionary medical condition such as but not limited to diabetes (insulin dependent), tuberculosis, bronchospastic disease (asthma), heart disease (or multiple risk factors for heart disease), angina pectoris, documented silent ischemia, or cardiac arrythmias requiring medication, or a clinically significant EKG abnormality."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Other pain diagnosis is primary presenting problem (e.g., fibromyalgia)", "unit": "NA", "evidence_text": "Other pain diagnosis is primary presenting problem (e.g., fibromyalgia)"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Has a substance abuse problem or a psychological disorder that prevents participation in study (e.g., unmanaged severe depression that requires immediate treatm", "unit": "NA", "evidence_text": "Has a substance abuse problem or a psychological disorder that prevents participation in study (e.g., unmanaged severe depression that requires immediate treatment or limits participation in home-based treatment)"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Hypersensitivity, intolerance or contraindication to use of Propranolol, Nadolol, Sumatriptan, or Rizatriptan", "unit": "NA", "evidence_text": "Hypersensitivity, intolerance or contraindication to use of Propranolol, Nadolol, Sumatriptan, or Rizatriptan"}]}
{"nct_id": "NCT00918944", "eligibility_text": "Inclusion Criteria:\n\n* Known patients with asthma\n\nExclusion Criteria:\n\n* None", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "Known patients with asthma", "unit": "NA", "evidence_text": "Known patients with asthma"}, {"type": "exclusion", "field": "history", "operator": "contains", "value": "None", "unit": "NA", "evidence_text": "None"}]}
{"nct_id": "NCT00923026", "eligibility_text": "* INCLUSION CRITERIA:\n* Age greater than or equal to 18 years.\n* Participants who have received treatment on an NCI-SB protocol, including gene therapy protocols. (Note: Participants may be enrolled on this protocol and, at the same time, participate in an active treatment study).\n* For Cohort A:Ability of participant or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. For Cohort B: Participant is able to provide informed consent.\n\nEXCLUSION CRITERIA:\n\n-For Cohort B: Individuals of child-bearing potential (IOCBP) who are pregnant or plan to become pregnant because of the potentially dangerous effects of the investigational treatments administered on NCI-SB treatment protocols.", "labeled_rules": [{"type": "inclusion", "field": "age", "operator": ">=", "value": "18", "unit": "years", "evidence_text": "Age greater than or equal to 18 years."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Participants who have received treatment on an NCI-SB protocol, including gene therapy protocols. (Note: Participants may be enrolled on this protocol and, at t", "unit": "NA", "evidence_text": "Participants who have received treatment on an NCI-SB protocol, including gene therapy protocols. (Note: Participants may be enrolled on this protocol and, at the same time, participate in an active treatment study)."}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "For Cohort A:Ability of participant or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. Fo", "unit": "NA", "evidence_text": "For Cohort A:Ability of participant or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. For Cohort B: Participant is able to provide informed consent."}, {"type": "exclusion", "field": "history", "operator": "!=", "value": "pregnant_or_breastfeeding", "unit": "NA", "evidence_text": "For Cohort B: Individuals of child-bearing potential (IOCBP) who are pregnant or plan to become pregnant because of the potentially dangerous effects of the investigational treatments administered on NCI-SB treatment protocols."}]}
{"nct_id": "NCT00928031", "eligibility_text": "Inclusion Criteria:\n\n1. Subjects who were previously enrolled in MDX-010 studies MDX010-02, MDX010-08, or MDX010-15.\n2. Subjects (or if applicable, next of kin), who are alive at the time of contact must have read, understood, and provided written informed consent and health Insurance Portability and Accountability Act (HIPAA) authorization after the nature of the study has been fully explained.\n3. For subjects who have died or have been lost to follow-up(the subject status at end of original ipilimumab study), approval from the appropriate site IRB, specifying or limiting appropriate means for obtaining information, must be granted prior to collection of any information.", "labeled_rules": [{"type": "inclusion", "field": "history", "operator": "contains", "value": "Subjects who were previously enrolled in MDX-010 studies MDX010-02, MDX010-08, or MDX010-15.", "unit": "NA", "evidence_text": "Subjects who were previously enrolled in MDX-010 studies MDX010-02, MDX010-08, or MDX010-15."}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Subjects (or if applicable, next of kin), who are alive at the time of contact must have read, understood, and provided written informed consent and health Insu", "unit": "NA", "evidence_text": "Subjects (or if applicable, next of kin), who are alive at the time of contact must have read, understood, and provided written informed consent and health Insurance Portability and Accountability Act (HIPAA) authorization after the nature of the study has been fully explained."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "For subjects who have died or have been lost to follow-up(the subject status at end of original ipilimumab study), approval from the appropriate site IRB, speci", "unit": "NA", "evidence_text": "For subjects who have died or have been lost to follow-up(the subject status at end of original ipilimumab study), approval from the appropriate site IRB, specifying or limiting appropriate means for obtaining information, must be granted prior to collection of any information."}]}
{"nct_id": "NCT00937703", "eligibility_text": "Inclusion Criteria:\n\n* Type 2 diabetes since more than 3 years and claiming a strict balance glycemic;\n* Patients treated since at least 3 months, by metformin and secreting insulinic (KNOWN or glinide);\n* Patients uncontrolled with HbA1c ≥ 7.5% and \\< 10% at the inclusion.\n* BMI \\< 40 ;\n* Patients requiring a insulin treatment\n* Patients agree to start a slow insulin treatment\n* Patients already practising the glycemic self-monitoring or agree to learn it and practise it;\n* Patients able to include/understand operation and to use the PDA-phone and/or the SVI;\n* Patient not taking part in another biomedical research study\n* Patients agree to carry out at least 2 finger sticks per day;\n* More than 18 years, there is no higher age limit.\n\nExclusion Criteria:\n\n* Patients introducing any evolutionary pathology associated and not stabilized, exhibitor with an uncontrolled diabetes during the year to come;\n* Patients in a situation which justifies of a clinical follow-up diabetologic more frequent than that (quarterly) envisaged by the study\n* Patients requiring a transitory passage to insulin;\n* Patients needing a hospitalization for the adaptation of insulin doses;\n* Patients presenting a cardiologic event\n* Patients presenting a hemoglobinopathy interfering with the proportioning of HbA1c;\n* Patients suffering from drug-addiction, alcoholism or psychological troubles\n* Type 1 or secondary diabetes\n* Patients who don't need strict metabolic objectives;\n* Pregnant or parturient patients\n* person with no freedom.", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "Type 2 diabetes since more than 3 years and claiming a strict balance glycemic;", "unit": "NA", "evidence_text": "Type 2 diabetes since more than 3 years and claiming a strict balance glycemic;"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "10", "unit": "%", "evidence_text": "Patients uncontrolled with HbA1c ≥ 7.5% and \\< 10% at the inclusion."}, {"type": "inclusion", "field": "procedure", "operator": "contains", "value": "Patients able to include/understand operation and to use the PDA-phone and/or the SVI;", "unit": "NA", "evidence_text": "Patients able to include/understand operation and to use the PDA-phone and/or the SVI;"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Patients introducing any evolutionary pathology associated and not stabilized, exhibitor with an uncontrolled diabetes during the year to come;", "unit": "NA", "evidence_text": "Patients introducing any evolutionary pathology associated and not stabilized, exhibitor with an uncontrolled diabetes during the year to come;"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Patients suffering from drug-addiction, alcoholism or psychological troubles", "unit": "NA", "evidence_text": "Patients suffering from drug-addiction, alcoholism or psychological troubles"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Type 1 or secondary diabetes", "unit": "NA", "evidence_text": "Type 1 or secondary diabetes"}, {"type": "exclusion", "field": "history", "operator": "!=", "value": "pregnant_or_breastfeeding", "unit": "NA", "evidence_text": "Pregnant or parturient patients"}]}
{"nct_id": "NCT00941577", "eligibility_text": "Inclusion Criteria:\n\n* Men and women with well controlled mild allergic asthma, aged 18 to 65 years\n* Only asthma med is short-acting bronchodilator used not more than twice weekly\n* FEV1 greater than 70% predicted and a demonstrated baseline late response to allergen induction", "labeled_rules": [{"type": "inclusion", "field": "age", "operator": "between", "value": "18-65", "unit": "years", "evidence_text": "Men and women with well controlled mild allergic asthma, aged 18 to 65 years"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Only asthma med is short-acting bronchodilator used not more than twice weekly", "unit": "NA", "evidence_text": "Only asthma med is short-acting bronchodilator used not more than twice weekly"}]}
{"nct_id": "NCT00942331", "eligibility_text": "Inclusion Criteria:\n\n* Patients must have histologically or cytologically documented metastatic or unresectable transitional cell (urothelial) carcinoma of the urinary tract (renal pelvis, ureter, bladder, prostate, or urethra), with metastatic or locally advanced disease (T4b, N2, N3, or M1); patients must not be candidates for potentially curative surgery or radiotherapy\n\n  * For patients that have had surgical resection prior to study enrollment, residual or unresected disease (measurable and/or unmeasurable) must be evident on post-surgical scans\n* Prior treatment for transitional cell carcinoma (TCC)\n\n  * Patients may not have received combination systemic chemotherapy for metastatic disease\n  * For the purposes of this study, radiosensitizing single agent chemotherapy is not considered prior systemic therapy\n  * Prior neoadjuvant or adjuvant systemic chemotherapy is permissible provided the interval from end of therapy to diagnosis of metastatic disease is at least 1 year\n  * \\>= 4 weeks since any prior radiation (including palliative) or major surgery and fully recovered\n  * \\>= 7 days since any minor surgery such as port placement\n  * \\>= 4 weeks since any intravesical therapy\n  * No prior treatment with bevacizumab or other angiogenesis inhibitors\n* No known history of brain metastases; brain imaging (magnetic resonance imaging \\[MRI\\]/computed tomography \\[CT\\]) is not required\n* No current congestive heart failure; New York Heart Association (NYHA) class II, III or IV\n* Patients with history of hypertension must be well controlled (\\< 150/90) on a regimen of anti-hypertensive therapy\n* Patients on full-dose anticoagulants must be on a stable dose of warfarin and have an in-range international normalized ratio (INR) (usually between 2 and 3) or be on a stable dose of low molecular weight (LMW) heparin; patients receiving anti-platelet agents are also eligible; in addition, patients who are on daily prophylactic aspirin or anticoagulation for atrial fibrillation are eligible\n* No significant history of bleeding events or gastrointestinal (GI) perforation\n\n  * Patients with a history of a significant bleeding episode (e.g. hemoptysis, upper or lower GI bleeding, grade 3 or 4 gross hematuria unable to be controlled by trans-urethral resection of the bladder tumor) within 6 months of registration are not eligible\n  * Patients with a history of GI perforation within 12 months of registration are not eligible\n  * Patients with a history of peritoneal carcinomatosis are not eligible\n* No arterial thrombotic events within 6 months of registration, including transient ischemic attack (TIA), cerebrovascular accident (CVA), peripheral arterial thrombus, unstable angina or angina requiring surgical or medical intervention in the past 6 months, or myocardial infarction (MI); patients with clinically significant peripheral artery disease (i.e., claudication on less than one block) are ineligible\n* Patients who have experienced a deep venous thrombosis or pulmonary embolus within the past 6 months must be on stable therapeutic anticoagulation to be enrolled to this study\n* No serious or non-healing wound, ulcer, or bone fracture\n* No sensory or motor peripheral neuropathy \\>= grade 2\n* Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies are not eligible\n* Patients that are pregnant or nursing are not eligible; women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin \\[HCG\\]) within 72 hours prior to registration\n\n  * For women of child-bearing potential with an elevated beta-HCG that is believed to be related to cancer and not pregnancy, a negative trans-vaginal ultrasound and gynecological examination are required\n  * Women of child-bearing potential include any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal \\[defined as amenorrhea \\>= 12 consecutive months; or women on hormone replacement therapy \\[HRT\\] with documented serum follicle stimulating hormone \\[FSH\\] level \\> 35 mIU/mL); even women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (or Karnofsky performance status \\[KPS\\] \\>= 80)\n* Absolute neutrophil count (ANC) \\>= 1,500/uL\n* Platelet count \\>= 100,000/uL\n* Calculated or measured creatinine clearance \\>= 50 mL/minute\n* Bilirubin =\\< 1.25 times upper limits of normal; for patients with Gilbert's disease, =\\< 2.5 x upper limit of normal (ULN) is allowed\n* Aspartate aminotransferase (AST) =\\< 2.0 x upper limits of normal\n* Urine protein to creatinine ratio \\< 1.0 or urine protein =\\< 1+ or 24-hour urine protein =\\< 1 gram", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "Patients must have histologically or cytologically documented metastatic or unresectable transitional cell (urothelial) carcinoma of the urinary tract (renal pe", "unit": "NA", "evidence_text": "Patients must have histologically or cytologically documented metastatic or unresectable transitional cell (urothelial) carcinoma of the urinary tract (renal pelvis, ureter, bladder, prostate, or urethra), with metastatic or locally advanced disease (T4b, N2, N3, or M1);"}, {"type": "inclusion", "field": "medication", "operator": "not_contains", "value": "patients must not be candidates for potentially curative surgery or radiotherapy", "unit": "NA", "evidence_text": "patients must not be candidates for potentially curative surgery or radiotherapy"}, {"type": "inclusion", "field": "procedure", "operator": "contains", "value": "For patients that have had surgical resection prior to study enrollment, residual or unresected disease (measurable and/or unmeasurable) must be evident on post", "unit": "NA", "evidence_text": "For patients that have had surgical resection prior to study enrollment, residual or unresected disease (measurable and/or unmeasurable) must be evident on post-surgical scans"}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "Prior treatment for transitional cell carcinoma (TCC)", "unit": "NA", "evidence_text": "Prior treatment for transitional cell carcinoma (TCC)"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Patients may not have received combination systemic chemotherapy for metastatic disease", "unit": "NA", "evidence_text": "Patients may not have received combination systemic chemotherapy for metastatic disease"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "For the purposes of this study, radiosensitizing single agent chemotherapy is not considered prior systemic therapy", "unit": "NA", "evidence_text": "For the purposes of this study, radiosensitizing single agent chemotherapy is not considered prior systemic therapy"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Prior neoadjuvant or adjuvant systemic chemotherapy is permissible provided the interval from end of therapy to diagnosis of metastatic disease is at least 1 ye", "unit": "NA", "evidence_text": "Prior neoadjuvant or adjuvant systemic chemotherapy is permissible provided the interval from end of therapy to diagnosis of metastatic disease is at least 1 year"}, {"type": "inclusion", "field": "procedure", "operator": "contains", "value": "\\>= 4 weeks since any prior radiation (including palliative) or major surgery and fully recovered", "unit": "NA", "evidence_text": "\\>= 4 weeks since any prior radiation (including palliative) or major surgery and fully recovered"}, {"type": "inclusion", "field": "procedure", "operator": "contains", "value": "\\>= 7 days since any minor surgery such as port placement", "unit": "NA", "evidence_text": "\\>= 7 days since any minor surgery such as port placement"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "\\>= 4 weeks since any intravesical therapy", "unit": "NA", "evidence_text": "\\>= 4 weeks since any intravesical therapy"}, {"type": "inclusion", "field": "medication", "operator": "not_contains", "value": "No prior treatment with bevacizumab or other angiogenesis inhibitors", "unit": "NA", "evidence_text": "No prior treatment with bevacizumab or other angiogenesis inhibitors"}, {"type": "inclusion", "field": "procedure", "operator": "not_contains", "value": "No known history of brain metastases; brain imaging (magnetic resonance imaging \\[MRI\\]/computed tomography \\[CT\\]) is not required", "unit": "NA", "evidence_text": "No known history of brain metastases; brain imaging (magnetic resonance imaging \\[MRI\\]/computed tomography \\[CT\\]) is not required"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "No current congestive heart failure; New York Heart Association (NYHA) class II, III or IV", "unit": "NA", "evidence_text": "No current congestive heart failure; New York Heart Association (NYHA) class II, III or IV"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Patients with history of hypertension must be well controlled (\\< 150/90) on a regimen of anti-hypertensive therapy", "unit": "NA", "evidence_text": "Patients with history of hypertension must be well controlled (\\< 150/90) on a regimen of anti-hypertensive therapy"}, {"type": "inclusion", "field": "history", "operator": "not_contains", "value": "No significant history of bleeding events or gastrointestinal (GI) perforation", "unit": "NA", "evidence_text": "No significant history of bleeding events or gastrointestinal (GI) perforation"}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "Patients with a history of a significant bleeding episode (e.g.", "unit": "NA", "evidence_text": "Patients with a history of a significant bleeding episode (e.g."}, {"type": "inclusion", "field": "history", "operator": "not_contains", "value": "hemoptysis, upper or lower GI bleeding, grade 3 or 4 gross hematuria unable to be controlled by trans-urethral resection of the bladder tumor) within 6 months o", "unit": "NA", "evidence_text": "hemoptysis, upper or lower GI bleeding, grade 3 or 4 gross hematuria unable to be controlled by trans-urethral resection of the bladder tumor) within 6 months of registration are not eligible"}, {"type": "inclusion", "field": "history", "operator": "not_contains", "value": "Patients with a history of GI perforation within 12 months of registration are not eligible", "unit": "NA", "evidence_text": "Patients with a history of GI perforation within 12 months of registration are not eligible"}, {"type": "inclusion", "field": "history", "operator": "not_contains", "value": "Patients with a history of peritoneal carcinomatosis are not eligible", "unit": "NA", "evidence_text": "Patients with a history of peritoneal carcinomatosis are not eligible"}, {"type": "inclusion", "field": "procedure", "operator": "not_contains", "value": "No arterial thrombotic events within 6 months of registration, including transient ischemic attack (TIA), cerebrovascular accident (CVA), peripheral arterial th", "unit": "NA", "evidence_text": "No arterial thrombotic events within 6 months of registration, including transient ischemic attack (TIA), cerebrovascular accident (CVA), peripheral arterial thrombus, unstable angina or angina requiring surgical or medical intervention in the past 6 months, or myocardial infarction (MI);"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "patients with clinically significant peripheral artery disease (i.e., claudication on less than one block) are ineligible", "unit": "NA", "evidence_text": "patients with clinically significant peripheral artery disease (i.e., claudication on less than one block) are ineligible"}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "Patients who have experienced a deep venous thrombosis or pulmonary embolus within the past 6 months must be on stable therapeutic anticoagulation to be enrolle", "unit": "NA", "evidence_text": "Patients who have experienced a deep venous thrombosis or pulmonary embolus within the past 6 months must be on stable therapeutic anticoagulation to be enrolled to this study"}, {"type": "inclusion", "field": "history", "operator": "not_contains", "value": "Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies are not eligible", "unit": "NA", "evidence_text": "Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies are not eligible"}, {"type": "inclusion", "field": "history", "operator": "!=", "value": "pregnant_or_breastfeeding", "unit": "NA", "evidence_text": "Patients that are pregnant or nursing are not eligible;"}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin \\[HCG\\]) within 72 hours prior to registration"}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "For women of child-bearing potential with an elevated beta-HCG that is believed to be related to cancer and not pregnancy, a negative trans-vaginal ultrasound and gynecological examination are required"}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Women of child-bearing potential include any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal \\[defined as amenorrhea \\>= 12 consecutive months;"}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "or women on hormone replacement therapy \\[HRT\\] with documented serum follicle stimulating hormone \\[FSH\\] level \\> 35 mIU/mL);"}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "even women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "80", "unit": "NA", "evidence_text": "Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (or Karnofsky performance status \\[KPS\\] \\>= 80)"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "1", "unit": "NA", "evidence_text": "Absolute neutrophil count (ANC) \\>= 1,500/uL"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "100", "unit": "NA", "evidence_text": "Platelet count \\>= 100,000/uL"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "50", "unit": "ml/minute", "evidence_text": "Calculated or measured creatinine clearance \\>= 50 mL/minute"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "1.25", "unit": "times", "evidence_text": "Bilirubin =\\< 1.25 times upper limits of normal; for patients with Gilbert's disease, =\\< 2.5 x upper limit of normal (ULN) is allowed"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "2.0", "unit": "x", "evidence_text": "Aspartate aminotransferase (AST) =\\< 2.0 x upper limits of normal"}]}
{"nct_id": "NCT00947674", "eligibility_text": "Inclusion Criteria:\n\n* Patients diagnosed to have UC in the active stage based on clinical symptoms and findings from endoscopy\n* Patients with pancolitis type or left-sided colitis type lesion of 15 cm or longer observed endoscopically\n* Patients with Mayo score between 5 and 10\n* Patients with Mayo sub-score (findings from flexible sigmoidoscopy) of 2 or 3\n* Patients not having received any corticosteroids (referred to as steroids) (p.o., i.v., enema, suppository) within the past 6 weeks\n\nExclusion Criteria:\n\n* Patients with a difficulty in peripheral vascular access\n* Patients having received ACE inhibitor (at least 10 times of its half-life time for interval needed before initiating the treatment)\n* Patients with toxic megacolon\n* Patients with a malignant disease or its experience\n* Patients with a severe cardiovascular disease (grade III or IV by the Classification of heart functions of the New York Heart Association (NYHA))\n* Patients with a liver or kidney disease (AST(GOT) or ALT(GPT) or total bilirubin or creatinine level which is 2 or more times higher than the upper limit of normal (abbreviated as ULN, hereinafter)\n* Patients suspected to have or having HBV or HCV or HIV or pathogenic bacteria\n* Patients on anticoagulant therapy or with abnormality in the blood coagulation system (PT or PTT levels which are 1.5 or more times higher than ULN\n* Pregnant women or patients with possible pregnancy\n* Breast feeding women\n* Patients weighing 40 kg or less\n* Patients with hemoglobin level of less than 6.5 mmol/L (10.5 g/dL)\n* Patients with platelet count of less than 150 x 103/mm3, 150 x 109/L (15 x 104/mm3)\n* Patients with white blood cell count of less than 3.5 x 109/L (3,500/mm3)\n* Patients with hypotension (with systolic blood pressure of 80 mmHg or less)", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "Patients diagnosed to have UC in the active stage based on clinical symptoms and findings from endoscopy", "unit": "NA", "evidence_text": "Patients diagnosed to have UC in the active stage based on clinical symptoms and findings from endoscopy"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Patients not having received any corticosteroids (referred to as steroids) (p.o., i.v., enema, suppository) within the past 6 weeks", "unit": "NA", "evidence_text": "Patients not having received any corticosteroids (referred to as steroids) (p.o., i.v., enema, suppository) within the past 6 weeks"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Patients with a malignant disease or its experience", "unit": "NA", "evidence_text": "Patients with a malignant disease or its experience"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Patients with a severe cardiovascular disease (grade III or IV by the Classification of heart functions of the New York Heart Association (NYHA))", "unit": "NA", "evidence_text": "Patients with a severe cardiovascular disease (grade III or IV by the Classification of heart functions of the New York Heart Association (NYHA))"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Patients with a liver or kidney disease (AST(GOT) or ALT(GPT) or total bilirubin or creatinine level which is 2 or more times higher than the upper limit of nor", "unit": "NA", "evidence_text": "Patients with a liver or kidney disease (AST(GOT) or ALT(GPT) or total bilirubin or creatinine level which is 2 or more times higher than the upper limit of normal (abbreviated as ULN, hereinafter)"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Patients on anticoagulant therapy or with abnormality in the blood coagulation system (PT or PTT levels which are 1.5 or more times higher than ULN", "unit": "NA", "evidence_text": "Patients on anticoagulant therapy or with abnormality in the blood coagulation system (PT or PTT levels which are 1.5 or more times higher than ULN"}, {"type": "exclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Pregnant women or patients with possible pregnancy"}, {"type": "exclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Breast feeding women"}, {"type": "exclusion", "field": "lab", "operator": "<", "value": "6.5", "unit": "mmol/l", "evidence_text": "Patients with hemoglobin level of less than 6.5 mmol/L (10.5 g/dL)"}, {"type": "exclusion", "field": "lab", "operator": "<", "value": "150", "unit": "x", "evidence_text": "Patients with platelet count of less than 150 x 103/mm3, 150 x 109/L (15 x 104/mm3)"}]}
{"nct_id": "NCT00960245", "eligibility_text": "Inclusion Criteria:\n\n* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.\n\nExclusion Criteria:\n\n* Positive test results for HIV or hepatitis B or C.\n* Treatment for drug or alcohol dependence.", "labeled_rules": [{"type": "exclusion", "field": "medication", "operator": "contains", "value": "Treatment for drug or alcohol dependence.", "unit": "NA", "evidence_text": "Treatment for drug or alcohol dependence."}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.", "unit": "NA", "evidence_text": "No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening."}, {"type": "exclusion", "field": "history", "operator": "contains", "value": "Positive test results for HIV or hepatitis B or C.", "unit": "NA", "evidence_text": "Positive test results for HIV or hepatitis B or C."}, {"type": "exclusion", "field": "history", "operator": "contains", "value": "Treatment for drug or alcohol dependence.", "unit": "NA", "evidence_text": "Treatment for drug or alcohol dependence."}]}
{"nct_id": "NCT00966043", "eligibility_text": "Inclusion Criteria:\n\n* Female \\> 18 years of age\n* Written and voluntary informed consent understood signed and dated\n* Histologically or cytologically confirmed measurable invasive adenocarcinoma of the breast, amenable to curative therapy.\n* Patients must be postmenopausal as defined by criteria in appendix 1.\n* Breast cancer should be considered as oestrogen receptor positive by the clinician using immunohistochemistry readings as is standard procedure for local pathologist\n* Prior endocrine tamoxifen therapy is not allowed\n* Patients are not previously treated with an endocrine agent or hormone replacement therapy needs being stopped for at least 6 months.\n* Prior chemotherapy and radiotherapy is allowed\n* Adequate renal and liver function Serum creatinine and serum bilirubin ≤ 1.5 X ULN Serum ALT and AST ≤ 2.5 X ULN (or ≤ 5 in case of liver metastases)\n* Serum calcium should be ≤ 11,6 mg/dl\n* ECOG performance status 0,1,2 (appendix 2)\n\nExclusion Criteria:\n\n* Male\n* Life threatening disease requiring a quick response (eg, extensive hepatic or pulmonary involvement)\n* Use of any endocrine treatment or recent/current use of hormone replacement therapy.\n* Contra indication for tamoxifen: history of DVT/vaginal bleeding of unknown origin\n* Dementia\n* History of other malignancy that may interfere with at least 6 months of tamoxifen therapy", "labeled_rules": [{"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Female \\> 18 years of age"}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Written and voluntary informed consent understood signed and dated", "unit": "NA", "evidence_text": "Written and voluntary informed consent understood signed and dated"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Histologically or cytologically confirmed measurable invasive adenocarcinoma of the breast, amenable to curative therapy.", "unit": "NA", "evidence_text": "Histologically or cytologically confirmed measurable invasive adenocarcinoma of the breast, amenable to curative therapy."}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Breast cancer should be considered as oestrogen receptor positive by the clinician using immunohistochemistry readings as is standard procedure for local pathol", "unit": "NA", "evidence_text": "Breast cancer should be considered as oestrogen receptor positive by the clinician using immunohistochemistry readings as is standard procedure for local pathologist"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Prior endocrine tamoxifen therapy is not allowed", "unit": "NA", "evidence_text": "Prior endocrine tamoxifen therapy is not allowed"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Patients are not previously treated with an endocrine agent or hormone replacement therapy needs being stopped for at least 6 months.", "unit": "NA", "evidence_text": "Patients are not previously treated with an endocrine agent or hormone replacement therapy needs being stopped for at least 6 months."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Prior chemotherapy and radiotherapy is allowed", "unit": "NA", "evidence_text": "Prior chemotherapy and radiotherapy is allowed"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Life threatening disease requiring a quick response (eg, extensive hepatic or pulmonary involvement)", "unit": "NA", "evidence_text": "Life threatening disease requiring a quick response (eg, extensive hepatic or pulmonary involvement)"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Use of any endocrine treatment or recent/current use of hormone replacement therapy.", "unit": "NA", "evidence_text": "Use of any endocrine treatment or recent/current use of hormone replacement therapy."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Contra indication for tamoxifen: history of DVT/vaginal bleeding of unknown origin", "unit": "NA", "evidence_text": "Contra indication for tamoxifen: history of DVT/vaginal bleeding of unknown origin"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "History of other malignancy that may interfere with at least 6 months of tamoxifen therapy", "unit": "NA", "evidence_text": "History of other malignancy that may interfere with at least 6 months of tamoxifen therapy"}]}
{"nct_id": "NCT00973557", "eligibility_text": "Inclusion Criteria:\n\n* Patients with colorectal cancer, lung cancer, breast cancer, and glioblastoma patients that have been treated with Bevacizumab for at least 1 month\n* Adults (18 years of age or older)\n\nExclusion Criteria:\n\n* Patients who are taking medications known to affect serum prolactin levels\n* Patients who are pregnant\n* Patients who have pituitary disease\n* Minors (Under the age of 18)", "labeled_rules": [{"type": "inclusion", "field": "medication", "operator": "contains", "value": "Patients with colorectal cancer, lung cancer, breast cancer, and glioblastoma patients that have been treated with Bevacizumab for at least 1 month", "unit": "NA", "evidence_text": "Patients with colorectal cancer, lung cancer, breast cancer, and glioblastoma patients that have been treated with Bevacizumab for at least 1 month"}, {"type": "inclusion", "field": "age", "operator": ">=", "value": "18", "unit": "years", "evidence_text": "Adults (18 years of age or older)"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Patients who are taking medications known to affect serum prolactin levels", "unit": "NA", "evidence_text": "Patients who are taking medications known to affect serum prolactin levels"}, {"type": "exclusion", "field": "history", "operator": "!=", "value": "pregnant_or_breastfeeding", "unit": "NA", "evidence_text": "Patients who are pregnant"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Patients who have pituitary disease", "unit": "NA", "evidence_text": "Patients who have pituitary disease"}]}
{"nct_id": "NCT00992797", "eligibility_text": "Inclusion criteria:\n\n1. Moderate (S-25OHD 25-50 nmol/l) to severe (S-25OHD \\< 25 nmol/l) vitamin D deficiency measured at Visit 1.\n2. Patients with type 2 diabetes, including drug naïve subjects, subjects using oral anti-diabetic medication and subjects on insulin treatment. All medication must be in stable doses during the 4 week lead-in period.\n3. HbA1c \\< 11 % at Visit 1.\n4. Able to communicate in Norwegian.\n5. Men and women ≥ 18 years.\n6. Norwegian or South Asian ethnicity.\n7. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study. All WOCBP must have negative serum or urine pregnancy test at enrollment, randomization, titration visit and final study assessment.\n8. Antihypertensive medication, lipid lowering drugs, oral contraceptives, hormone replacement therapy, multivitamin supplements and nutritional supplements are allowed if the subjects adhere to the same regimen during the study\n\nExclusion Criteria:\n\n1. Subjects not having type 2 diabetes.\n2. SBP ≥ 160 or DBP ≥ 95 at Visit 1.\n3. Significant renal disease or chronic renal impairment, GFR\\< 30 ml/min.\n4. Significant liver disease or ASAT or ALAT \\>3x UNL.\n5. Malignancy during the last five years.\n6. Hypercalcemia at Visit 1.\n7. A history of kidney stone disease\n8. WOCBP unwilling or unable to use an acceptable method to avoid pregnancy.\n9. Pregnant or breastfeeding women.\n10. Chronic inflammatory disease in active phase\n11. Long term (\\>2 weeks) use of corticosteroids last 3 months\n12. Mental condition (psychiatric or organic cerebral disease) rendering the subject unable to understand the nature, scope and possible consequences of the study.\n13. Drug or alcohol abuse.\n14. BMI \\> 45 kg/m2 or bariatric surgery (\\<5 years).\n15. Anemia\n16. Cardiovascular disease (myocardial infarction, unstable angina pectoris or stroke) during the last 6 months.\n17. Any medical condition that in the judgment of the investigator would jeopardize the subject's safety or evaluation of the study drug for efficacy and safety.", "labeled_rules": [{"type": "inclusion", "field": "medication", "operator": "contains", "value": "Patients with type 2 diabetes, including drug naïve subjects, subjects using oral anti-diabetic medication and subjects on insulin treatment. All medication mus", "unit": "NA", "evidence_text": "Patients with type 2 diabetes, including drug naïve subjects, subjects using oral anti-diabetic medication and subjects on insulin treatment. All medication must be in stable doses during the 4 week lead-in period."}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "11", "unit": "%", "evidence_text": "HbA1c \\< 11 % at Visit 1."}, {"type": "inclusion", "field": "sex", "operator": "in", "value": "male,female", "unit": "NA", "evidence_text": "Men and women ≥ 18 years."}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study."}, {"type": "inclusion", "field": "lab", "operator": "=", "value": "negative", "unit": "NA", "evidence_text": "All WOCBP must have negative serum or urine pregnancy test at enrollment, randomization, titration visit and final study assessment."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Antihypertensive medication, lipid lowering drugs, oral contraceptives, hormone replacement therapy, multivitamin supplements and nutritional supplements are al", "unit": "NA", "evidence_text": "Antihypertensive medication, lipid lowering drugs, oral contraceptives, hormone replacement therapy, multivitamin supplements and nutritional supplements are allowed if the subjects adhere to the same regimen during the study"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Subjects not having type 2 diabetes.", "unit": "NA", "evidence_text": "Subjects not having type 2 diabetes."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Significant renal disease or chronic renal impairment, GFR\\< 30 ml/min.", "unit": "NA", "evidence_text": "Significant renal disease or chronic renal impairment, GFR\\< 30 ml/min."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Significant liver disease or ASAT or ALAT \\>3x UNL.", "unit": "NA", "evidence_text": "Significant liver disease or ASAT or ALAT \\>3x UNL."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "A history of kidney stone disease", "unit": "NA", "evidence_text": "A history of kidney stone disease"}, {"type": "exclusion", "field": "history", "operator": "!=", "value": "pregnant_or_breastfeeding", "unit": "NA", "evidence_text": "WOCBP unwilling or unable to use an acceptable method to avoid pregnancy."}, {"type": "exclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Pregnant or breastfeeding women."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Chronic inflammatory disease in active phase", "unit": "NA", "evidence_text": "Chronic inflammatory disease in active phase"}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "2", "unit": "weeks", "evidence_text": "Long term (\\>2 weeks) use of corticosteroids last 3 months"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Mental condition (psychiatric or organic cerebral disease) rendering the subject unable to understand the nature, scope and possible consequences of the study.", "unit": "NA", "evidence_text": "Mental condition (psychiatric or organic cerebral disease) rendering the subject unable to understand the nature, scope and possible consequences of the study."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Drug or alcohol abuse.", "unit": "NA", "evidence_text": "Drug or alcohol abuse."}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "BMI \\> 45 kg/m2 or bariatric surgery (\\<5 years).", "unit": "NA", "evidence_text": "BMI \\> 45 kg/m2 or bariatric surgery (\\<5 years)."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Cardiovascular disease (myocardial infarction, unstable angina pectoris or stroke) during the last 6 months.", "unit": "NA", "evidence_text": "Cardiovascular disease (myocardial infarction, unstable angina pectoris or stroke) during the last 6 months."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Any medical condition that in the judgment of the investigator would jeopardize the subject's safety or evaluation of the study drug for efficacy and safety.", "unit": "NA", "evidence_text": "Any medical condition that in the judgment of the investigator would jeopardize the subject's safety or evaluation of the study drug for efficacy and safety."}]}
{"nct_id": "NCT00995800", "eligibility_text": "Inclusion Criteria:\n\n1. Male or female subjects aged between 18 and 55 years inclusive.\n2. Females less than one year post-menopausal must have a negative serum or urine pregnancy test recorded at the screening visit prior to the first dose of study medication in each treatment period, be non-lactating, and be willing to use adequate and highly effective methods of contraception throughout the study. A highly effective method of birth control is defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, some IUDs (Intrauterine Device, hormonal), sexual abstinence or vasectomised partner.\n3. Known history of mild to moderate asthma for ≥ 6 months prior to the screening visit.\n4. Subject has not received systemic (injectable or oral) corticosteroid medication in the 12 weeks prior to the study screening visit.\n5. Demonstrate a FEV1 of ≥ 60% predicted FEV1 (Quanjer et al, 1993) at the screening visit, following appropriate withholding of asthma medications (no long-acting β2-agonist or short-acting β2-agonist/anticholinergic use 12 hours and 6 hours prior to screening, respectively).\n6. Demonstrate AMP challenge PC20FEV1 \\< 60 mg/mL, following appropriate withholding of asthma medication (no short-acting bronchodilator use 6 hours prior to the AMP challenge test at Visit 2).\n7. Non-smoker for at least 12 months prior to study screening. Ex-smokers must have a smoking history equivalent to less than \"10 pack years\" (i.e. at least 1 pack of 20 cigarettes per day for 10 years or 10 packs per day for 1 year, etc.).\n8. Demonstrate satisfactory technique in the use of the pMDI.\n9. Willing and able to enter information in the diary and attend all study visits.\n10. Willing and able to substitute study medication for their pre-study prescribed asthma medication for the duration of the study.\n11. Written informed consent obtained.\n\nExclusion Criteria:\n\n1. Near fatal or life-threatening (including intubation) asthma within the past year.\n2. Hospitalisation or an emergency visit for asthma within 4 weeks prior to the screening visit.\n3. History of omalizumab use within the past 6 months.\n4. Current evidence or history of any clinically significant disease or abnormality including uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia. 'Clinically significant' is defined as any disease that, in the opinion of the Investigator, would put the subject at risk through study participation, or which would affect the outcome of the study.\n5. In the investigator's opinion a clinically significant upper or lower respiratory infection within 4 weeks prior to the screening visit.\n6. Significant, non-reversible, active pulmonary disease (e.g. chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, tuberculosis).\n7. Known Human Immunodeficiency Virus (HIV)-positive status.\n8. Current evidence or history of alcohol and/or substance abuse within 12 months prior to the screening visit.\n9. Subjects who have taken beta-blocking agents, tricyclic antidepressants, monoamine oxidase inhibitors, astemizole (Hismanal), quinidine type antiarrhythmics, or potent CYP 3A4 inhibitors such as ketoconazole within one week prior to the screening visit.\n10. History of leukotriene receptor antagonist use, e.g. montelukast, within one week prior to the screening visit.\n11. Current use of medications other than those allowed in the protocol that will have an effect on bronchospasm and/or pulmonary function.\n12. Anti-histamines within 2 weeks prior to the screening visit; non-steroidal anti-inflammatory drugs, oral decongestants, inhaled cromolyn sodium, nedocromil sodium within one week prior to the screening visit.\n13. Current evidence or history of hypersensitivity or idiosyncratic reaction to test medications, rescue medication, or components.\n14. Use of an investigational drug within 30 days prior to the screening visit (12 weeks if an oral or injectable steroid).\n15. Current participation in a clinical study.", "labeled_rules": [{"type": "inclusion", "field": "age", "operator": "between", "value": "18-55", "unit": "years", "evidence_text": "Male or female subjects aged between 18 and 55 years inclusive."}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Females less than one year post-menopausal must have a negative serum or urine pregnancy test recorded at the screening visit prior to the first dose of study medication in each treatment period, be non-lactating, and be willing to use adequate and highly effective methods of contraception throughout the study."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "A highly effective method of birth control is defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and corre", "unit": "NA", "evidence_text": "A highly effective method of birth control is defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, some IUDs (Intrauterine Device, hormonal), sexual abstinence or vasectomised partner."}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "Known history of mild to moderate asthma for ≥ 6 months prior to the screening visit.", "unit": "NA", "evidence_text": "Known history of mild to moderate asthma for ≥ 6 months prior to the screening visit."}, {"type": "inclusion", "field": "medication", "operator": "not_contains", "value": "Subject has not received systemic (injectable or oral) corticosteroid medication in the 12 weeks prior to the study screening visit.", "unit": "NA", "evidence_text": "Subject has not received systemic (injectable or oral) corticosteroid medication in the 12 weeks prior to the study screening visit."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Demonstrate a FEV1 of ≥ 60% predicted FEV1 (Quanjer et al, 1993) at the screening visit, following appropriate withholding of asthma medications (no long-acting", "unit": "NA", "evidence_text": "Demonstrate a FEV1 of ≥ 60% predicted FEV1 (Quanjer et al, 1993) at the screening visit, following appropriate withholding of asthma medications (no long-acting β2-agonist or short-acting β2-agonist/anticholinergic use 12 hours and 6 hours prior to screening, respectively)."}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "60", "unit": "mg/ml", "evidence_text": "Demonstrate AMP challenge PC20FEV1 \\< 60 mg/mL, following appropriate withholding of asthma medication (no short-acting bronchodilator use 6 hours prior to the AMP challenge test at Visit 2)."}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "Non-smoker for at least 12 months prior to study screening.", "unit": "NA", "evidence_text": "Non-smoker for at least 12 months prior to study screening."}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Willing and able to enter information in the diary and attend all study visits.", "unit": "NA", "evidence_text": "Willing and able to enter information in the diary and attend all study visits."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Willing and able to substitute study medication for their pre-study prescribed asthma medication for the duration of the study.", "unit": "NA", "evidence_text": "Willing and able to substitute study medication for their pre-study prescribed asthma medication for the duration of the study."}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Written informed consent obtained.", "unit": "NA", "evidence_text": "Written informed consent obtained."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Near fatal or life-threatening (including intubation) asthma within the past year.", "unit": "NA", "evidence_text": "Near fatal or life-threatening (including intubation) asthma within the past year."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Hospitalisation or an emergency visit for asthma within 4 weeks prior to the screening visit.", "unit": "NA", "evidence_text": "Hospitalisation or an emergency visit for asthma within 4 weeks prior to the screening visit."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "History of omalizumab use within the past 6 months.", "unit": "NA", "evidence_text": "History of omalizumab use within the past 6 months."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Current evidence or history of any clinically significant disease or abnormality including uncontrolled coronary artery disease, congestive heart failure, myoca", "unit": "NA", "evidence_text": "Current evidence or history of any clinically significant disease or abnormality including uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "'Clinically significant' is defined as any disease that, in the opinion of the Investigator, would put the subject at risk through study participation, or which", "unit": "NA", "evidence_text": "'Clinically significant' is defined as any disease that, in the opinion of the Investigator, would put the subject at risk through study participation, or which would affect the outcome of the study."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "In the investigator's opinion a clinically significant upper or lower respiratory infection within 4 weeks prior to the screening visit.", "unit": "NA", "evidence_text": "In the investigator's opinion a clinically significant upper or lower respiratory infection within 4 weeks prior to the screening visit."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Significant, non-reversible, active pulmonary disease (e.g. chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, tuberculosis).", "unit": "NA", "evidence_text": "Significant, non-reversible, active pulmonary disease (e.g. chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, tuberculosis)."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Current evidence or history of alcohol and/or substance abuse within 12 months prior to the screening visit.", "unit": "NA", "evidence_text": "Current evidence or history of alcohol and/or substance abuse within 12 months prior to the screening visit."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Subjects who have taken beta-blocking agents, tricyclic antidepressants, monoamine oxidase inhibitors, astemizole (Hismanal), quinidine type antiarrhythmics, or", "unit": "NA", "evidence_text": "Subjects who have taken beta-blocking agents, tricyclic antidepressants, monoamine oxidase inhibitors, astemizole (Hismanal), quinidine type antiarrhythmics, or potent CYP 3A4 inhibitors such as ketoconazole within one week prior to the screening visit."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "History of leukotriene receptor antagonist use, e.g. montelukast, within one week prior to the screening visit.", "unit": "NA", "evidence_text": "History of leukotriene receptor antagonist use, e.g. montelukast, within one week prior to the screening visit."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Current use of medications other than those allowed in the protocol that will have an effect on bronchospasm and/or pulmonary function.", "unit": "NA", "evidence_text": "Current use of medications other than those allowed in the protocol that will have an effect on bronchospasm and/or pulmonary function."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Anti-histamines within 2 weeks prior to the screening visit; non-steroidal anti-inflammatory drugs, oral decongestants, inhaled cromolyn sodium, nedocromil sodi", "unit": "NA", "evidence_text": "Anti-histamines within 2 weeks prior to the screening visit; non-steroidal anti-inflammatory drugs, oral decongestants, inhaled cromolyn sodium, nedocromil sodium within one week prior to the screening visit."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Current evidence or history of hypersensitivity or idiosyncratic reaction to test medications, rescue medication, or components.", "unit": "NA", "evidence_text": "Current evidence or history of hypersensitivity or idiosyncratic reaction to test medications, rescue medication, or components."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Use of an investigational drug within 30 days prior to the screening visit (12 weeks if an oral or injectable steroid).", "unit": "NA", "evidence_text": "Use of an investigational drug within 30 days prior to the screening visit (12 weeks if an oral or injectable steroid)."}]}
{"nct_id": "NCT01001234", "eligibility_text": "Inclusion Criteria:\n\n* Patient weighs at least 20 kg (44 pounds)\n* Patient has had a history of migraine with or without aura \\> 6 months with \\>= 1 to \\<= 8 moderate or severe migraine attacks per month in the 2 months prior to screening Visit 1\n* Patient has a history of migraine defined by International Headache Society (IHS) migraine definitions\n* Patient is willing to stay awake for at least 2 hours after administration of the first dose of study medication\n* Patient has not experienced satisfactory relief from migraine pain with nonsteroidal anti-inflammatory drugs (NSAIDs) or N-acetyl-p-aminophenol (APAP) treatment\n* The parent or guardian and patient agree to the patient's participation in the study as indicated by parental/guardian signature on the consent form and\n\npatient assent\n\n\\- For patients taking migraine prophylactic medication, treatment regimen is stable and has been taken for at least 3 months prior to Visit 1.\n\nExclusion Criteria:\n\n* Patient is pregnant or breast-feeding, or is a female expecting to conceive within the projected duration of study participation\n* Patient has a history of mild migraine attacks or migraines that resolve in less than 2 hours\n* Patient has basilar or hemiplegic migraine headaches\n* Patient has \\>15 headache-days per month OR has taken medication for acute\n\nheadache on more than 10 days per month in any of the 3 months prior to screening\n\n* Patient has uncontrolled high blood pressure, uncontrolled diabetes, human immunodeficiency virus (HIV), any\n\ncancer, or any other significant disease\n\n* Patient has a history or clinical evidence of cardiovascular problems or stroke\n* Patient has either demonstrated hypersensitivity to or experienced a serious\n\nadverse event in response to rizatriptan\n\n* Patient did not experience satisfactory relief from migraine pain to prior treatment with 2 or more adequate courses of 5-hydroxytryptamine 1 (5HT1) agonists\n* Patient has a recent history (within the past year) or current evidence of drug or alcohol abuse or is a \"recreational user\" of illicit drugs\n* Patient is currently taking monoamine oxidase inhibitors, methysergide, selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) or propranolol, and is unable to tolerate withdrawal of these medications for the intervals required\n* Patient is currently participating or has participated in a study with an\n\ninvestigational compound or device within 30 days of screening\n\n\\- Patient is legally or mentally incapacitated.", "labeled_rules": [{"type": "inclusion", "field": "history", "operator": "not_contains", "value": "Patient has had a history of migraine with or without aura \\> 6 months with \\>= 1 to \\<= 8 moderate or severe migraine attacks per month in the 2 months prior t", "unit": "NA", "evidence_text": "Patient has had a history of migraine with or without aura \\> 6 months with \\>= 1 to \\<= 8 moderate or severe migraine attacks per month in the 2 months prior to screening Visit 1"}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "Patient has a history of migraine defined by International Headache Society (IHS) migraine definitions", "unit": "NA", "evidence_text": "Patient has a history of migraine defined by International Headache Society (IHS) migraine definitions"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Patient is willing to stay awake for at least 2 hours after administration of the first dose of study medication", "unit": "NA", "evidence_text": "Patient is willing to stay awake for at least 2 hours after administration of the first dose of study medication"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Patient has not experienced satisfactory relief from migraine pain with nonsteroidal anti-inflammatory drugs (NSAIDs) or N-acetyl-p-aminophenol (APAP) treatment", "unit": "NA", "evidence_text": "Patient has not experienced satisfactory relief from migraine pain with nonsteroidal anti-inflammatory drugs (NSAIDs) or N-acetyl-p-aminophenol (APAP) treatment"}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "The parent or guardian and patient agree to the patient's participation in the study as indicated by parental/guardian signature on the consent form and", "unit": "NA", "evidence_text": "The parent or guardian and patient agree to the patient's participation in the study as indicated by parental/guardian signature on the consent form and"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "\\- For patients taking migraine prophylactic medication, treatment regimen is stable and has been taken for at least 3 months prior to Visit 1.", "unit": "NA", "evidence_text": "\\- For patients taking migraine prophylactic medication, treatment regimen is stable and has been taken for at least 3 months prior to Visit 1."}, {"type": "exclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Patient is pregnant or breast-feeding, or is a female expecting to conceive within the projected duration of study participation"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Patient has a history of mild migraine attacks or migraines that resolve in less than 2 hours", "unit": "NA", "evidence_text": "Patient has a history of mild migraine attacks or migraines that resolve in less than 2 hours"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Patient has basilar or hemiplegic migraine headaches", "unit": "NA", "evidence_text": "Patient has basilar or hemiplegic migraine headaches"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Patient has \\>15 headache-days per month OR has taken medication for acute", "unit": "NA", "evidence_text": "Patient has \\>15 headache-days per month OR has taken medication for acute"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "headache on more than 10 days per month in any of the 3 months prior to screening", "unit": "NA", "evidence_text": "headache on more than 10 days per month in any of the 3 months prior to screening"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Patient has uncontrolled high blood pressure, uncontrolled diabetes, human immunodeficiency virus (HIV), any", "unit": "NA", "evidence_text": "Patient has uncontrolled high blood pressure, uncontrolled diabetes, human immunodeficiency virus (HIV), any"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "cancer, or any other significant disease", "unit": "NA", "evidence_text": "cancer, or any other significant disease"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Patient has a history or clinical evidence of cardiovascular problems or stroke", "unit": "NA", "evidence_text": "Patient has a history or clinical evidence of cardiovascular problems or stroke"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Patient has either demonstrated hypersensitivity to or experienced a serious", "unit": "NA", "evidence_text": "Patient has either demonstrated hypersensitivity to or experienced a serious"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Patient did not experience satisfactory relief from migraine pain to prior treatment with 2 or more adequate courses of 5-hydroxytryptamine 1 (5HT1) agonists", "unit": "NA", "evidence_text": "Patient did not experience satisfactory relief from migraine pain to prior treatment with 2 or more adequate courses of 5-hydroxytryptamine 1 (5HT1) agonists"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Patient has a recent history (within the past year) or current evidence of drug or alcohol abuse or is a \"recreational user\" of illicit drugs", "unit": "NA", "evidence_text": "Patient has a recent history (within the past year) or current evidence of drug or alcohol abuse or is a \"recreational user\" of illicit drugs"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Patient is currently taking monoamine oxidase inhibitors, methysergide, selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inh", "unit": "NA", "evidence_text": "Patient is currently taking monoamine oxidase inhibitors, methysergide, selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) or propranolol, and is unable to tolerate withdrawal of these medications for the intervals required"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "investigational compound or device within 30 days of screening", "unit": "NA", "evidence_text": "investigational compound or device within 30 days of screening"}]}
{"nct_id": "NCT01040910", "eligibility_text": "Inclusion Criteria:\n\n1. Patients with a diagnosis IBD at least 3 months before recruitment will be eligible to the study.\n2. Patients with active disease who are resistant to either 5 ASA, steroids or immunomodulators, or who can not receive those drugs due to adverse reactions will be offered the possibility of smoking cannabis at a dose of two cigarettes a day which will contain either regular cannabis or pre treated cannabis as placebo.\n3. Disease activity index of either CDAI of more then 200 in Crohn's disease or Mayo score above 3 in UC.\n4. Age above 20.\n\nExclusion Criteria:\n\n1. Patients with a known mental disorder\n2. Patients who are deemed to be at a high risk of abuse or addiction to the study drug.\n3. Pregnant women\n4. Patients who are sensitive to any of the ingredients of the study medication.\n5. Patients who are unable to give informed consent.\n6. Patients who may need surgery in the near future.", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "Patients with a diagnosis IBD at least 3 months before recruitment will be eligible to the study.", "unit": "NA", "evidence_text": "Patients with a diagnosis IBD at least 3 months before recruitment will be eligible to the study."}, {"type": "inclusion", "field": "medication", "operator": "not_contains", "value": "Patients with active disease who are resistant to either 5 ASA, steroids or immunomodulators, or who can not receive those drugs due to adverse reactions will b", "unit": "NA", "evidence_text": "Patients with active disease who are resistant to either 5 ASA, steroids or immunomodulators, or who can not receive those drugs due to adverse reactions will be offered the possibility of smoking cannabis at a dose of two cigarettes a day which will contain either regular cannabis or pre treated cannabis as placebo."}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Disease activity index of either CDAI of more then 200 in Crohn's disease or Mayo score above 3 in UC.", "unit": "NA", "evidence_text": "Disease activity index of either CDAI of more then 200 in Crohn's disease or Mayo score above 3 in UC."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Patients who are deemed to be at a high risk of abuse or addiction to the study drug.", "unit": "NA", "evidence_text": "Patients who are deemed to be at a high risk of abuse or addiction to the study drug."}, {"type": "exclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Pregnant women"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Patients who are sensitive to any of the ingredients of the study medication.", "unit": "NA", "evidence_text": "Patients who are sensitive to any of the ingredients of the study medication."}, {"type": "exclusion", "field": "other", "operator": "contains", "value": "Patients who are unable to give informed consent.", "unit": "NA", "evidence_text": "Patients who are unable to give informed consent."}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Patients who may need surgery in the near future.", "unit": "NA", "evidence_text": "Patients who may need surgery in the near future."}]}
{"nct_id": "NCT01042366", "eligibility_text": "Inclusion Criteria:\n\n* Subjects must have Stage III-IV melanoma (any tumor thickness and any number of lymph node involvement, and in-transit metastases, or distant metastases) (AJCC). Each diagnosis will be confirmed by pathology review at the Melanoma Center of the University of Pittsburgh Cancer Institute.\n* All subjects have to be HLA-A2 positive (required for immunologic testing).\n* Subjects must have recovered fully from surgery.\n* Availability of resectable or tissue banked tumor cells for autologous tumor dendritic cell vaccine preparation.\n* Sufficient number of tumor cells available for autologous tumor dendritic cell vaccine preparation (min 2.6 x 10 7).\n* Sufficient number of DCs of at least 12 X 10 6 for preparation of the autologous tumor dendritic cell vaccine preparation (if less than needed number of cells will be obtained by one course of leukopheresis, the second leukopheresis will be repeated 2 weeks apart).\n* Subjects must not have received any chemotherapy or immunotherapy within the four weeks preceding vaccination (six weeks for nitrosourea, mitomycin).\n* Subjects must have an expected survival of greater than or equal to 12 months.\n* Subjects must have an ECOG performance status 0 or 1.\n* Subjects must have the following initial and subsequent pretreatment\n* laboratory parameters: Granulocytes \\>=2,500/mm3 Lymphocytes \\>=1000/mm3 Platelets \\>100,000/mm3 Serum Creatinine \\<=1.5 X the ULN AST, ALT, GGT, LDH, Alk phos \\<= 2.5 X the ULN Serum Bilirubin \\<=1.5 X ULN\n* Subjects must be \\>= 18 years of age and must be able to understand the written informed consent.\n* No evidence of active infection, regardless of the degree of severity or localization. Subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection. Subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment.\n* Subjects with measurable disease must have an evaluation for extent of disease (tumor staging) performed within 30 days of start of treatment.\n* Pretreatment baseline evaluations for laboratory parameters must be obtained within 10 to18 days of subject registration\n\nExclusion Criteria:\n\n* Subjects currently treated with anti inflammatory agents including glucocorticoid therapy are ineligible.\n* Subjects currently on treatment with steroids are ineligible, but may receive the DC autologous tumor dendritic cell vaccine 4 weeks after steroid cessation. Subjects on maintenance steroids because of adrenal insufficiency are eligible.\n* Subjects with severely abnormal liver function tests \\[AST (SGOT), ALT (SGPT), GGT, Alk.Phos, LDH, and total bilirubin greater than 2 X ULN\\].\n* Subjects with uncontrolled pain.\n* Subjects with autoimmune disease, HIV, and hepatitis\n* Subjects with symptomatic brain metastasis.\n* Subjects with active prior malignancy (with exception of non-melanoma skin cancers and carcinoma in situ of the cervix).\n* Subjects who have been previously immunized with melanoma vaccine until 10 subjects have been registered in each treatment arm.\n* Subjects who are pregnant.\n* Subjects who have sensitivity to drugs to provide local anesthesia.", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "Subjects must have Stage III-IV melanoma (any tumor thickness and any number of lymph node involvement, and in-transit metastases, or distant metastases) (AJCC)", "unit": "NA", "evidence_text": "Subjects must have Stage III-IV melanoma (any tumor thickness and any number of lymph node involvement, and in-transit metastases, or distant metastases) (AJCC)."}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Each diagnosis will be confirmed by pathology review at the Melanoma Center of the University of Pittsburgh Cancer Institute.", "unit": "NA", "evidence_text": "Each diagnosis will be confirmed by pathology review at the Melanoma Center of the University of Pittsburgh Cancer Institute."}, {"type": "inclusion", "field": "procedure", "operator": "contains", "value": "Subjects must have recovered fully from surgery.", "unit": "NA", "evidence_text": "Subjects must have recovered fully from surgery."}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Availability of resectable or tissue banked tumor cells for autologous tumor dendritic cell vaccine preparation.", "unit": "NA", "evidence_text": "Availability of resectable or tissue banked tumor cells for autologous tumor dendritic cell vaccine preparation."}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Sufficient number of tumor cells available for autologous tumor dendritic cell vaccine preparation (min 2.6 x 10 7).", "unit": "NA", "evidence_text": "Sufficient number of tumor cells available for autologous tumor dendritic cell vaccine preparation (min 2.6 x 10 7)."}, {"type": "inclusion", "field": "medication", "operator": "not_contains", "value": "Subjects must not have received any chemotherapy or immunotherapy within the four weeks preceding vaccination (six weeks for nitrosourea, mitomycin).", "unit": "NA", "evidence_text": "Subjects must not have received any chemotherapy or immunotherapy within the four weeks preceding vaccination (six weeks for nitrosourea, mitomycin)."}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "2", "unit": "NA", "evidence_text": "laboratory parameters: Granulocytes \\>=2,500/mm3 Lymphocytes \\>=1000/mm3 Platelets \\>100,000/mm3 Serum Creatinine \\<=1.5 X the ULN AST, ALT, GGT, LDH, Alk phos \\<= 2.5 X the ULN Serum Bilirubin \\<=1.5 X ULN"}, {"type": "inclusion", "field": "age", "operator": ">=", "value": "18", "unit": "years", "evidence_text": "Subjects must be \\>= 18 years of age and must be able to understand the written informed consent."}, {"type": "inclusion", "field": "history", "operator": "not_contains", "value": "No evidence of active infection, regardless of the degree of severity or localization.", "unit": "NA", "evidence_text": "No evidence of active infection, regardless of the degree of severity or localization."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection.", "unit": "NA", "evidence_text": "Subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment.", "unit": "NA", "evidence_text": "Subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment."}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "Subjects with measurable disease must have an evaluation for extent of disease (tumor staging) performed within 30 days of start of treatment.", "unit": "NA", "evidence_text": "Subjects with measurable disease must have an evaluation for extent of disease (tumor staging) performed within 30 days of start of treatment."}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "Pretreatment baseline evaluations for laboratory parameters must be obtained within 10 to18 days of subject registration", "unit": "NA", "evidence_text": "Pretreatment baseline evaluations for laboratory parameters must be obtained within 10 to18 days of subject registration"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Subjects currently treated with anti inflammatory agents including glucocorticoid therapy are ineligible.", "unit": "NA", "evidence_text": "Subjects currently treated with anti inflammatory agents including glucocorticoid therapy are ineligible."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Subjects currently on treatment with steroids are ineligible, but may receive the DC autologous tumor dendritic cell vaccine 4 weeks after steroid cessation.", "unit": "NA", "evidence_text": "Subjects currently on treatment with steroids are ineligible, but may receive the DC autologous tumor dendritic cell vaccine 4 weeks after steroid cessation."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Subjects on maintenance steroids because of adrenal insufficiency are eligible.", "unit": "NA", "evidence_text": "Subjects on maintenance steroids because of adrenal insufficiency are eligible."}, {"type": "exclusion", "field": "lab", "operator": ">", "value": "2", "unit": "x", "evidence_text": "Subjects with severely abnormal liver function tests \\[AST (SGOT), ALT (SGPT), GGT, Alk.Phos, LDH, and total bilirubin greater than 2 X ULN\\]."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Subjects with autoimmune disease, HIV, and hepatitis", "unit": "NA", "evidence_text": "Subjects with autoimmune disease, HIV, and hepatitis"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Subjects with active prior malignancy (with exception of non-melanoma skin cancers and carcinoma in situ of the cervix).", "unit": "NA", "evidence_text": "Subjects with active prior malignancy (with exception of non-melanoma skin cancers and carcinoma in situ of the cervix)."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Subjects who have been previously immunized with melanoma vaccine until 10 subjects have been registered in each treatment arm.", "unit": "NA", "evidence_text": "Subjects who have been previously immunized with melanoma vaccine until 10 subjects have been registered in each treatment arm."}, {"type": "exclusion", "field": "history", "operator": "!=", "value": "pregnant_or_breastfeeding", "unit": "NA", "evidence_text": "Subjects who are pregnant."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Subjects who have sensitivity to drugs to provide local anesthesia.", "unit": "NA", "evidence_text": "Subjects who have sensitivity to drugs to provide local anesthesia."}]}
{"nct_id": "NCT01045018", "eligibility_text": "Inclusion Criteria:\n\nAdults with newly diagnosed ulcerative colitis or with relapse following prior treatment and who met all the following criteria were eligible for participation in the study:\n\n1. IRB approved consent form signed and dated prior to any study-related activities\n2. Male or, if female, had undergone sterilization (hysterectomy or bilateral tubal ligation), was post-menopausal (defined as 1 year without menses) or has a negative pregnancy test at screening and, if heterosexually active, had used and agreed to continue to use: double-barrier method of contraception (condom and spermicide), oral or patch contraceptives, intrauterine device, or was in a monogamous relationship with a partner who had undergone a vasectomy.\n3. 18 years of age or older\n4. Newly diagnosed with ulcerative colitis or relapsed following prior treatment\n5. Patient had not taken \\> 1.6 g/day of mesalamine or equivalent for 14 days prior to randomization\n6. Disease extending ≥ 15 cm above the anal verge on screening sigmoidoscopy or colonoscopy with confirming biopsy\n7. Mild to moderate ulcerative colitis, defined as a Disease Activity Index (DAI) score between 4 and 9, inclusive, at study entry, and with a PGA of 1 or 2 and mucosal appearance (determined by endoscopy exam) score of 1 or 2 (mild/moderate)\n8. Able and willing to have kept a daily diary during the study\n\nExclusion Criteria:\n\n1. Treatment with topical rectal, oral, or intravenous (IV) corticosteroids within 30 days of screening or immunosuppressives (e.g. azathioprine, 6-mercaptopurine) within the 90 days immediately preceding Screening\n2. Use of rectal - administered aminosalicylates within 7 days of randomization\n3. Patient had taken greater than 1.6 g/day of mesalamine or equivalent within 14 days of randomization\n4. Crohn's disease, ischemic colitis, or disease of bacterial origin\n5. Known allergy or hypersensitivity to aspirin or salicylate compounds\n6. History of or laboratory results showing significant hepatic or renal disease or other significant medical condition which in the opinion of the investigator precluded participation in the study based on efficacy/safety assessments\n7. History of cancer other than basal cell carcinoma within the five years immediately preceding study entry\n8. In relapse for \\> 3 weeks prior to the screening visit\n9. Proctitis below 15 cm from the anal verge\n10. History of or current gastrointestinal bleeding other than bloody stools associated with ulcerative colitis\n11. History of bleeding disorder\n12. Active peptic ulcer disease, history of gastrointestinal obstruction including severe constipation, or anatomic abnormality of the GI tract\n13. Previous colonic surgery\n14. History of alcohol or other substance abuse within the year immediately preceding anticipated study entry\n15. HIV positive\n16. \\> 6 bloody stools per day\n17. Positive stool culture for ova and/or parasites, enteric pathogens including Salmonella, Shigella, Yersinia, and Campylobacter, or positive stool assay for C. difficile toxin\n18. Pregnant or breast feeding\n19. Used an investigational drug in the 30 days prior to randomization\n20. BUN or serum creatinine levels of 1.5 times the upper limit of normal (ULN) or liver enzyme levels \\> 2 times the ULN", "labeled_rules": [{"type": "inclusion", "field": "history", "operator": "contains", "value": "Adults with newly diagnosed ulcerative colitis or with relapse following prior treatment and who met all the following criteria were eligible for participation ", "unit": "NA", "evidence_text": "Adults with newly diagnosed ulcerative colitis or with relapse following prior treatment and who met all the following criteria were eligible for participation in the study:"}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "IRB approved consent form signed and dated prior to any study-related activities", "unit": "NA", "evidence_text": "IRB approved consent form signed and dated prior to any study-related activities"}, {"type": "inclusion", "field": "lab", "operator": "=", "value": "negative", "unit": "NA", "evidence_text": "Male or, if female, had undergone sterilization (hysterectomy or bilateral tubal ligation), was post-menopausal (defined as 1 year without menses) or has a negative pregnancy test at screening and, if heterosexually active, had used and agreed to continue to use: double-barrier method of contraception (condom and spermicide), oral or patch contraceptives, intrauterine device, or was in a monogamous relationship with a partner who had undergone a vasectomy."}, {"type": "inclusion", "field": "age", "operator": ">=", "value": "18", "unit": "years", "evidence_text": "18 years of age or older"}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "Newly diagnosed with ulcerative colitis or relapsed following prior treatment", "unit": "NA", "evidence_text": "Newly diagnosed with ulcerative colitis or relapsed following prior treatment"}, {"type": "inclusion", "field": "history", "operator": "not_contains", "value": "Patient had not taken \\> 1.6 g/day of mesalamine or equivalent for 14 days prior to randomization", "unit": "NA", "evidence_text": "Patient had not taken \\> 1.6 g/day of mesalamine or equivalent for 14 days prior to randomization"}, {"type": "inclusion", "field": "procedure", "operator": "contains", "value": "Disease extending ≥ 15 cm above the anal verge on screening sigmoidoscopy or colonoscopy with confirming biopsy", "unit": "NA", "evidence_text": "Disease extending ≥ 15 cm above the anal verge on screening sigmoidoscopy or colonoscopy with confirming biopsy"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Mild to moderate ulcerative colitis, defined as a Disease Activity Index (DAI) score between 4 and 9, inclusive, at study entry, and with a PGA of 1 or 2 and mu", "unit": "NA", "evidence_text": "Mild to moderate ulcerative colitis, defined as a Disease Activity Index (DAI) score between 4 and 9, inclusive, at study entry, and with a PGA of 1 or 2 and mucosal appearance (determined by endoscopy exam) score of 1 or 2 (mild/moderate)"}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Able and willing to have kept a daily diary during the study", "unit": "NA", "evidence_text": "Able and willing to have kept a daily diary during the study"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Treatment with topical rectal, oral, or intravenous (IV) corticosteroids within 30 days of screening or immunosuppressives (e.g. azathioprine, 6-mercaptopurine)", "unit": "NA", "evidence_text": "Treatment with topical rectal, oral, or intravenous (IV) corticosteroids within 30 days of screening or immunosuppressives (e.g. azathioprine, 6-mercaptopurine) within the 90 days immediately preceding Screening"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Use of rectal - administered aminosalicylates within 7 days of randomization", "unit": "NA", "evidence_text": "Use of rectal - administered aminosalicylates within 7 days of randomization"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Patient had taken greater than 1.6 g/day of mesalamine or equivalent within 14 days of randomization", "unit": "NA", "evidence_text": "Patient had taken greater than 1.6 g/day of mesalamine or equivalent within 14 days of randomization"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Crohn's disease, ischemic colitis, or disease of bacterial origin", "unit": "NA", "evidence_text": "Crohn's disease, ischemic colitis, or disease of bacterial origin"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Known allergy or hypersensitivity to aspirin or salicylate compounds", "unit": "NA", "evidence_text": "Known allergy or hypersensitivity to aspirin or salicylate compounds"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "History of or laboratory results showing significant hepatic or renal disease or other significant medical condition which in the opinion of the investigator pr", "unit": "NA", "evidence_text": "History of or laboratory results showing significant hepatic or renal disease or other significant medical condition which in the opinion of the investigator precluded participation in the study based on efficacy/safety assessments"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "History of cancer other than basal cell carcinoma within the five years immediately preceding study entry", "unit": "NA", "evidence_text": "History of cancer other than basal cell carcinoma within the five years immediately preceding study entry"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "In relapse for \\> 3 weeks prior to the screening visit", "unit": "NA", "evidence_text": "In relapse for \\> 3 weeks prior to the screening visit"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "History of or current gastrointestinal bleeding other than bloody stools associated with ulcerative colitis", "unit": "NA", "evidence_text": "History of or current gastrointestinal bleeding other than bloody stools associated with ulcerative colitis"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "History of bleeding disorder", "unit": "NA", "evidence_text": "History of bleeding disorder"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Active peptic ulcer disease, history of gastrointestinal obstruction including severe constipation, or anatomic abnormality of the GI tract", "unit": "NA", "evidence_text": "Active peptic ulcer disease, history of gastrointestinal obstruction including severe constipation, or anatomic abnormality of the GI tract"}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Previous colonic surgery", "unit": "NA", "evidence_text": "Previous colonic surgery"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "History of alcohol or other substance abuse within the year immediately preceding anticipated study entry", "unit": "NA", "evidence_text": "History of alcohol or other substance abuse within the year immediately preceding anticipated study entry"}, {"type": "exclusion", "field": "history", "operator": "!=", "value": "pregnant_or_breastfeeding", "unit": "NA", "evidence_text": "Pregnant or breast feeding"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Used an investigational drug in the 30 days prior to randomization", "unit": "NA", "evidence_text": "Used an investigational drug in the 30 days prior to randomization"}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "2", "unit": "times", "evidence_text": "BUN or serum creatinine levels of 1.5 times the upper limit of normal (ULN) or liver enzyme levels \\> 2 times the ULN"}]}
{"nct_id": "NCT01050803", "eligibility_text": "Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes (according to the WHO criteria)\n* Older than 18 years\n\nExclusion Criteria:\n\n* Pregnancy\n* Unable to participate in a group program (for example, housebound or unable to communicate in Farsi)\n* Having reduced cognitive ability", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "Diagnosed with type 2 diabetes (according to the WHO criteria)", "unit": "NA", "evidence_text": "Diagnosed with type 2 diabetes (according to the WHO criteria)"}, {"type": "exclusion", "field": "history", "operator": "!=", "value": "pregnant_or_breastfeeding", "unit": "NA", "evidence_text": "Pregnancy"}, {"type": "exclusion", "field": "other", "operator": "contains", "value": "Having reduced cognitive ability", "unit": "NA", "evidence_text": "Having reduced cognitive ability"}]}
{"nct_id": "NCT01054118", "eligibility_text": "Inclusion Criteria:\n\n* Body Mass Index (BMI) between 27.0 and 38.0 kg/m2 (inclusive)\n* Healthy on the basis of physical examination including medical history, vital signs, 12-lead ECG, and all other screening lab tests\n* Men must agree to use a double barrier method of birth control (e.g., condom for them and use of spermicide with diaphragm, hormonal contraceptives or intrauterine devices by female partner) during the study and for three months following the last dose of study medication, and to not donate sperm during the study and for 3 months after receiving the last dose of study medication\n\nExclusion Criteria:\n\n* History of, or currently active, illness or medical condition or disorder that the Investigator considers to be clinically significant\n* Smoker or tobacco user within the past 6 months\n* History of recent major surgery (within 6 months of study start)\n* Positive test for alcohol and/or drugs of abuse\n* Psychological and/or emotional problems, which would render the informed consent invalid, or limit the ability of the volunteer to comply with the study requirements\n* Any condition that, in the opinion of the investigator, would compromise the well being of the volunteer or the study or prevent the volunteer from meeting or performing study requirements", "labeled_rules": [{"type": "inclusion", "field": "procedure", "operator": "contains", "value": "Healthy on the basis of physical examination including medical history, vital signs, 12-lead ECG, and all other screening lab tests", "unit": "NA", "evidence_text": "Healthy on the basis of physical examination including medical history, vital signs, 12-lead ECG, and all other screening lab tests"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Men must agree to use a double barrier method of birth control (e.g., condom for them and use of spermicide with diaphragm, hormonal contraceptives or intrauter", "unit": "NA", "evidence_text": "Men must agree to use a double barrier method of birth control (e.g., condom for them and use of spermicide with diaphragm, hormonal contraceptives or intrauterine devices by female partner) during the study and for three months following the last dose of study medication, and to not donate sperm during the study and for 3 months after receiving the last dose of study medication"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "History of, or currently active, illness or medical condition or disorder that the Investigator considers to be clinically significant", "unit": "NA", "evidence_text": "History of, or currently active, illness or medical condition or disorder that the Investigator considers to be clinically significant"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Smoker or tobacco user within the past 6 months", "unit": "NA", "evidence_text": "Smoker or tobacco user within the past 6 months"}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "History of recent major surgery (within 6 months of study start)", "unit": "NA", "evidence_text": "History of recent major surgery (within 6 months of study start)"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Positive test for alcohol and/or drugs of abuse", "unit": "NA", "evidence_text": "Positive test for alcohol and/or drugs of abuse"}, {"type": "exclusion", "field": "other", "operator": "contains", "value": "Psychological and/or emotional problems, which would render the informed consent invalid, or limit the ability of the volunteer to comply with the study require", "unit": "NA", "evidence_text": "Psychological and/or emotional problems, which would render the informed consent invalid, or limit the ability of the volunteer to comply with the study requirements"}]}
{"nct_id": "NCT01078402", "eligibility_text": "Inclusion Criteria:\n\n\\- Adult patients with active RA, PsA or AS for whom Humira therapy is indicated according to the local product label and who meet the following criteria:\n\n* Are newly prescribed Humira therapy (no prior history of treatment with Humira), including patients with infliximab or etanercept treatment history OR\n* Completed Abbott sponsored interventional clinical trials and are continuing treatment with commercial Humira thereafter.\n\nExclusion Criteria:\n\n* Patients who are being treated or will be treated with drugs at risk of interactions with Humira (see Humira Summary of Product Characteristics)\n* Patients currently participating in another clinical trial\n* Patients with diagnosis of active tuberculosis", "labeled_rules": [{"type": "inclusion", "field": "medication", "operator": "contains", "value": "\\- Adult patients with active RA, PsA or AS for whom Humira therapy is indicated according to the local product label and who meet the following criteria:", "unit": "NA", "evidence_text": "\\- Adult patients with active RA, PsA or AS for whom Humira therapy is indicated according to the local product label and who meet the following criteria:"}, {"type": "inclusion", "field": "medication", "operator": "not_contains", "value": "Are newly prescribed Humira therapy (no prior history of treatment with Humira), including patients with infliximab or etanercept treatment history OR", "unit": "NA", "evidence_text": "Are newly prescribed Humira therapy (no prior history of treatment with Humira), including patients with infliximab or etanercept treatment history OR"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Completed Abbott sponsored interventional clinical trials and are continuing treatment with commercial Humira thereafter.", "unit": "NA", "evidence_text": "Completed Abbott sponsored interventional clinical trials and are continuing treatment with commercial Humira thereafter."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Patients who are being treated or will be treated with drugs at risk of interactions with Humira (see Humira Summary of Product Characteristics)", "unit": "NA", "evidence_text": "Patients who are being treated or will be treated with drugs at risk of interactions with Humira (see Humira Summary of Product Characteristics)"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Patients with diagnosis of active tuberculosis", "unit": "NA", "evidence_text": "Patients with diagnosis of active tuberculosis"}]}
{"nct_id": "NCT01080677", "eligibility_text": "Inclusion Criteria:1. Subject has a minimum 12-month migraine history that the investigator determines meets the International Headache Society (IHS) Migraine Diagnostic Criteria for migraine with or without aura 2. Subject is between 18-50 years of age. 3. Subject experiences an average of 2-8 migraines per month. 4. If on preventive migraine therapy, medication regimen has been stable for 30 days and will remain stable for the duration of participation.\n\n5\\. Subject is able to communicate adequately and comply with the requirements of the study as determined by the investigator.\n\n6\\. Subject is able to read and understand the informed consent written in English and voluntarily consents to sign the informed consent form.\n\nExclusion Criteria:1. Subject#s age of migraine onset is greater than 50 years. 2. Subject has more than 6 non-migraine headache days per month. 3. Subject has less than 48 hours of freedom from headache between attacks of migraine.\n\n4\\. Subject meets the criteria for complicated and/or brainstem migraines. 5. Subject is pregnant or lactating. 6. Subject has history of alcohol or drug abuse within the past 2 years. 7. Subject has existing systolic blood pressure \\< 100mm Hg, existing systolic blood pressure \\> 150mm Hg, and or heart rate \\<50 beats per minute.\n\n8\\. Subject has heart block greater than 1st degree without a functioning pacemaker 9. Subject has a history of tachyarrythmias 10. Subject has uncompensated congestive heart failure (CHF) 11. Subject has severe chronic obstructive pulmonary disease or severe asthma. 12. Subject has consumed caffeine within 6 hours. 13. Subjects with existing generalized anxiety disorder (GAD) and/or panic disorder.\n\n14\\. Subjects with existing severe hepatic and/or renal insufficiency. 15. Subjects with existing Raynaud#s disease. 16. Subject is participating in another clinical trial during or within 30 days prior to study enrollment.", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "Subject has a minimum 12-month migraine history that the investigator determines meets the International Headache Society (IHS) Migraine Diagnostic Criteria for", "unit": "NA", "evidence_text": "Subject has a minimum 12-month migraine history that the investigator determines meets the International Headache Society (IHS) Migraine Diagnostic Criteria for migraine with or without aura 2."}, {"type": "inclusion", "field": "age", "operator": "between", "value": "18-50", "unit": "years", "evidence_text": "Subject is between 18-50 years of age."}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Subject experiences an average of 2-8 migraines per month.", "unit": "NA", "evidence_text": "Subject experiences an average of 2-8 migraines per month."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "If on preventive migraine therapy, medication regimen has been stable for 30 days and will remain stable for the duration of participation.", "unit": "NA", "evidence_text": "If on preventive migraine therapy, medication regimen has been stable for 30 days and will remain stable for the duration of participation."}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "6\\. Subject is able to read and understand the informed consent written in English and voluntarily consents to sign the informed consent form.", "unit": "NA", "evidence_text": "6\\. Subject is able to read and understand the informed consent written in English and voluntarily consents to sign the informed consent form."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Subject meets the criteria for complicated and/or brainstem migraines.", "unit": "NA", "evidence_text": "Subject meets the criteria for complicated and/or brainstem migraines."}, {"type": "exclusion", "field": "history", "operator": "!=", "value": "pregnant_or_breastfeeding", "unit": "NA", "evidence_text": "Subject is pregnant or lactating."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Subject has history of alcohol or drug abuse within the past 2 years.", "unit": "NA", "evidence_text": "Subject has history of alcohol or drug abuse within the past 2 years."}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "100", "unit": "mm", "evidence_text": "Subject has existing systolic blood pressure \\< 100mm Hg, existing systolic blood pressure \\> 150mm Hg, and or heart rate \\<50 beats per minute."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Subject has a history of tachyarrythmias 10.", "unit": "NA", "evidence_text": "Subject has a history of tachyarrythmias 10."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Subject has uncompensated congestive heart failure (CHF) 11.", "unit": "NA", "evidence_text": "Subject has uncompensated congestive heart failure (CHF) 11."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Subject has severe chronic obstructive pulmonary disease or severe asthma.", "unit": "NA", "evidence_text": "Subject has severe chronic obstructive pulmonary disease or severe asthma."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Subject has consumed caffeine within 6 hours.", "unit": "NA", "evidence_text": "Subject has consumed caffeine within 6 hours."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Subjects with existing Raynaud#s disease.", "unit": "NA", "evidence_text": "Subjects with existing Raynaud#s disease."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Subject is participating in another clinical trial during or within 30 days prior to study enrollment.", "unit": "NA", "evidence_text": "Subject is participating in another clinical trial during or within 30 days prior to study enrollment."}]}
{"nct_id": "NCT01110395", "eligibility_text": "Inclusion Criteria:\n\n* Individuals with left ventricular dysfunction\n\nExclusion Criteria:\n\n* Age \\< 18, pregnant, history of excessive alcohol use, or any condition (e.g. claustrophobia, a pacemaker) that would prevent him/her from completing the magnetic resonance spectroscopy study", "labeled_rules": [{"type": "exclusion", "field": "age", "operator": "<", "value": "18", "unit": "years", "evidence_text": "Age \\< 18, pregnant, history of excessive alcohol use, or any condition (e.g. claustrophobia, a pacemaker) that would prevent him/her from completing the magnetic resonance spectroscopy study"}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "Individuals with left ventricular dysfunction", "unit": "NA", "evidence_text": "Individuals with left ventricular dysfunction"}, {"type": "exclusion", "field": "history", "operator": "contains", "value": "Age \\< 18, pregnant, history of excessive alcohol use, or any condition (e.g. claustrophobia, a pacemaker) that would prevent him/her from completing the magnet", "unit": "NA", "evidence_text": "Age \\< 18, pregnant, history of excessive alcohol use, or any condition (e.g. claustrophobia, a pacemaker) that would prevent him/her from completing the magnetic resonance spectroscopy study"}]}
{"nct_id": "NCT01120561", "eligibility_text": "Inclusion Criteria:\n\n* Histologically or cytologically documented breast cancer\n* Locally advanced or metastatic breast cancer\n* HER2-positive breast cancer documented as FISH-positive, IHC 3 + or CISH-positive by local laboratory assessment\n* Histologically or cytologically confirmed invasive breast cancer: incurable, unresectable, locally advanced breast cancer previously treated with multimodality therapy or metastatic breast cancer\n* Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or metastatic setting must include both: a taxane, alone or in combination with another agent, and Trastuzumab, alone or in combination with another agent in the adjuvant, unresectable, locally advanced, or metastatic setting\n* Documented progression of incurable unresectable, locally advanced, or metastatic breast cancer during their most recent treatment regimen\n* Progression must occur during or after most recent treatment for locally advanced/metastatic breast cancer or within 6 months after completing adjuvant therapy\n* Adequate hematologic and end organ function\n* Agreement to use an effective form of birth control throughout the study\n* Life expectancy ≥ 90 days as assessed by the investigator\n\nExclusion Criteria:\n\n* Less than 14 days from the first study treatment since the last anti-cancer therapy, including chemotherapy, biologic, experimental, immune, hormonal or endocrine therapy\n* Prior T-DM1 therapy\n* History of exposure to cumulative doses of select anthracyclines\n* History of intolerance or hypersensitivity to trastuzumab, murine proteins, or any of the excipients, that resulted in trastuzumab being permanently discontinued\n* Brain metastases that are untreated or progressive or currently require any type of therapy, including radiation, surgery, and/or steroids to control symptoms from brain metastases within 30 days before the first study treatment\n* Peripheral neuropathy of Grade ≥ 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0, at the time of the first study treatment\n* History of clinically significant cardiac dysfunction\n* Current known active infection with HIV, hepatitis B virus, or hepatitis C virus\n* Current severe, uncontrolled systemic disease\n* Major surgical procedure or significant traumatic injury within 28 days prior to first study treatment\n* Pregnancy or lactation\n\nNOTE: The site selection process has been completed. Patients can enroll at participating sites.", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "Histologically or cytologically documented breast cancer", "unit": "NA", "evidence_text": "Histologically or cytologically documented breast cancer"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Locally advanced or metastatic breast cancer", "unit": "NA", "evidence_text": "Locally advanced or metastatic breast cancer"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "HER2-positive breast cancer documented as FISH-positive, IHC 3 + or CISH-positive by local laboratory assessment", "unit": "NA", "evidence_text": "HER2-positive breast cancer documented as FISH-positive, IHC 3 + or CISH-positive by local laboratory assessment"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Histologically or cytologically confirmed invasive breast cancer: incurable, unresectable, locally advanced breast cancer previously treated with multimodality ", "unit": "NA", "evidence_text": "Histologically or cytologically confirmed invasive breast cancer: incurable, unresectable, locally advanced breast cancer previously treated with multimodality therapy or metastatic breast cancer"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or metastatic setting must include both: a taxane, alone or in combination wi", "unit": "NA", "evidence_text": "Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or metastatic setting must include both: a taxane, alone or in combination with another agent, and Trastuzumab, alone or in combination with another agent in the adjuvant, unresectable, locally advanced, or metastatic setting"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Documented progression of incurable unresectable, locally advanced, or metastatic breast cancer during their most recent treatment regimen", "unit": "NA", "evidence_text": "Documented progression of incurable unresectable, locally advanced, or metastatic breast cancer during their most recent treatment regimen"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Progression must occur during or after most recent treatment for locally advanced/metastatic breast cancer or within 6 months after completing adjuvant therapy", "unit": "NA", "evidence_text": "Progression must occur during or after most recent treatment for locally advanced/metastatic breast cancer or within 6 months after completing adjuvant therapy"}, {"type": "exclusion", "field": "lab", "operator": "<", "value": "14", "unit": "days", "evidence_text": "Less than 14 days from the first study treatment since the last anti-cancer therapy, including chemotherapy, biologic, experimental, immune, hormonal or endocrine therapy"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Prior T-DM1 therapy", "unit": "NA", "evidence_text": "Prior T-DM1 therapy"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "History of exposure to cumulative doses of select anthracyclines", "unit": "NA", "evidence_text": "History of exposure to cumulative doses of select anthracyclines"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "History of intolerance or hypersensitivity to trastuzumab, murine proteins, or any of the excipients, that resulted in trastuzumab being permanently discontinue", "unit": "NA", "evidence_text": "History of intolerance or hypersensitivity to trastuzumab, murine proteins, or any of the excipients, that resulted in trastuzumab being permanently discontinued"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Brain metastases that are untreated or progressive or currently require any type of therapy, including radiation, surgery, and/or steroids to control symptoms f", "unit": "NA", "evidence_text": "Brain metastases that are untreated or progressive or currently require any type of therapy, including radiation, surgery, and/or steroids to control symptoms from brain metastases within 30 days before the first study treatment"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Peripheral neuropathy of Grade ≥ 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0, at the time of the fir", "unit": "NA", "evidence_text": "Peripheral neuropathy of Grade ≥ 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0, at the time of the first study treatment"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "History of clinically significant cardiac dysfunction", "unit": "NA", "evidence_text": "History of clinically significant cardiac dysfunction"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Current known active infection with HIV, hepatitis B virus, or hepatitis C virus", "unit": "NA", "evidence_text": "Current known active infection with HIV, hepatitis B virus, or hepatitis C virus"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Current severe, uncontrolled systemic disease", "unit": "NA", "evidence_text": "Current severe, uncontrolled systemic disease"}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Major surgical procedure or significant traumatic injury within 28 days prior to first study treatment", "unit": "NA", "evidence_text": "Major surgical procedure or significant traumatic injury within 28 days prior to first study treatment"}, {"type": "exclusion", "field": "history", "operator": "!=", "value": "pregnant_or_breastfeeding", "unit": "NA", "evidence_text": "Pregnancy or lactation"}]}
{"nct_id": "NCT01126177", "eligibility_text": "1. Male or female aged 18 to 65 years of age at the time of screening.\n2. Symptoms of asthma for at least 2 years pri or to the Screening Visit, confirmed by a medical history and:\n\n   1. ≥12% and 200mL bronchodilator reversibility at screening or documented in the past, OR,\n   2. evidence of bronchial hyper-responsiveness at screening or documented in the past, OR,\n   3. a documented hospital admission (including an Accident and Emergency admission) for asthma since the age of 18, OR.\n   4. documented evidence that they have attended their GP surgery, out-of-hours clinic (or alternative health care provider) for worsening of asthma symptoms, since the age of 18\n3. Must answer \"Yes\" to the question \"Does a cold make your asthma worse?\"\n4. To have had at least one asthma exacerbation suspected to have been caused by a respiratory virus in the last 24 months which required the use of oral steroids and/or additional treatment with antibiotics on one or more occasion.\n5. Must be taking regular inhaled corticosteroids.\n6. Pre-bronchodilator FEV1 ≥ 40 % predicted at screening.\n7. Post-bronchodilator FEV1 ≥ 50 % predicted at screening.\n8. Provide written informed consent.\n9. Females of childbearing potential must be using a medically acceptable adequate form of birth control and agree to maintain this usage throughout the duration of and four weeks post the Treatment Phase of the study.\n10. Motivation (in the Investigator\"s opinion) to complete all study visits, the ability to communicate well with the Investigator and be capable of understanding the nature of the research and its treatment including its risks and benefits.", "labeled_rules": [{"type": "inclusion", "field": "age", "operator": "between", "value": "18-65", "unit": "years", "evidence_text": "Male or female aged 18 to 65 years of age at the time of screening."}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Symptoms of asthma for at least 2 years pri or to the Screening Visit, confirmed by a medical history and:", "unit": "NA", "evidence_text": "Symptoms of asthma for at least 2 years pri or to the Screening Visit, confirmed by a medical history and:"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "a documented hospital admission (including an Accident and Emergency admission) for asthma since the age of 18, OR.", "unit": "NA", "evidence_text": "a documented hospital admission (including an Accident and Emergency admission) for asthma since the age of 18, OR."}, {"type": "inclusion", "field": "procedure", "operator": "contains", "value": "documented evidence that they have attended their GP surgery, out-of-hours clinic (or alternative health care provider) for worsening of asthma symptoms, since ", "unit": "NA", "evidence_text": "documented evidence that they have attended their GP surgery, out-of-hours clinic (or alternative health care provider) for worsening of asthma symptoms, since the age of 18"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Must answer \"Yes\" to the question \"Does a cold make your asthma worse?\"", "unit": "NA", "evidence_text": "Must answer \"Yes\" to the question \"Does a cold make your asthma worse?\""}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "To have had at least one asthma exacerbation suspected to have been caused by a respiratory virus in the last 24 months which required the use of oral steroids ", "unit": "NA", "evidence_text": "To have had at least one asthma exacerbation suspected to have been caused by a respiratory virus in the last 24 months which required the use of oral steroids and/or additional treatment with antibiotics on one or more occasion."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Must be taking regular inhaled corticosteroids.", "unit": "NA", "evidence_text": "Must be taking regular inhaled corticosteroids."}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Provide written informed consent.", "unit": "NA", "evidence_text": "Provide written informed consent."}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Females of childbearing potential must be using a medically acceptable adequate form of birth control and agree to maintain this usage throughout the duration of and four weeks post the Treatment Phase of the study."}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Motivation (in the Investigator\"s opinion) to complete all study visits, the ability to communicate well with the Investigator and be capable of understanding t", "unit": "NA", "evidence_text": "Motivation (in the Investigator\"s opinion) to complete all study visits, the ability to communicate well with the Investigator and be capable of understanding the nature of the research and its treatment including its risks and benefits."}]}
{"nct_id": "NCT01138046", "eligibility_text": "Inclusion Criteria:\n\n* Prior written consent in participating in the study by the subject or his/her private attorney.\n* Japanese female \\>=18 years of age.\n* Invasive breast cancer with stage IV disease.\n* Documentation by local laboratory of ErbB2 status by immunohistochemistry (IHC) or amplification by fluorescence in situ hybridization (FISH).\n* If a taxane had been administered in the neoadjuvant or adjuvant setting, progression must have occurred \\>12 months after completion of this treatment and the patients recovered from all associated toxicities.\n* Measurable lesion(s) according to RECIST criteria.\n* Radiotherapy as palliative treatment for painful metastatic disease is permitted but must have been stopped within 2 weeks prior to initiation of any investigational treatment.\n* For those patients whose disease is ER+ and/or PR+ one of the following criteria should be met:\n\n  * Patient with visceral disease that requires chemotherapy (e.g., patients with liver or lung metastases).\n  * Rapidly progressing or life threatening disease that are considered to be inapplicable to hormonal therapy, as determined by the investigator.\n  * Patients who received hormonal therapy and are no longer benefiting from this therapy and the hormonal treatment must have been stopped before the first dose of investigational treatment.\n  * Subjects recovered from all the associated toxicities by prior endocrine therapy.\n* Eastern cooperative oncology group (ECOG) Performance status (PS) of 0 or 1.\n* Able to swallow and retain oral medication.\n* Cardiac ejection fraction within institutional range of normal as measured by echocardiogram. MUGA scan is accepted in cases where an echocardiogram cannot be performed or is inconclusive.\n* Adequate organ function.\n\nExclusion Criteria:\n\n* Pregnant or lactating females at anytime during the study.\n* Received prior chemotherapy, immunotherapy, biologic therapy or anti-ErbB1/ErbB2 therapy for metastatic disease.\n* History of other malignancy.\n* Prior therapy with an ErbB1 and/or ErbB2 inhibitor, other than trastuzumab, in the adjuvant setting.\n* Planned concurrent anti-cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy) while taking investigational treatment.\n* Used an investigational drug within 30 days or five half-lives, whichever is longer, preceding the first dose of investigational treatment.\n* Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior anti-cancer treatment.\n* Uncontrolled infection.\n* Patients having at least positive antibody either to HBs or HBc.\n* Patients who have had a positive HCV antibody.\n* Peripheral neuropathy grade 2 or greater.\n* Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded.\n* Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.\n* Known history or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis.\n* Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety.\n* Known history or concurrent condition of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure.\n* Concurrent treatment with prohibited medications.\n* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to paclitaxel or lapatinib or their excipients.\n* Have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment).", "labeled_rules": [{"type": "inclusion", "field": "history", "operator": "contains", "value": "Prior written consent in participating in the study by the subject or his/her private attorney.", "unit": "NA", "evidence_text": "Prior written consent in participating in the study by the subject or his/her private attorney."}, {"type": "inclusion", "field": "age", "operator": ">=", "value": "18", "unit": "years", "evidence_text": "Japanese female \\>=18 years of age."}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Invasive breast cancer with stage IV disease.", "unit": "NA", "evidence_text": "Invasive breast cancer with stage IV disease."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Radiotherapy as palliative treatment for painful metastatic disease is permitted but must have been stopped within 2 weeks prior to initiation of any investigat", "unit": "NA", "evidence_text": "Radiotherapy as palliative treatment for painful metastatic disease is permitted but must have been stopped within 2 weeks prior to initiation of any investigational treatment."}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "For those patients whose disease is ER+ and/or PR+ one of the following criteria should be met:", "unit": "NA", "evidence_text": "For those patients whose disease is ER+ and/or PR+ one of the following criteria should be met:"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Patient with visceral disease that requires chemotherapy (e.g., patients with liver or lung metastases).", "unit": "NA", "evidence_text": "Patient with visceral disease that requires chemotherapy (e.g., patients with liver or lung metastases)."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Rapidly progressing or life threatening disease that are considered to be inapplicable to hormonal therapy, as determined by the investigator.", "unit": "NA", "evidence_text": "Rapidly progressing or life threatening disease that are considered to be inapplicable to hormonal therapy, as determined by the investigator."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Patients who received hormonal therapy and are no longer benefiting from this therapy and the hormonal treatment must have been stopped before the first dose of", "unit": "NA", "evidence_text": "Patients who received hormonal therapy and are no longer benefiting from this therapy and the hormonal treatment must have been stopped before the first dose of investigational treatment."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Subjects recovered from all the associated toxicities by prior endocrine therapy.", "unit": "NA", "evidence_text": "Subjects recovered from all the associated toxicities by prior endocrine therapy."}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Able to swallow and retain oral medication.", "unit": "NA", "evidence_text": "Able to swallow and retain oral medication."}, {"type": "inclusion", "field": "history", "operator": "not_contains", "value": "Cardiac ejection fraction within institutional range of normal as measured by echocardiogram. MUGA scan is accepted in cases where an echocardiogram cannot be p", "unit": "NA", "evidence_text": "Cardiac ejection fraction within institutional range of normal as measured by echocardiogram. MUGA scan is accepted in cases where an echocardiogram cannot be performed or is inconclusive."}, {"type": "exclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Pregnant or lactating females at anytime during the study."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Received prior chemotherapy, immunotherapy, biologic therapy or anti-ErbB1/ErbB2 therapy for metastatic disease.", "unit": "NA", "evidence_text": "Received prior chemotherapy, immunotherapy, biologic therapy or anti-ErbB1/ErbB2 therapy for metastatic disease."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "History of other malignancy.", "unit": "NA", "evidence_text": "History of other malignancy."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Prior therapy with an ErbB1 and/or ErbB2 inhibitor, other than trastuzumab, in the adjuvant setting.", "unit": "NA", "evidence_text": "Prior therapy with an ErbB1 and/or ErbB2 inhibitor, other than trastuzumab, in the adjuvant setting."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Planned concurrent anti-cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy) while taking investigational treatme", "unit": "NA", "evidence_text": "Planned concurrent anti-cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy) while taking investigational treatment."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Used an investigational drug within 30 days or five half-lives, whichever is longer, preceding the first dose of investigational treatment.", "unit": "NA", "evidence_text": "Used an investigational drug within 30 days or five half-lives, whichever is longer, preceding the first dose of investigational treatment."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior anti-cancer treatment.", "unit": "NA", "evidence_text": "Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior anti-cancer treatment."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis ", "unit": "NA", "evidence_text": "Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.", "unit": "NA", "evidence_text": "Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Known history or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis.", "unit": "NA", "evidence_text": "Known history or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the ", "unit": "NA", "evidence_text": "Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Known history or concurrent condition of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure.", "unit": "NA", "evidence_text": "Known history or concurrent condition of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Concurrent treatment with prohibited medications.", "unit": "NA", "evidence_text": "Concurrent treatment with prohibited medications."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to paclitaxel or lapatinib or their excipients.", "unit": "NA", "evidence_text": "Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to paclitaxel or lapatinib or their excipients."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic ", "unit": "NA", "evidence_text": "Have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)."}]}
{"nct_id": "NCT01139086", "eligibility_text": "Inclusion Criteria:\n\n* Age 40-75 years\n* Chronic heart failure: ejection fraction\\<40% and at stable condition\n* Coronary Disease and dilated cardiomyopathy without heart failure\n* Control group without diagnosis of any heart disease\n\nExclusion Criteria:\n\n* Clinical diagnosis of neuromusculoskeletal , pulmonary, or other systemic diseases that may affect the testing of the study", "labeled_rules": [{"type": "inclusion", "field": "age", "operator": "between", "value": "40-75", "unit": "years", "evidence_text": "Age 40-75 years"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "40", "unit": "%", "evidence_text": "Chronic heart failure: ejection fraction\\<40% and at stable condition"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Coronary Disease and dilated cardiomyopathy without heart failure", "unit": "NA", "evidence_text": "Coronary Disease and dilated cardiomyopathy without heart failure"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Control group without diagnosis of any heart disease", "unit": "NA", "evidence_text": "Control group without diagnosis of any heart disease"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Clinical diagnosis of neuromusculoskeletal , pulmonary, or other systemic diseases that may affect the testing of the study", "unit": "NA", "evidence_text": "Clinical diagnosis of neuromusculoskeletal , pulmonary, or other systemic diseases that may affect the testing of the study"}]}
{"nct_id": "NCT01158274", "eligibility_text": "Inclusion Criteria:\n\n* Patients must have histologically or cytologically confirmed advanced or metastatic solid tumor; patients with lymphoma will be eligible\n* Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \\>= 20 mm with conventional techniques or as \\>= 10 mm with spiral CT scan\n* Patients must be at least 4 weeks since prior chemotherapy, 6 weeks if the last regimen included BCNU or mitomycin C; prior radiation is allowed as long as the radiation was completed 4 weeks prior to study treatment and no more than 35% of marrow irradiated\n* Life expectancy of greater than 3 months\n* ECOG performance status =\\< 2 (Karnofsky \\>= 60%)\n* Hemoglobin \\>= 9 g/dL\n* Leukocytes \\>= 3,000/mcL\n* Absolute neutrophil count \\>= 1,500/mcL\n* Platelets \\>= 100,000/mcL\n* Total bilirubin within normal institutional limits\n* AST (SGOT)/ALT (SGPT) =\\< 2.5 X institutional upper limit of normal\n* Creatinine within normal institutional limits OR creatinine clearance \\>= 60 mL/min/1.73 m\\^2 for patients with creatinine levels above institutional normal; a 24 hour urine collection and creatinine clearance can be measured if indicated\n* Treated, stable brain metastases are allowed; patients must be four weeks from radiation with stable brain imaging and off any medications used to treat brain metastases, excepting those anti-epileptics not metabolized by cytochrome P450\n* Women of childbearing potential and men must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks prior to study entry, for the duration of study participation, and for at least 12 months post-treatment; should a woman become pregnant or suspect she is pregnant while she or her partner are participating in this study and for 12 months after study participation, the patient should inform the treating physician immediately\n* Women of childbearing potential are required to have a negative serum pregnancy test (with a sensitivity of at least 25 mIU/mL) within 10-14 days and within 24 hours prior to the first dose of RO4929097 (serum or urine); a pregnancy test (serum or urine) will be administered every 4 weeks if their menstrual cycles are regular or every 2 weeks if their cycles are irregular while on study within the 24-hour period prior to the administration of RO4929097; a positive urine test must be confirmed by a serum pregnancy test; prior to dispensing RO4929097, the investigator must confirm and document the patient's use of two contraceptive methods, dates of negative pregnancy test, and confirm the patient's understanding of the teratogenic potential of RO4929097\n* Female patients of childbearing potential are defined as follows:\n\n  * Patients with regular menses\n  * Patients, after menarche with amenorrhea, irregular cycles, or using a contraceptive method that precludes withdrawal bleeding\n  * Women who have had tubal ligation\n* Female patients may be considered NOT to be of childbearing potential for the following reasons:\n\n  * The patient has undergone total abdominal hysterectomy with bilateral salpingo-oophorectomy or bilateral oophorectomy\n  * The patient is medically confirmed to be menopausal (no menstrual period) for 24 consecutive months\n  * Pre-pubertal females. The parent or guardian of young female patients who have not yet started menstruation should verify that menstruation has not begun. If a young female patient reaches menarche during the study, then she is to be considered as a woman of childbearing potential from that time forward\n* Patients must demonstrate an ability to understand and the willingness to sign a written informed consent document\n* Preclinical studies indicate that RO4929097 is a substrate of CYP3A4 and inducer of CYP3A4 enzyme activity; caution should be exercised when dosing RO4929097 concurrently with CYP3A4 substrates, inducers, and/or inhibitors; furthermore, patients who are taking concurrent medications that are strong inducers/inhibitors or substrates of CYP3A4 should be switched to alternative medications to minimize any potential risk; if such patients cannot be switched to alternative medications, they will be ineligible to participate in this study\n* PART 2A (MTD EXPANSION COLORECTAL CANCER):\n* For this cohort patients must have histologically or cytologically documented advanced or metastatic colorectal cancer; patients must have had at least one prior chemotherapy regimen for their disease but no more than 2\n* All 5 patients in this cohort must be willing and able to have tumor biopsies performed as part of the correlative studies associated with this trial\n* PART 2B (MTD EXPANSION BREAST CANCER):\n* For this cohort, patients must have histologically or cytologically documented advanced or metastatic breast cancer\n* Patient must be HER2/neu negative; HER2 negative will be defined as HER2 neither over-expressed or amplified; HER2 will be considered NOT over-expressed if the tumor stains as 0 or 1+ for HER2 by immunohistochemistry (IHC); if the IHC for HER2 is 2+, fluorescence in-site hybridization (FISH) ratio must be less than 2 to be considered NOT amplified; any tumor for which only FISH was performed must have a ratio of less than 2 to be considered NOT amplified\n* All 5 patients in this breast cancer cohort must be willing and able to have tumor biopsies performed as part of the correlative studies associated with this trial\n\nExclusion Criteria:\n\n* Patients may not be receiving any other investigational agents\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to RO4929097 or capecitabine\n* Patients taking medications with narrow therapeutic indices that are metabolized by cytochrome P450 (CYP450), including warfarin sodium (Coumadin®) are ineligible\n* Patients with malabsorption syndrome or other condition that would interfere with intestinal absorption; patients must be able to swallow tablets\n* Patients who are serologically positive for Hepatitis A, B or C, or have a history of liver disease, other forms of hepatitis or cirrhosis are ineligible\n* Patients with uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia or hypokalemia defined as less than the lower limit of normal for the institution, despite adequate electrolyte supplementation are excluded from this study; note: it is acceptable to use corrected calcium when interpreting calcium levels\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, and a history of torsades de pointes or other significant cardiac arrhythmia other than chronic, stable atrial fibrillation, or psychiatric illness/social situations that would limit compliance with study requirements\n* Pregnant women are excluded from this study; breastfeeding should be discontinued\n* HIV-positive patients, who are not on anti-retroviral therapy but have CD4 cells less than 200, should be excluded; HIV-positive patients are eligible if they are on HAART (highly active anti-retroviral therapy) which are not CYP3A4 substrates, inducers and/or inhibitors and meet all other criteria\n* Cardiovascular: baseline QTcF \\> 450 msec\n* Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency enzyme are excluded\n* Patients who have not recovered to \\< CTCAE grade 2 toxicities related to prior therapy are not eligible to participate in this study\n* A requirement for antiarrhythmics or other medications known to prolong QTc\n* PART2B (MTD EXPANSION BREAST CANCER):\n* Patients may not have had more than 1 prior cytotoxic chemotherapy for metastatic disease; prior endocrine or immunotherapy regimens for metastatic disease will not be counted as cytotoxic", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "Patients must have histologically or cytologically confirmed advanced or metastatic solid tumor; patients with lymphoma will be eligible", "unit": "NA", "evidence_text": "Patients must have histologically or cytologically confirmed advanced or metastatic solid tumor; patients with lymphoma will be eligible"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "20", "unit": "mm", "evidence_text": "Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \\>= 20 mm with conventional techniques or as \\>= 10 mm with spiral CT scan"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Patients must be at least 4 weeks since prior chemotherapy, 6 weeks if the last regimen included BCNU or mitomycin C;", "unit": "NA", "evidence_text": "Patients must be at least 4 weeks since prior chemotherapy, 6 weeks if the last regimen included BCNU or mitomycin C;"}, {"type": "inclusion", "field": "procedure", "operator": "contains", "value": "prior radiation is allowed as long as the radiation was completed 4 weeks prior to study treatment and no more than 35% of marrow irradiated", "unit": "NA", "evidence_text": "prior radiation is allowed as long as the radiation was completed 4 weeks prior to study treatment and no more than 35% of marrow irradiated"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "2", "unit": "NA", "evidence_text": "ECOG performance status =\\< 2 (Karnofsky \\>= 60%)"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "9", "unit": "g/dl", "evidence_text": "Hemoglobin \\>= 9 g/dL"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "1", "unit": "NA", "evidence_text": "Absolute neutrophil count \\>= 1,500/mcL"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "100", "unit": "NA", "evidence_text": "Platelets \\>= 100,000/mcL"}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "Total bilirubin within normal institutional limits", "unit": "NA", "evidence_text": "Total bilirubin within normal institutional limits"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "2.5", "unit": "x", "evidence_text": "AST (SGOT)/ALT (SGPT) =\\< 2.5 X institutional upper limit of normal"}, {"type": "inclusion", "field": "lab", "operator": "contains", "value": "60", "unit": "ml/min/1", "evidence_text": "Creatinine within normal institutional limits OR creatinine clearance \\>= 60 mL/min/1.73 m\\^2 for patients with creatinine levels above institutional normal;"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "patients must be four weeks from radiation with stable brain imaging and off any medications used to treat brain metastases, excepting those anti-epileptics not", "unit": "NA", "evidence_text": "patients must be four weeks from radiation with stable brain imaging and off any medications used to treat brain metastases, excepting those anti-epileptics not metabolized by cytochrome P450"}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "Women of childbearing potential and men must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks", "unit": "NA", "evidence_text": "Women of childbearing potential and men must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks prior to study entry, for the duration of study participation, and for at least 12 months post-treatment;"}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "should a woman become pregnant or suspect she is pregnant while she or her partner are participating in this study and for 12 months after study participation, the patient should inform the treating physician immediately"}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Women of childbearing potential are required to have a negative serum pregnancy test (with a sensitivity of at least 25 mIU/mL) within 10-14 days and within 24 hours prior to the first dose of RO4929097 (serum or urine);"}, {"type": "inclusion", "field": "lab", "operator": "required", "value": "pregnancy test", "unit": "NA", "evidence_text": "a pregnancy test (serum or urine) will be administered every 4 weeks if their menstrual cycles are regular or every 2 weeks if their cycles are irregular while on study within the 24-hour period prior to the administration of RO4929097;"}, {"type": "inclusion", "field": "lab", "operator": "required", "value": "pregnancy test", "unit": "NA", "evidence_text": "a positive urine test must be confirmed by a serum pregnancy test;"}, {"type": "inclusion", "field": "lab", "operator": "=", "value": "negative", "unit": "NA", "evidence_text": "prior to dispensing RO4929097, the investigator must confirm and document the patient's use of two contraceptive methods, dates of negative pregnancy test, and confirm the patient's understanding of the teratogenic potential of RO4929097"}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Female patients of childbearing potential are defined as follows:"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Patients, after menarche with amenorrhea, irregular cycles, or using a contraceptive method that precludes withdrawal bleeding", "unit": "NA", "evidence_text": "Patients, after menarche with amenorrhea, irregular cycles, or using a contraceptive method that precludes withdrawal bleeding"}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Women who have had tubal ligation"}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Female patients may be considered NOT to be of childbearing potential for the following reasons:"}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Pre-pubertal females."}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "The parent or guardian of young female patients who have not yet started menstruation should verify that menstruation has not begun."}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "If a young female patient reaches menarche during the study, then she is to be considered as a woman of childbearing potential from that time forward"}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Patients must demonstrate an ability to understand and the willingness to sign a written informed consent document", "unit": "NA", "evidence_text": "Patients must demonstrate an ability to understand and the willingness to sign a written informed consent document"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "furthermore, patients who are taking concurrent medications that are strong inducers/inhibitors or substrates of CYP3A4 should be switched to alternative medica", "unit": "NA", "evidence_text": "furthermore, patients who are taking concurrent medications that are strong inducers/inhibitors or substrates of CYP3A4 should be switched to alternative medications to minimize any potential risk;"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "if such patients cannot be switched to alternative medications, they will be ineligible to participate in this study", "unit": "NA", "evidence_text": "if such patients cannot be switched to alternative medications, they will be ineligible to participate in this study"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "PART 2A (MTD EXPANSION COLORECTAL CANCER):", "unit": "NA", "evidence_text": "PART 2A (MTD EXPANSION COLORECTAL CANCER):"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "For this cohort patients must have histologically or cytologically documented advanced or metastatic colorectal cancer; patients must have had at least one prio", "unit": "NA", "evidence_text": "For this cohort patients must have histologically or cytologically documented advanced or metastatic colorectal cancer; patients must have had at least one prior chemotherapy regimen for their disease but no more than 2"}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "All 5 patients in this cohort must be willing and able to have tumor biopsies performed as part of the correlative studies associated with this trial", "unit": "NA", "evidence_text": "All 5 patients in this cohort must be willing and able to have tumor biopsies performed as part of the correlative studies associated with this trial"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "PART 2B (MTD EXPANSION BREAST CANCER):", "unit": "NA", "evidence_text": "PART 2B (MTD EXPANSION BREAST CANCER):"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "For this cohort, patients must have histologically or cytologically documented advanced or metastatic breast cancer", "unit": "NA", "evidence_text": "For this cohort, patients must have histologically or cytologically documented advanced or metastatic breast cancer"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "All 5 patients in this breast cancer cohort must be willing and able to have tumor biopsies performed as part of the correlative studies associated with this tr", "unit": "NA", "evidence_text": "All 5 patients in this breast cancer cohort must be willing and able to have tumor biopsies performed as part of the correlative studies associated with this trial"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to RO4929097 or capecitabine", "unit": "NA", "evidence_text": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to RO4929097 or capecitabine"}]}
{"nct_id": "NCT01170676", "eligibility_text": "Inclusion Criteria:\n\n* AA ethnicity\n* in 9th - 11th grade of selected rural schools\n* have an asthma diagnosis and/or asthma-like symptoms by screening eligible on the Lung Health Survey\n* have access to a telephone or mobile phone\n* being the parent of a student meeting the above criteria with whom the student resides the majority of the time.\n\nExclusion Criteria:\n\n* Not meeting the above criteria.", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "have an asthma diagnosis and/or asthma-like symptoms by screening eligible on the Lung Health Survey", "unit": "NA", "evidence_text": "have an asthma diagnosis and/or asthma-like symptoms by screening eligible on the Lung Health Survey"}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "AA ethnicity", "unit": "NA", "evidence_text": "AA ethnicity"}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "in 9th - 11th grade of selected rural schools", "unit": "NA", "evidence_text": "in 9th - 11th grade of selected rural schools"}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "have access to a telephone or mobile phone", "unit": "NA", "evidence_text": "have access to a telephone or mobile phone"}]}
{"nct_id": "NCT01196455", "eligibility_text": "Inclusion Criteria:\n\n* Histologically/cytologically confirmed breast cancer\n* Metastatic breast cancer, having at least one target lesion according to the RECIST criteria. Bone metastases, leptomeningeal disease, ascites, pleural or pericardial effusions, inflammatory breast disease, lymphangitic spread or cystic lesions are not acceptable as target lesions. Target lesions must be ≥ 10 mm longest diameter measured in one dimension using spiral CT, or ≥ 20 mm longest diameter measured in one dimension using conventional techniques. In addition to the definitions pertaining to the target lesion(s) from the RECIST criteria above, the target lesion(s) must not have been previously irradiated (newly arising lesions in previously irradiated areas are acceptable).\n* Age \\> 18 years\n* Signed informed consent obtained prior to initiation of any study-specific procedures or treatment\n\nExclusion Criteria:\n\n* Prior cytotoxic chemotherapy or active/passive immunotherapy for metastatic breast disease\n* Prior usage of capecitabine or mitomycin as adjuvant or neoadjuvant treatment\n* Life expectancy \\< 3 months\n* Not-ambulatory or with an ECOG performance status \\> 1\n* Insufficient hematological, renal and hepatic functions:\n* hemoglobin \\< 8.0 g/dL\n* absolute neutrophils count (ANC) \\< 1.5 x 109/L\n* platelet count \\< 100 x 109/L\n* serum creatinine \\> 1.25 x N\\*\n* total bilirubin \\> 2.0 x N\\*\n* ASAT and/or ALAT \\> 2.5 x N\\* (in case of liver metastases \\> 5 x N\\*)\n* alkaline phosphatase \\> 2.5 x N\\* (in case of liver metastases \\> 5 x N\\*, in case of bone metastases \\> 10 x N\\*) \\*N = upper limit of standard range\n* Severe renal impairment \\[creatinine clearance \\< 30 mL/min (calculated according to cockcroft and Gault)\\]", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "Histologically/cytologically confirmed breast cancer", "unit": "NA", "evidence_text": "Histologically/cytologically confirmed breast cancer"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Metastatic breast cancer, having at least one target lesion according to the RECIST criteria.", "unit": "NA", "evidence_text": "Metastatic breast cancer, having at least one target lesion according to the RECIST criteria."}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Bone metastases, leptomeningeal disease, ascites, pleural or pericardial effusions, inflammatory breast disease, lymphangitic spread or cystic lesions are not a", "unit": "NA", "evidence_text": "Bone metastases, leptomeningeal disease, ascites, pleural or pericardial effusions, inflammatory breast disease, lymphangitic spread or cystic lesions are not acceptable as target lesions."}, {"type": "inclusion", "field": "history", "operator": "not_contains", "value": "In addition to the definitions pertaining to the target lesion(s) from the RECIST criteria above, the target lesion(s) must not have been previously irradiated ", "unit": "NA", "evidence_text": "In addition to the definitions pertaining to the target lesion(s) from the RECIST criteria above, the target lesion(s) must not have been previously irradiated (newly arising lesions in previously irradiated areas are acceptable)."}, {"type": "inclusion", "field": "age", "operator": ">", "value": "18", "unit": "years", "evidence_text": "Age \\> 18 years"}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "Signed informed consent obtained prior to initiation of any study-specific procedures or treatment", "unit": "NA", "evidence_text": "Signed informed consent obtained prior to initiation of any study-specific procedures or treatment"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Prior cytotoxic chemotherapy or active/passive immunotherapy for metastatic breast disease", "unit": "NA", "evidence_text": "Prior cytotoxic chemotherapy or active/passive immunotherapy for metastatic breast disease"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Prior usage of capecitabine or mitomycin as adjuvant or neoadjuvant treatment", "unit": "NA", "evidence_text": "Prior usage of capecitabine or mitomycin as adjuvant or neoadjuvant treatment"}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "1", "unit": "NA", "evidence_text": "Not-ambulatory or with an ECOG performance status \\> 1"}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "8.0", "unit": "g/dl", "evidence_text": "hemoglobin \\< 8.0 g/dL"}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "1.5", "unit": "x", "evidence_text": "absolute neutrophils count (ANC) \\< 1.5 x 109/L"}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "100", "unit": "x", "evidence_text": "platelet count \\< 100 x 109/L"}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "1.25", "unit": "x", "evidence_text": "serum creatinine \\> 1.25 x N\\*"}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "2.0", "unit": "x", "evidence_text": "total bilirubin \\> 2.0 x N\\*"}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "2.5", "unit": "x", "evidence_text": "ASAT and/or ALAT \\> 2.5 x N\\* (in case of liver metastases \\> 5 x N\\*)"}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "2.5", "unit": "x", "evidence_text": "alkaline phosphatase \\> 2.5 x N\\* (in case of liver metastases \\> 5 x N\\*, in case of bone metastases \\> 10 x N\\*) \\*N = upper limit of standard range"}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "30", "unit": "ml/min", "evidence_text": "Severe renal impairment \\[creatinine clearance \\< 30 mL/min (calculated according to cockcroft and Gault)\\]"}]}
{"nct_id": "NCT01206322", "eligibility_text": "Inclusion Criteria:\n\nDiabetes group:\n\n* 30 men and women aged \\>50 years old diagnosed with T2DM and treated \\> 5 years with oral agents\n* Diabetes severity will be assessed from diabetes duration, hemoglobin A1C, and fasting glucose levels.\n\nControl group:\n\n* 30 healthy men and women aged \\>50 years selected to have the same age and sex distributions as the diabetic subjects\n* Normotensive, not treated for any systemic disease, and have normal fasting blood glucose.\n\nExclusion Criteria:\n\n* Type 1 Diabetes Mellitus\n* History of severe hypoglycemia or hypoglycemic episode during home baseline monitoring\n* Positive stress test for CAD or other ischemic conditions\n* Carotid stenosis \\> 50% by medical history\n* History of a clinically documented stroke\n* Treatment with any medications administered intranasally including intranasal steroids\n* Any previous adverse or allergic reactions to insulin\n* Acute or unstable medical condition including Myocardial infarction or major illness and surgery within six months\n* Liver or renal failure or transplant\n* Uncontrolled hypertension (systolic BP \\>180 and/or diastolic BP \\>100 mm Hg or subjects taking more than 3 antihypertensive medications)\n* Seizure disorders\n* Malignant tumors\n* Clinical dementia (by history) or inability to follow details of the protocol(MMSE (Mini Mental Status Exam) score (≥3 points below the Comparative Normal Value for the subject's age group and education level, or ≤ 24)\n* Current recreational drug or alcohol abuse\n* Morbid obesity (BMI \\>40)\n* Inability to obtain permission for participation from the primary care physician\n* Transcranial Doppler (TCD) exclusion criterion - poor insonation window and TCD signal\n* MR exclusion criteria - any metal or bioimplants not compatible with 3 Tesla MRI and claustrophobia\n* Clinically significant and movement limiting hip, knee and/or back disorders or injury, and rheumatoid arthritis", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "Diabetes group:", "unit": "NA", "evidence_text": "Diabetes group:"}, {"type": "inclusion", "field": "sex", "operator": "in", "value": "male,female", "unit": "NA", "evidence_text": "30 men and women aged \\>50 years old diagnosed with T2DM and treated \\> 5 years with oral agents"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Diabetes severity will be assessed from diabetes duration, hemoglobin A1C, and fasting glucose levels.", "unit": "NA", "evidence_text": "Diabetes severity will be assessed from diabetes duration, hemoglobin A1C, and fasting glucose levels."}, {"type": "inclusion", "field": "sex", "operator": "in", "value": "male,female", "unit": "NA", "evidence_text": "30 healthy men and women aged \\>50 years selected to have the same age and sex distributions as the diabetic subjects"}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Normotensive, not treated for any systemic disease, and have normal fasting blood glucose.", "unit": "NA", "evidence_text": "Normotensive, not treated for any systemic disease, and have normal fasting blood glucose."}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Type 1 Diabetes Mellitus", "unit": "NA", "evidence_text": "Type 1 Diabetes Mellitus"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "History of severe hypoglycemia or hypoglycemic episode during home baseline monitoring", "unit": "NA", "evidence_text": "History of severe hypoglycemia or hypoglycemic episode during home baseline monitoring"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "History of a clinically documented stroke", "unit": "NA", "evidence_text": "History of a clinically documented stroke"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Treatment with any medications administered intranasally including intranasal steroids", "unit": "NA", "evidence_text": "Treatment with any medications administered intranasally including intranasal steroids"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Any previous adverse or allergic reactions to insulin", "unit": "NA", "evidence_text": "Any previous adverse or allergic reactions to insulin"}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Acute or unstable medical condition including Myocardial infarction or major illness and surgery within six months", "unit": "NA", "evidence_text": "Acute or unstable medical condition including Myocardial infarction or major illness and surgery within six months"}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Liver or renal failure or transplant", "unit": "NA", "evidence_text": "Liver or renal failure or transplant"}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "180", "unit": "and/or", "evidence_text": "Uncontrolled hypertension (systolic BP \\>180 and/or diastolic BP \\>100 mm Hg or subjects taking more than 3 antihypertensive medications)"}, {"type": "exclusion", "field": "other", "operator": "contains", "value": "Clinical dementia (by history) or inability to follow details of the protocol(MMSE (Mini Mental Status Exam) score (≥3 points below the Comparative Normal Value", "unit": "NA", "evidence_text": "Clinical dementia (by history) or inability to follow details of the protocol(MMSE (Mini Mental Status Exam) score (≥3 points below the Comparative Normal Value for the subject's age group and education level, or ≤ 24)"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Current recreational drug or alcohol abuse", "unit": "NA", "evidence_text": "Current recreational drug or alcohol abuse"}, {"type": "exclusion", "field": "other", "operator": "contains", "value": "Inability to obtain permission for participation from the primary care physician", "unit": "NA", "evidence_text": "Inability to obtain permission for participation from the primary care physician"}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "MR exclusion criteria - any metal or bioimplants not compatible with 3 Tesla MRI and claustrophobia", "unit": "NA", "evidence_text": "MR exclusion criteria - any metal or bioimplants not compatible with 3 Tesla MRI and claustrophobia"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Clinically significant and movement limiting hip, knee and/or back disorders or injury, and rheumatoid arthritis", "unit": "NA", "evidence_text": "Clinically significant and movement limiting hip, knee and/or back disorders or injury, and rheumatoid arthritis"}]}
{"nct_id": "NCT01209000", "eligibility_text": "Cohort A (biopsy cohort) Inclusion Criteria:\n\nPatients presenting with an incipient clinical diagnosis for FSGS/MCD or MN or pediatric participants not previously biopsied, with a clinical diagnosis for FSGS/MCD or MN meeting the following inclusion criteria:\n\n* Documented urinary protein excretion ≥1500 mg/24 hours or spot protein: creatinine ratio equivalent at the time of diagnosis or within 3 months of the screening/eligibility visit.\n* Scheduled renal biopsy\n\nCohort B (non-biopsy, cNEPTUNE) Inclusion Criteria:\n\n* Age \\<19 years of age\n* Initial presentation with \\<30 days immunosuppression therapy\n* Proteinuria/nephrotic\n\n  * UA\\>2+ and edema OR\n  * UA\\>2+ and serum albumin \\<3 OR\n  * UPC \\> 2g/g and serum albumin \\<3\n\nExclusion Criteria (Cohort A\\&B):\n\n* Prior solid organ transplant\n* A clinical diagnosis of glomerulopathy without diagnostic renal biopsy\n* Clinical, serological or histological evidence of systemic lupus erythematosus (SLE) as defined by the ARA criteria. Patients with membranous in combination with SLE will be excluded because this entity is well defined within the International Society of Nephrology/Renal Pathology Society categories of lupus nephritis, and frequently overlaps with other classification categories of SLE nephritis (68)\n* Clinical or histological evidence of other renal diseases (Alport, Nail Patella, Diabetic Nephropathy, IgA-nephritis, monoclonal gammopathy (multiple myelomas), genito-urinary malformations with vesico-urethral reflux or renal dysplasia)\n* Known systemic disease diagnosis at time of enrollment with a life expectancy less than 6 months\n* Unwillingness or inability to give a comprehensive informed consent\n* Unwillingness to comply with study procedures and visit schedule\n* Institutionalized individuals (e.g., prisoners)", "labeled_rules": [{"type": "inclusion", "field": "procedure", "operator": "contains", "value": "Cohort A (biopsy cohort) Inclusion Criteria:", "unit": "NA", "evidence_text": "Cohort A (biopsy cohort) Inclusion Criteria:"}, {"type": "inclusion", "field": "history", "operator": "not_contains", "value": "Patients presenting with an incipient clinical diagnosis for FSGS/MCD or MN or pediatric participants not previously biopsied, with a clinical diagnosis for FSG", "unit": "NA", "evidence_text": "Patients presenting with an incipient clinical diagnosis for FSGS/MCD or MN or pediatric participants not previously biopsied, with a clinical diagnosis for FSGS/MCD or MN meeting the following inclusion criteria:"}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "Documented urinary protein excretion ≥1500 mg/24 hours or spot protein: creatinine ratio equivalent at the time of diagnosis or within 3 months of the screening", "unit": "NA", "evidence_text": "Documented urinary protein excretion ≥1500 mg/24 hours or spot protein: creatinine ratio equivalent at the time of diagnosis or within 3 months of the screening/eligibility visit."}, {"type": "inclusion", "field": "procedure", "operator": "contains", "value": "Scheduled renal biopsy", "unit": "NA", "evidence_text": "Scheduled renal biopsy"}, {"type": "inclusion", "field": "procedure", "operator": "contains", "value": "Cohort B (non-biopsy, cNEPTUNE) Inclusion Criteria:", "unit": "NA", "evidence_text": "Cohort B (non-biopsy, cNEPTUNE) Inclusion Criteria:"}, {"type": "inclusion", "field": "age", "operator": "<", "value": "19", "unit": "years", "evidence_text": "Age \\<19 years of age"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Initial presentation with \\<30 days immunosuppression therapy", "unit": "NA", "evidence_text": "Initial presentation with \\<30 days immunosuppression therapy"}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Prior solid organ transplant", "unit": "NA", "evidence_text": "Prior solid organ transplant"}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "A clinical diagnosis of glomerulopathy without diagnostic renal biopsy", "unit": "NA", "evidence_text": "A clinical diagnosis of glomerulopathy without diagnostic renal biopsy"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Patients with membranous in combination with SLE will be excluded because this entity is well defined within the International Society of Nephrology/Renal Patho", "unit": "NA", "evidence_text": "Patients with membranous in combination with SLE will be excluded because this entity is well defined within the International Society of Nephrology/Renal Pathology Society categories of lupus nephritis, and frequently overlaps with other classification categories of SLE nephritis (68)"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Clinical or histological evidence of other renal diseases (Alport, Nail Patella, Diabetic Nephropathy, IgA-nephritis, monoclonal gammopathy (multiple myelomas),", "unit": "NA", "evidence_text": "Clinical or histological evidence of other renal diseases (Alport, Nail Patella, Diabetic Nephropathy, IgA-nephritis, monoclonal gammopathy (multiple myelomas), genito-urinary malformations with vesico-urethral reflux or renal dysplasia)"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Known systemic disease diagnosis at time of enrollment with a life expectancy less than 6 months", "unit": "NA", "evidence_text": "Known systemic disease diagnosis at time of enrollment with a life expectancy less than 6 months"}, {"type": "exclusion", "field": "other", "operator": "contains", "value": "Unwillingness or inability to give a comprehensive informed consent", "unit": "NA", "evidence_text": "Unwillingness or inability to give a comprehensive informed consent"}, {"type": "exclusion", "field": "other", "operator": "contains", "value": "Unwillingness to comply with study procedures and visit schedule", "unit": "NA", "evidence_text": "Unwillingness to comply with study procedures and visit schedule"}]}
{"nct_id": "NCT01209091", "eligibility_text": "Inclusion Criteria:\n\nAge \\> 18\n\nExclusion Criteria:\n\nN/A", "labeled_rules": [{"type": "inclusion", "field": "age", "operator": ">", "value": "18", "unit": "years", "evidence_text": "Age \\> 18"}, {"type": "inclusion", "field": "history", "operator": "contains", "value": "Age \\> 18", "unit": "NA", "evidence_text": "Age \\> 18"}]}
{"nct_id": "NCT01219582", "eligibility_text": "Inclusion Criteria:\n\n* Female and male patients ≥ 18 years of age with Type 2 Diabetes where investigator feels that addition of Glucobay®-M would be beneficial to patients.\n* The diagnosis will be made based on the ADA criteria by the attending physician.\n* Patients will be defined as included in the study if they have a documented prescription of Glucobay-M by the physician.\n* Patients willing to provide signed \\& dated informed consent.\n* Patients willing to comply with study requirements.\n\nExclusion Criteria:\n\n* According to the local product information", "labeled_rules": [{"type": "inclusion", "field": "condition", "operator": "contains", "value": "Female and male patients ≥ 18 years of age with Type 2 Diabetes where investigator feels that addition of Glucobay®-M would be beneficial to patients.", "unit": "NA", "evidence_text": "Female and male patients ≥ 18 years of age with Type 2 Diabetes where investigator feels that addition of Glucobay®-M would be beneficial to patients."}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "The diagnosis will be made based on the ADA criteria by the attending physician.", "unit": "NA", "evidence_text": "The diagnosis will be made based on the ADA criteria by the attending physician."}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Patients willing to provide signed \\& dated informed consent.", "unit": "NA", "evidence_text": "Patients willing to provide signed \\& dated informed consent."}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Patients willing to comply with study requirements.", "unit": "NA", "evidence_text": "Patients willing to comply with study requirements."}]}
{"nct_id": "NCT01242722", "eligibility_text": "Inclusion Criteria:\n\n* Patients who have a COGNIS CRT-D device implanted for at least 24 hours, with or without a right atrial lead\n* Patients who have an active LV bipolar lead\n* Patients who have an active right ventricular (RV) defibrillation lead\n* Patients who are willing and capable of participating in all testing associated with this Clinical Investigation\n* Patients who are age 18 or above, or of legal age to give informed consent specific to state and national law\n\nExclusion Criteria:\n\n* Patients who have a COGNIS CRT-D that has less than or equal to one year of battery life remaining\n* Patients who are pacemaker-dependent\n* Patients who will not tolerate a pacing pause of up to 6 seconds\n* Patients who have a unipolar LV pace/sense lead, unless the patient has any commercially available epicardial leads with at least two electrodes (from one or more leads)\n* Patients with pre-existing leads other than those specified in this investigational plan\n* Patients with a pre-existing unipolar pacemaker\n* Patients who are unable or unwilling to maintain a supine or sitting position for 40-50 minutes\n* Patients enrolled in any concurrent study, without Boston Scientific written approval\n* Women who are pregnant", "labeled_rules": [{"type": "inclusion", "field": "other", "operator": "contains", "value": "Patients who are willing and capable of participating in all testing associated with this Clinical Investigation", "unit": "NA", "evidence_text": "Patients who are willing and capable of participating in all testing associated with this Clinical Investigation"}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Patients who are age 18 or above, or of legal age to give informed consent specific to state and national law", "unit": "NA", "evidence_text": "Patients who are age 18 or above, or of legal age to give informed consent specific to state and national law"}, {"type": "exclusion", "field": "other", "operator": "contains", "value": "Patients who have a unipolar LV pace/sense lead, unless the patient has any commercially available epicardial leads with at least two electrodes (from one or mo", "unit": "NA", "evidence_text": "Patients who have a unipolar LV pace/sense lead, unless the patient has any commercially available epicardial leads with at least two electrodes (from one or more leads)"}, {"type": "exclusion", "field": "other", "operator": "contains", "value": "Patients who are unable or unwilling to maintain a supine or sitting position for 40-50 minutes", "unit": "NA", "evidence_text": "Patients who are unable or unwilling to maintain a supine or sitting position for 40-50 minutes"}, {"type": "exclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Women who are pregnant"}]}
{"nct_id": "NCT01253265", "eligibility_text": "Inclusion Criteria:\n\n* Ambulatory male or female patients between the ages of 20 and 75 years\n* Male patients: Agree to use a reliable method of birth control during the study including barrier contraceptives or a monogamous relationship with a partner who is not child bearing. Female patients: Are women who test negative for pregnancy at the time of entry based on a pregnancy test and are not breast feeding. Women of child bearing potential must agree to use a reliable method of birth control during the study.\n* Patients who are between the body weight of 40 and 105 kilogram (kg)\n* Patients who have an established diagnosis of Rheumatoid Arthritis (RA)\n* Patients who have C reactive protein (CRP) measurement greater than the upper limit of normal or erythrocyte sedimentation rate of at least 28 millimeters per hour (mm/hr)\n* Patients who have been treated with regular use of Methotrexate (MTX) for at least 12 weeks, and stable treatment (at least 7.5 milligrams per week (mg/week)) for at least 8 weeks\n* Patients who have given written informed consent approved by the Sponsor and the Institutional Review Board (IRB) governing the investigational site\n* Patients who have reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures\n\nExclusion Criteria:\n\n* Patients who use oral corticosteroids at average daily doses of \\>10 mg/day of prednisone or its equivalent or use of variable doses of oral corticosteroids within the last 4 weeks\n* Patients who have had a live vaccination within the last 12 weeks, or intend to have a live vaccination during the course of the study, or have participated in a vaccine clinical study within the last 12 weeks\n* Patients who have a diagnosis of any systemic inflammatory condition other than RA\n* Patients who have evidence of active vasculitis or uveitis\n* Patients who have a diagnosis of Felty's syndrome\n* Patients who have had surgical treatment of a joint within the last 8 weeks, or will require it during the study\n* Patients who have had lymphoma, leukemia, or any malignancy within the last 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease\n* Patients who have suffered a serious bacterial infection within the last 12 weeks, or a recent or ongoing infection\n* Patients who have an evidence or suspicion of active tuberculosis (TB) by medical history, physical examination, and/or chest radiograph or documentation of TB by a positive purified protein derivative (PPD) test\n* Patients who have uncontrolled arterial hypertension characterized by a systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>100 mmHg\n* Patients who have an evidence of positive hepatitis B (HBV) surface antigen, positive hepatitis B surface antibody, positive hepatitis B core antibody, or hepatitis B DNA (HBV DNA); an evidence of human immunodeficiency virus (HIV), evidence of hepatitis B; or an evidence of hepatitis C\n* Patients who have clinical laboratory test results at entry that are outside the normal reference range, or results with unacceptable deviations that are considered clinically significant by the investigator\n* Patients who have a serum creatinine \\>2.0 milligrams per deciliter (mg/dL)\n* Patients who have known hypogammaglobulinemia or a serum immunoglobulin (Ig) G (IgG), IgM, or IgA concentration less than the lower limit of normal\n* Patients who have an abnormality in the 12 lead electrocardiogram (ECG).\n* Patients who have donated of blood more than 200 mL within the past 30 days, or more than 400 milliliters (mL) within the past 90 days\n* Patients who are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off label use of an investigational drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. For unapproved Disease-Modifying Anti-Rheumatic Drug (DMARDs), have received 30 days or 5 fold of the half life prior to inclusion whichever is longer\n* Patients who previously completed or withdrawn from this study or any other study investigating LY2439821\n* Patients who have been treated with any biologic DMARD currently or previously for 5 half lives\n* Patients who have had serious reaction to other biologic Disease-Modifying Anti-Rheumatic Drug (DMARDs)\n* Patients who have received non biologics DMARDs (other than MTX, sulfasalazine, bucillamine or hydroxychloroquine)", "labeled_rules": [{"type": "inclusion", "field": "sex", "operator": "=", "value": "male", "unit": "NA", "evidence_text": "Male patients: Agree to use a reliable method of birth control during the study including barrier contraceptives or a monogamous relationship with a partner who is not child bearing."}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Female patients: Are women who test negative for pregnancy at the time of entry based on a pregnancy test and are not breast feeding."}, {"type": "inclusion", "field": "sex", "operator": "=", "value": "female", "unit": "NA", "evidence_text": "Women of child bearing potential must agree to use a reliable method of birth control during the study."}, {"type": "inclusion", "field": "condition", "operator": "contains", "value": "Patients who have an established diagnosis of Rheumatoid Arthritis (RA)", "unit": "NA", "evidence_text": "Patients who have an established diagnosis of Rheumatoid Arthritis (RA)"}, {"type": "inclusion", "field": "medication", "operator": "contains", "value": "Patients who have been treated with regular use of Methotrexate (MTX) for at least 12 weeks, and stable treatment (at least 7.5 milligrams per week (mg/week)) f", "unit": "NA", "evidence_text": "Patients who have been treated with regular use of Methotrexate (MTX) for at least 12 weeks, and stable treatment (at least 7.5 milligrams per week (mg/week)) for at least 8 weeks"}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Patients who have given written informed consent approved by the Sponsor and the Institutional Review Board (IRB) governing the investigational site", "unit": "NA", "evidence_text": "Patients who have given written informed consent approved by the Sponsor and the Institutional Review Board (IRB) governing the investigational site"}, {"type": "inclusion", "field": "other", "operator": "contains", "value": "Patients who have reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures", "unit": "NA", "evidence_text": "Patients who have reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures"}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "10", "unit": "mg/day", "evidence_text": "Patients who use oral corticosteroids at average daily doses of \\>10 mg/day of prednisone or its equivalent or use of variable doses of oral corticosteroids within the last 4 weeks"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Patients who have had a live vaccination within the last 12 weeks, or intend to have a live vaccination during the course of the study, or have participated in ", "unit": "NA", "evidence_text": "Patients who have had a live vaccination within the last 12 weeks, or intend to have a live vaccination during the course of the study, or have participated in a vaccine clinical study within the last 12 weeks"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Patients who have a diagnosis of any systemic inflammatory condition other than RA", "unit": "NA", "evidence_text": "Patients who have a diagnosis of any systemic inflammatory condition other than RA"}, {"type": "exclusion", "field": "condition", "operator": "contains", "value": "Patients who have a diagnosis of Felty's syndrome", "unit": "NA", "evidence_text": "Patients who have a diagnosis of Felty's syndrome"}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Patients who have had surgical treatment of a joint within the last 8 weeks, or will require it during the study", "unit": "NA", "evidence_text": "Patients who have had surgical treatment of a joint within the last 8 weeks, or will require it during the study"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Patients who have had lymphoma, leukemia, or any malignancy within the last 5 years except for basal cell or squamous epithelial carcinomas of the skin that hav", "unit": "NA", "evidence_text": "Patients who have had lymphoma, leukemia, or any malignancy within the last 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Patients who have suffered a serious bacterial infection within the last 12 weeks, or a recent or ongoing infection", "unit": "NA", "evidence_text": "Patients who have suffered a serious bacterial infection within the last 12 weeks, or a recent or ongoing infection"}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "160", "unit": "mmhg", "evidence_text": "Patients who have uncontrolled arterial hypertension characterized by a systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>100 mmHg"}, {"type": "exclusion", "field": "lab", "operator": "contains", "value": "2.0", "unit": "milligrams", "evidence_text": "Patients who have a serum creatinine \\>2.0 milligrams per deciliter (mg/dL)"}, {"type": "exclusion", "field": "procedure", "operator": "not_contains", "value": "Patients who have an abnormality in the 12 lead electrocardiogram (ECG).", "unit": "NA", "evidence_text": "Patients who have an abnormality in the 12 lead electrocardiogram (ECG)."}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Patients who have donated of blood more than 200 mL within the past 30 days, or more than 400 milliliters (mL) within the past 90 days", "unit": "NA", "evidence_text": "Patients who have donated of blood more than 200 mL within the past 30 days, or more than 400 milliliters (mL) within the past 90 days"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Patients who are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off label use of an investigational drug or ", "unit": "NA", "evidence_text": "Patients who are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off label use of an investigational drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study."}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "For unapproved Disease-Modifying Anti-Rheumatic Drug (DMARDs), have received 30 days or 5 fold of the half life prior to inclusion whichever is longer", "unit": "NA", "evidence_text": "For unapproved Disease-Modifying Anti-Rheumatic Drug (DMARDs), have received 30 days or 5 fold of the half life prior to inclusion whichever is longer"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Patients who previously completed or withdrawn from this study or any other study investigating LY2439821", "unit": "NA", "evidence_text": "Patients who previously completed or withdrawn from this study or any other study investigating LY2439821"}, {"type": "exclusion", "field": "history", "operator": "not_contains", "value": "Patients who have been treated with any biologic DMARD currently or previously for 5 half lives", "unit": "NA", "evidence_text": "Patients who have been treated with any biologic DMARD currently or previously for 5 half lives"}, {"type": "exclusion", "field": "medication", "operator": "contains", "value": "Patients who have had serious reaction to other biologic Disease-Modifying Anti-Rheumatic Drug (DMARDs)", "unit": "NA", "evidence_text": "Patients who have had serious reaction to other biologic Disease-Modifying Anti-Rheumatic Drug (DMARDs)"}]}
